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1	  
Introduction	  
	  
Alkaloids	  are	  a	  diverse	  group	  of	  low	  molecular	  weight,	  nitrogen-­‐containing	  
molecules	   found	   in	   about	   20%	   of	   plant	   species.	   Many	   of	   the	   !16,000	  
alkaloids	  for	  which	  structures	  have	  been	  described	  function	  in	  the	  defense	  
of	  plants	  against	  herbivores,	  microbes,	  viruses	  and	  competing	  plants.	  Many	  
alkaloids	   are	   infamous	   for	   their	   strong	   toxicity	   towards	   animals	   and	  
humans.	  Most	  of	  the	  deadly	  alkaloids	  fall	  into	  the	  class	  of	  neurotoxins	  and	  
the	  others	  have	  cytotoxic	  properties.	  A	  cytotoxic	  effect	  can	  be	  generated	  
when	   cell	   membranes	   are	   made	   leaky	   (as	   by	   saponins	   or	   steroidal	  
alkaloids),	  or	  when	  elements	  of	  the	  cytoskeleton	  are	  inhibited.	  The	  spindle	  
poisons	   vinblastine,	   vincristine,	   colchicine,	   and	   taxol	   are	   particularly	  
famous.	   Actin	   filament	   formation	   is	   blocked	   by	   fungal	   poisons	   such	   as	  
phalloidin	  from	  Amanita	  phalloides.	  1,2,3	  
DNA	  can	  also	  be	  a	   target	   for	   alkaloids:	   planar	   and	   lipophilic	   alkaloids	   are	  
intercalating	   compounds	   that	   assemble	   between	   the	   stacks	   of	   paired	  
nucleotides	   in	   the	   DNA	   double	   helix.	   DNA	   intercalation	   can	   disturb	  
replication,	   DNA	   repair,	   and	   DNA	   topoisomerases.	   Frameshift	   mutations	  
are	   one	   of	   the	   adverse	   consequences	   of	   intercalating	   compounds.	   Some	  
alkaloids,	   such	   as	   pyrrolizidine	   alkaloids,	   aristolochic	   acids,	   cycasin,	   and	  
furoquinoline	   alkaloids,	   are	   known	   to	   form	   covalent	   adducts	   with	   DNA	  
bases.4	   Mutations	   and	   tumor	   formation	   can	   be	   the	   result	   of	   such	  
interactions.	  DNA	  alkylation	  occurs	   in	  some	  alkaloids	  only	  after	  activation	  
by	   liver	   enzymes,	   such	   as	   cytochrome	   p450	   oxidases	   (pyrrolizidine	  
alkaloids,	  aristolochic	  acids).5	  
Ribosomal	  protein	  biosynthesis	  is	  often	  inhibited	  by	  alkaloids	  that	  interact	  
with	  nucleic	  acids.	  There	  are	  also	  more	  specific	  inhibitors,	  such	  as	  emetine.	  
Disturbances	   of	   the	   cytoskeleton,	   DNA	   replication,	   and	   DNA	  
topoisomerase,	   or	   DNA	   alkylation	   and	   intercalation	   usually	   lead	   to	   cell	  
death	   by	   apoptosis.	   The	   cytotoxic	   properties	   are	   usually	   not	   specific	   for	  
animals	   but	   also	   affect	   bacteria,	   fungi,	   other	   plants,	   and	   even	   viruses.	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Alkaloids	  thus	  defend	  plants	  against	  a	  wide	  diversity	  of	  enemies.	  They	  have	  
the	  disadvantage	  that	  a	  producing	  plant	  could	  theoretically	  kill	  itself	  by	  its	  
own	   poison.	   Compartmentation,	   target-­‐site	   insensitivity,	   and	   other	  
mechanisms	  (which	  are	  largely	  unknown)	  must	  have	  evolved	  to	  overcome	  
such	  problems.6	  
Cancer	   is	   a	   group	   of	   diseases	   characterized	   by	   uncontrolled	   growth	   and	  
spread	  of	  abnormal	  cells.	  The	  estimated	  worldwide	   incidence	  of	  cancer	   is	  
about	  6	  million	  new	  cases	  per	  year.	  In	  the	  United	  States,	  cancer	  is	  now	  the	  
leading	   cause	   of	   death	   for	   people	   younger	   than	   85	   years,	   and	   it	   is	   only	  
exceeded	   by	   heart	   disease	   in	   older	   individuals.	   The	   treatment	   of	   many	  
diseases	  is	  highly	  dependent	  on	  natural	  products,	  and	  this	  is	  especially	  true	  
for	   the	   treatment	   of	   cancer.	   Unique	   classes	   of	   natural	   products,	   such	   as	  
alkaloids,	  have	  shown	  significant	  antitumor	  action.7,8	  
	  
1.1	  	  
Antitumor	  alkaloids	  	  
	  
1.1.1	  
Antitumor	  alkaloids	  in	  clinical	  use	  
	  
1.1.1.1	  
	  Vinca	  alkaloids	  
	  
The	  vinca	  alkaloids,	  isolated	  from	  the	  Madagascar	  periwinkle,	  Catharantus	  
roseus	  G.	  Don.,	  comprise	  a	  group	  of	  about	  130	  terpenoid	  indole	  alkaloids.	  
Their	  clinical	  value	  was	  clearly	  identified	  as	  early	  as	  1965	  and	  so	  this	  class	  
of	   compounds	  has	  been	  used	  as	   anticancer	   agents	   for	  over	  40	   years	   and	  
represents	   a	   true	   lead	   compound	   for	   drug	   development	   .	   Today,	   two	  
natural	   compounds,	  vinblastine	   (VLB,	  1)	   and	  vincristine	   (VCR,	  2),	   and	   two	  
semisynthetic	   derivatives,	   vindesine	   (VDS,	   3)	   and	   vinorelbine	   (VRLB,	   4),	  
have	  been	  registered	  (Figure	  1.1).8	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Owing	  to	  the	  pharmaceutical	   importance	  and	  the	   low	  content	  of	  VLB	  and	  
the	   related	   alkaloid	   VCR,	   Catharanthus	   roseus	   became	   one	   of	   the	   best-­‐
studied	  medicinal	   plants.	   Among	   the	  many	   biochemical	   effects	   observed	  
after	  exposure	  of	  cells	  and	  tissues	  to	  the	  vinca	  alkaloids	  are	  disruption	  of	  
microtubules,	   inhibition	   of	   synthesis	   of	   proteins	   and	   nucleic	   acids,	  
elevation	   of	   oxidized	   glutathione,	   alteration	   of	   lipid	  metabolism	   and	   the	  
lipid	  content	  of	  membranes,	  elevation	  of	  cyclic	  adenosine	  monophosphate	  
(cAMP),	   and	   inhibition	   of	   calcium-­‐calmodulin-­‐regulated	   cAMP	  
phosphodiesterase.9	  
Among themany biochemical effects observed after exposure of cells and tissues to
the vinca alkaloids are disruption ofmicrotubules, inhibition of synthesis of proteins
and nucleic acids, elevation of oxidized glutathione, alteration of lipid metabolism
and the lipid content of membranes, elevation of cyclic adenosine monophosphate
(cAMP), and inhibition of calcium-calmodulin-regulated cAMP phosphodiesterase
[8–16]. Despite these multiple biochemical actions, the antineoplastic activity of the
vinca alkaloids is usually attributed to disruption of microtubules, resulting in
dissolution of mitotic spindles and metaphase arrest in dividing cells [9,17–20].
Microtubules are involved in many cellular processes in addition to mitosis, and
exposure to vinca alkaloids gives rise to diverse biological effects, many of which
could impair essential functions, both in dividing and in nondividing cells [21–23].
The effects of the vinca alkaloids on the organization and function ofmicrotubules
have been extensively characterized [8]. It appears that each heterodimer of a-b-
tubulin possesses a single ‘‘vinca-specific’’ site of high intrinsic affinity and an
unknown number of nonspecific sites of low affinity [24]. The relative strength of
drug binding to vinca-specific sites on the a- and b-heterodimers of tubulins is
VCR > VDS > VLB > VRLB > VFL [25–27]. From the several effects of VLB on the
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Despite	   these	  multiple	   biochemical	   actions,	   the	   antineopla tic	   activity	   of	  
the	   vinca	   alkalo ds	   i 	   usually	   attributed	   to	   disruption	   of	   m crotubules,	  
resulting	  in	  dissolution	  of	  mitotic	  spindles	  and	  metaphase	  arrest	  in	  dividing	  
cells.	  Microtubules	   are	   involved	   in	  many	   cellular	   processes	   in	   addition	   to	  
mitosis,	   and	   exposure	   to	   vinca	   alkaloids	   gives	   rise	   to	   diverse	   biological	  
effects,	  many	   of	   which	   could	   impair	   essential	   functions,	   both	   in	   dividing	  
and	  in	  nondividing	  cells.10	  
Among	   anticancer	   drugs,	   the	   vinca	   alk loids	   are	   classified	   a 	   mitotic	  
inhibitors,	  with	  their	  primary	  site	  of	  action	  being	  M	  phase	  of	  the	  cell	  cycle,	  
but	   it	   is	   not	   certain	   that	   mitotic	   inhibition	   is	   the	   predominant	   in	   vivo	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cytotoxic	   mechanism.	   Recent	   studies	   suggest	   that	   disruption	   of	   the	   cell	  
cycle	  may	  lead	  to	  cell	  death	  through	  apoptosis.	  The	  many	  biological	  actions	  
of	   the	   clinically	  active	  vinca	  alkaloids	  are	   seen	  over	  a	  wide	   range	  of	  drug	  
concentrations,	   and	   there	   are	   selective	   effects	   in	   various	   normal	   and	  
neoplastic	  tissues.11	  
	  
1.1.1.2	  	  
Camptothecin	  and	  Analogues	  
 
See	  chapter	  3	  
 
1.1.1.3	  
	  Taxanes	  
  
Taxanes	   are	   a	   class	   of	   structurally	   complex	   yet	   homogenous	   diterpene	  
alkaloids	  that	  occur	  in	  the	  genus	  Taxus,	  commonly	  known	  as	  the	  yew.	  This	  
family	  of	   diterpenoids	  has	   long	  been	   known	   for	   its	   toxicity	   as	  well	   as	   for	  
other	  biological	  activities.	  The	  first	  chemical	  study	  of	  the	  metabolites	  of	  the	  
yew	  dates	  backs	  to	  the	  mid-­‐nineteenth	  century,	  when	  a	  mixture	  of	  taxanes	  
was	   obtained	   by	   the	   German	   pharmacist	   Lucas	   in	   1856.11	   The	   structure	  
characterization	  of	   these	  compounds,	  which	  were	  named	   taxine	  by	  Lucas	  
was,	  however,	  extremely	   slow,	  owing	   to	   the	  complexity	  of	   the	   substance	  
and	  the	  lack	  of	  modern	  spectroscopic	  techniques.	  In	  1963,	  the	  constitution	  
of	   the	   taxane	   nucleus	   was	   established	   for	   the	   first	   time	   by	   independent	  
work	  of	   Lythgoe’s	  group,	  Nakanishi’s	  group,	  and	  Uyeo’s	  group	  as	   tricyclic	  
polyalcohols	  esterified	  with	  acids,	  such	  as	  taxinine	  ,	  whose	  stereochemistry	  
was	  established	   three	  years	   later.12	  More	   importantly,	   in	  1971,	  Wani	  and	  
Wall	   discovered	   the	   highly	   potent	   anticancer	   agent	  paclitaxel	   (14,	   Figure	  
1.2).13,	  14	  This	  remarkable	  accomplishment	  not	  only	  shifted	  the	  attention	  of	  
the	   scientific	   community	   to	   paclitaxel	   itself,	   but	   also	   attracted	   extensive	  
studies	  on	  various	  species	  of	  yew	  tree	  that	  led	  to	  the	  isolation	  of	  many	  new	  
taxane	  family	  members..	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Fig	  1.2 
To	  date,	  over	  100	  taxanes	  have	  been	   isolated	  and	  structurally	  elucidated.	  
Paclitaxel,	  and	  an	  analog,	  docetaxel,	  are	  currently	  regarded	  as	  very	  useful	  
anticancer	  chemotherapeutic	  agents	  
Paclitaxel	  (14,	  Figure	  1.3),	  a	  complex	  diterpenoid	  alkaloid,	  occurs	  widely	  in	  
plants	  of	  Taxus	  species.	  Among	  various	  Taxus	  species	  and	  various	  parts	  of	  
taxus	   trees,	   the	   bark	   of	   T.	   brevifolia	   Nutt.	   has	   the	   highest	   content	   of	  
paclitaxel.	  However,	  even	  this	  content	  is	  relatively	  low	  –	  only	  about	  0.01	  %	  
on	   a	   dry	   weight	   basis.	  Moreover,	   yew	   trees	   grow	   very	   slowly.	   Paclitaxel	  
isolation	   is	   therefore	   restricted	   as	   a	   result	   of	   the	   relative	   scarcity	   of	   the	  
Pacific	  yew	  tree	  and	  the	  low	  yield	  of	   its	  bark.	  However,	  other	  species	  and	  
other	   parts	   of	   taxus	   trees	   also	   produce	   paclitaxel	   and	   related	   taxanes.15	  
The	  major	   barrier	   to	   early	   clinical	   development	   of	   paclitaxel	   was	   its	   low	  
abundance	   in	   the	   yew	   trees,	   since	   chemical	   synthesis	   had	   not	   been	  
possible;	   there	   simply	   was	   not	   enough	   paclitaxel	   to	   perform	   the	  
appropriate	  trials.	  This	  situation	  has	  changed	  because	  of	  the	  development	  
of	   novel	   semisynthetic	  methods	   and	   the	   identification	   of	   new	   sources	   of	  
taxanes.	   An	   important	   biosynthetic	   precursor	   of	   paclitaxel,	   10-­‐
deacetylbaccatin	  III,	  was	  isolated	  in	  1981	  in	  reasonably	  good	  yield	  from	  the	  
leaves	  of	  Taxus	  baccata	  L.,	  as	  a	  renewable	  source,	  as	  well	  as	  from	  the	  bark	  
of	   Taxus	   brevifolia	   in	   1982.16	   It	   serves	   as	   the	   starting	   material	   for	   the	  
production	  of	  paclitaxel	  through	  a	  coupling	  reaction	  with	  an	  appropriately	  
protected	  side	  chain	  that	  can	  be	  prepared	  synthetically.	  The	  total	  synthesis	  
of	  paclitaxel	  has	  also	  been	  a	   challenging	   target	   for	   a	  number	  of	   research	  
groups.	   Both	   the	   Holton	   group	   and	   the	   Nicolaou	   group	   synthesized	  
paclitaxel	   almost	   simultaneously	   in	   1994,	   but	   both	   syntheses	   are	   too	  
cumbersome	  to	  have	  commercial	  value.17	  
bark of T. brevifolia Nutt. has the highest content of paclitaxel [124]. However, even
this content is relatively low – only about 0.01 % on a dry weight basis. Moreover,
yew trees grow very slowly. Paclitaxel isolation is therefore restricted as a result of
the relative scarcity of the Pacific yew tree and the low yield of its bark. However,
other species and other parts of taxus trees also produce paclitaxel and related
taxanes [125]. The major barrier to early clinical development of paclitaxel was its
low abundance in the yew trees, since chemical synthesis had not been possible;
there simply was not enough paclitaxel to perform the appropriate trials. This
situation has changed because of the development of novel semisynthetic methods
and the identification of new sources of taxanes. An important biosynthetic
precursor of paclitaxel, 10-deacetylbaccatin III, was isolated in 1981 [126] in
reasonably good yield from the leaves of Taxus baccata L., as a renewable source,
as well as from the bark of Taxus brevifolia in 1982 [127]. It s rves as the starting
material for the production of paclitaxel through a coupling reaction with an
appropriately protected side chain that can be prepared synthetically. The total
synthesis of paclitaxel has also been a challenging target for a number of research
groups. Both the Holton group and the Nicolaou group synthesized paclitaxel
almost simultaneously in 1994, but both syntheses are too cumbersome to have
commercial value [128,129].
Among antineoplastic drugs that interfere with microtubules, paclitaxel exhibits a
unique mechanism of action [130–133]. Paclitaxel promotes assembly of microtu-
bules by shifting the equilibrium between soluble tubulin and microtubules toward
assembly, reducing the critical concentration of tubulin required for assembly. The
result is stabilization of microtubules, even in the presence of conditions that
normally promote disassembly of microtubules. The remarkable stability of micro-
tubules induced by paclitaxel is d maging to cells because f the perturbation in the
dynamics of variousmicrotubule-dependent cytoplasmic structures that are required
for such functions as mitosis ma tenance of cellular morphology, shape changes,
neurite formation, locomotion, and secretion [134–137]. The binding site for
paclitaxel is distinct from the binding sites for the vinca alkaloids, colchicine or
podophyllotoxin [132]. Other natural products, such as epothilone and discodermo-
lide, have also been reported to share the mechanism of paclitaxel in promoting
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Among	   antineoplastic	   drugs	   that	   interfere	   with	   microtubules,	   paclitaxel	  
exhibits	   a	   unique	  mechanism	   of	   action.	   Paclitaxel	   promotes	   assembly	   of	  
microtubules	   by	   shifting	   the	   equilibrium	   between	   soluble	   tubulin	   and	  
microtubules	   toward	   assembly,	   reducing	   the	   critical	   concentration	   of	  
tubulin	   required	   for	   assembly.	   The	   result	   is	   stabilization	   of	  microtubules,	  
even	   in	   the	  presence	  of	  conditions	  that	  normally	  promote	  disassembly	  of	  
microtubules.	   The	   remarkable	   stability	   of	   microtubules	   induced	   by	  
paclitaxel	  is	  damaging	  to	  cells	  because	  of	  the	  perturbation	  in	  the	  dynamics	  
of	  various	  microtubule-­‐dependent	  cytoplasmic	  structures	  that	  are	  required	  
for	   such	   functions	  as	  mitosis,	  maintenance	  of	   cellular	  morphology,	   shape	  
changes,	  neurite	  formation,	  locomotion,	  and	  secretion.18-­‐20	  The	  binding	  site	  
for	   paclitaxel	   is	   distinct	   from	   the	   binding	   sites	   for	   the	   vinca	   alkaloids,	  
colchicine	   or	   podophyllotoxin.	   Cells	   treated	  with	   pharmacologic	   levels	   of	  
paclitaxel	  are	  arrested	  in	  the	  G2	  and	  M	  phases	  of	  the	  cell	  cycle	  and	  contain	  
disorganized	  arrays	  of	  microtubules,	  often	  aligned	  in	  parallel	  bundles.	  
Docetaxel	   (15,	  Figure	  1.2),	  a	  semisynthetic	  side-­‐chain	  analog	  of	  paclitaxel,	  
also	   has	   potent	   antitumor	   activities.	   It	   was	   first	   synthesized	   by	   Potier’s	  
group	  in	  1984,	  from	  one	  of	  the	  yew	  tree	  taxanes,	  10-­‐deacetyl-­‐baccatin	  III,	  
found	  in	  the	  leaves	  of	  Taxus	  baccata	  L.	  This	  has	  the	  advantage	  of	  being	  a	  
renewable	   source.	   Although	   the	   mechanisms	   of	   action	   of	   the	   taxanes	  
docetaxel	   and	   paclitaxel	   are	   identical,	   docetaxel	   has	   almost	   a	   twofold	  
higher	  binding	  affinity	  for	  the	  target	  site,	  b-­‐tubulin.16 
 
1.1.2	  	  
Antitumor	  alkaloids	  in	  clinical	  trials	  
 
1.1.2.1	  	  
Ecteinascidin-­‐743	  (Yondelis,	  Trabectedin)	  
 
Ecteinascidin-­‐743	   (ET-­‐743,	   16,	   Figure	   1.3)	   is	   a	   tetrahydroisoquinoline	  
alkaloid	   isolated	   from	   Ecteinascidia	   turbinata	   Herdman,	   a	   tunicate	   that	  
grows	  on	  mangrove	  roots	   throughout	   the	  Caribbean	  Sea.	  Most	   likely,	   the	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compound	  is	  produced	  by	  the	  marine	  tunicate	  as	  a	  defense	  mechanism	  to	  
survive	  in	  its	  natural	  environment.21,22	  
ET-­‐743	   binds	   to	   the	   N2	   position	   of	   guanine	   in	   the	  minor	   groove	   of	   DNA	  
with	   some	   degree	   of	   sequence	   specificity,	   altering	   the	   transcription	  
regulation	  of	  induced	  genes.	  ET-­‐743	  was	  selected	  for	  clinical	  development	  
cycles of docetaxol had fluid retention, which could be largely controlled through the
use of diuretics, andwere less frequent in patients premedicatedwith glucocorticoids
[153].
2.3
Antitumor Alkaloids in Clinical Trials
2.3.1
Ecteinascidin-743 (Yondelis, Trabectedin)
Ecteinascidin-743 (ET-743, 16, Figure 2.4) is a tetrahydroisoquinolone alkaloid
isolated from Ecteinascidia turbinata Herdman, a tunicate that grows on mangrove
roots throughout the Caribbean Sea [154]. Most likely, the compound is produced by
the marine tunicate as a defense mechanism to survive in its natural environment
[155].
ET-743 binds to the N2 position of guanine in theminor groove of DNAwith some
degree of sequence specificity, altering the transcription regulation of induced genes
[156]. ET-743 was selected for clinical development because of its original mode of
action involvingDNArepairmachinery [157] and its cytotoxic activity against a variety
of solid tumor cell lines, including sarcoma cell lines, even those resistant to many
other cytotoxic agents [158]. In phase I clinical trials, ET-743 was generally well
tolerated with noncumulative hematological and hepatic toxicities being the most
commonly reported adverse events. The dose-limiting toxicities were neutropenia
and fatigue. A dose-related asymptomatic and reversible rise in transaminase levels
was prevalent, but not a treatment-limiting toxicity [159]. Patients with any baseline
liver-function test exceeding the up r l mit of the normal ranges have significantly
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because	  of	  its	  original	  mode	  of	  action	  involving	  DNA	  repair	  machinery	  and	  
its	   cytotoxic	   activity	   against	   a	   variety	   of	   solid	   tumor	   cell	   lines,	   including	  
sarcoma	  cell	  lines,	  even	  those	  resistant	  to	  many	  other	  cytotoxic	  agents.23	  
	  
1.1.2.2	  	  
	  7-­‐Hydroxystaurosporine	  (UCN-­‐01)	  
	  
Staurosporine	  (17,	  Figure	  1.3),	  an	  alkaloid	  isolated	  from	  Streptomyces	  spp.,	  
is	  a	  potent	  nonspecific	  protein	  and	  tyrosine	  kinase	   inhibitor.	  Thus,	  efforts	  
to	   find	   analogs	   of	   staurosporine	   have	   identified	   compounds	   specific	   for	  
protein	   kinases.	   UCN-­‐01	   (18,	   Figure	   1.3)	   is	   a	   potent	   inhibitor	   of	   protein	  
kinase	   C,24	   and	   has	   antiproliferative	   activity	   in	   several	   human	   tumor	   cell	  
lines.	   Work	   from	   several	   groups	   supports	   the	   hypothesis	   that	   UCN-­‐01	  
promotes	   its	   antitumor	   activity	   through	   induction	   of	   apoptosis	   by	   either	  
modulation	   of	   cyclin-­‐dependent	   kinases	   or	   inhibition	   of	   cell	   cycle	  
checkpoints.	  UCN-­‐01	  may	  act	  by	  abrogating	  the	  G2	  block	  often	  induced	  by	  
cellular	   damage,	   thus	   causing	   inappropriate	   progression	   to	   G2	   and	  
subsequent	   apoptosis.	   Also,	   synergistic	   effects	   of	   UCN-­‐01	   have	   been	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observed	  with	  many	   chemotherapeutic	   agents,	   including	  mitomycin	  C,	   5-­‐
fluorouracil,	  and	  camptothecin.25,26	  	  
	  
	  1.1.2.3	  
	  Ellipticine	  and	  analogs	  
	  
Ellipticine	   (19)	   and	   its	   other	   two	   naturally	   occurring	   analogs,	   9-­‐
methoxyellipticine	   (20)	   and	   olivacine	   (21),	   showed	   promising	   activity	   as	  
potential	  anticancer	  drugs	  (Figure	  1.4).	  Ellipticine	  was	  first	  isolated	  in	  1959	  
from	   the	   leaves	   of	   the	   evergreen	   tree	   Ochrosia	   elliptica	   Labill.,	   but	   its	  
biological	  activities	  were	  only	  recognized	  in	  1967.27	  Since	  then,	  the	  design,	  
synthesis,	   and	   structure–activity	   relationships	   of	   this	   class	   of	   compounds	  
have	  been	  studied	  by	  a	  number	  of	  laboratories.	  Studies	  on	  the	  mechanism	  
of	   cytotoxicity	   and	   anticancer	   activity	   of	   the	   ellipticine	   analogs	   suggest	   a	  
complex	   set	   of	   effects,	   including	   DNA	   intercalation,	   inhibition	   of	  
topoisomerase,	   covalent	  alkylation	  of	  macromolecules,	  and	  generation	  of	  
cytotoxic	  free	  radicals.28,29	  
	  
	  
	  
	  
	  
	  
	  
	  
Fig	  1.4	  
	  
1.1.2.4	  	  
Acronycine	  and	  analogs	  
	  
The	   pyranoacridone	   alkaloid,	   acronycine	   (22,	   Figure	   1.4),	   isolated	   from	  
Acronychia	   baueri	   Schott.,30	   was	   shown	   to	   exhibit	   promising	   activity	  
against	  a	  broad	  spectrum	  of	  solid	  tumors.	  However,	  its	  moderate	  potency	  
Studies on the mechanism of cytotoxicity and anticancer activity of the ellipticine
analogs suggest a complex set of effects, including DNA intercalation, inhibition of
topoisomerase, covalent alkylation of macromolecules, and generation of cytotoxic-
free radicals [176,177]. Owing to cardiovascular toxicity and hemolysis observed
during preclinical toxicity studies, development of the parent compound ellipticine
was halted. Interest then shifted to the 9-substituted derivatives, including
9-hydroxyellipticine, 9-methoxyellipticine, and elliptinium. Only limited activity
was observed in clinical trials with 9-hydroxyellipticine and 9-methoxyellipticine.
Phase II clinical trials of elliptinium yieldedmoderately promising results. S16020, a
cytotoxic agent derived from 9-hydroxyolivacine, was tested in phase I studies, and
demonstrated improved toxicities by showing no hemolysis and no detection of anti-
S16020 antibodies [178]. None of the ellipticine derivatives have reached clinical
practice, but the ellipticine family may still yield clinically useful anticancer drugs.
2.3.4
Acronycine and Analogs
The pyranoacridone alkaloid, acronycine (22, Figure 2.5), isolated from Acronychia
baueriSchott. [179], was shown to exhibit promising activity against a broad spectrum
of solid tumors [180]. However, its moderate potency and poor solubility in aq eous
solvents severely hampered subsequent clinical trials, which were rapidly discon-
tinu d, owing to odest therapeutic eff cts and dose-limiting gastrointestinal
toxicity after oral administration [181]. Consequently, the development of structural
analogs with increas d potency and/or better water solubility was highly desirable.
Efforts to design more potent derivatives were guided by the hypothesis of in vivo
bioactivation of the 1,2-do ble bond of acronycine into the corresponding epoxide.
The high reactivity of acronycine 1,2-epoxide, which readily reacts with water to give
the corresponding cis and trans diols, suggested that this compound could be the
active metabolite of acronycine, able to alkylate some nucleophilic target within
the tumor cell. Accordingly, significant improvements in terms of potency were
obtained with derivatives modified in the pyran ring, which had a similar reactivity
toward nucleophilic agents such as acronycine epoxide but improved chemical
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and	   poor	   solubility	   in	   aqueous	   solvents	   severely	   hampered	   subsequent	  
clinical	   trials,	   which	   were	   rapidly	   discontinued,	   owing	   to	   modest	  
therapeutic	   effects	   and	   dose-­‐limiting	   gastrointestinal	   toxicity	   after	   oral	  
administration.31	   Consequently,	   the	   development	   of	   structural	   analogs	  
with	  increased	  potency	  and/or	  better	  water	  solubility	  was	  highly	  desirable.	  
Efforts	  to	  design	  more	  potent	  derivatives	  were	  guided	  by	  the	  hypothesis	  of	  
in	   vivo	   bioactivation	   of	   the	   1,2-­‐double	   bond	   of	   acronycine	   into	   the	  
corresponding	   epoxide.	   The	   high	   reactivity	   of	   acronycine	   1,2-­‐epoxide,	  
which	   readily	   reacts	   with	   water	   to	   give	   the	   corresponding	   cis	   and	   trans	  
diols,	   suggested	   that	   this	   compound	   could	   be	   the	   active	   metabolite	   of	  
acronycine,	  able	  to	  alkylate	  some	  nucleophilic	  target	  within	  the	  tumor	  cell.	  
Accordingly,	   significant	   improvements	   in	   terms	  of	  potency	  were	  obtained	  
with	  derivatives	  modified	   in	   the	  pyran	  ring,	  which	  had	  a	  similar	   reactivity	  
toward	   nucleophilic	   agents	   such	   as	   acronycine	   epoxide	   but	   improved	  
chemical	  stability.32	  
	  
1.1.2.5	  	  
Colchicine	  and	  analogs	  
	  
Colchicine	   (23,	  Figure	  1.5)	   is	  a	   three-­‐ring	  amine	  alkaloid	  derived	   from	  the	  
corms	   of	   Colchicum	   autumnale	   L.	   Like	   the	   anticancer	   indole	   alkaloids,	  
vinblastine	   and	   vincristine,	   it	   depolymerizes	   microtubules	   at	   high	  
concentrations	  and	  stabilizes	  microtubule	  dynamics	  at	  low	  concentrations.	  
It	  was	  recognized	  as	  having	  damaging	  effects	  on	  tumor	  vasculature	  as	  long	  
ago	  as	  the	  1930s	  and	  1940s,	  causing	  hemorrhage	  and	  extensive	  necrosis	  in	  
both	  animal	  and	  human	  tumors.33,34	  
	  
stability [182,183]. The benzo[b]acronycine derivative S23906-1 demonstrated a
marked antitumor activity in human orthotopic models of lung, ovarian, and colon
cancers xenografted in nude mice, and is currently in phase I clinical trials. The
mechanism of its action implies alkylation of the 2-amino group of DNA guanine
residues by the carbocation resulting from the elimination of the ester leaving group
at position 1 of the drug [184].
2.3.5
Colchicine and Analogs
Colchicine (23, Figure 2.6) is a three-ring amine alkaloid derived from the corms of
Colchicum autumnale L. Like the anticancer indole alkaloids, vinblastine and vincris-
tine, it depolymerizes microtubules at high concentrations and stabilizes micro-
tubule dynamics at low concentrations. It was recognized as having damaging effects
on tumor vasculature as long ago as the 1930s and 1940s, causing hemorrhage and
extensive necrosis in both animal and human tumors [185,186]. Although its toxicity
precluded further clinical development, sporadic reports of tumor vascular damage
induced by related compounds, such as podophyllotoxin, continued to emerge [187].
Since the late 1990s, the combretastatins and N-acetylcolchinol-O-phosphate
(ZD6126, 24, Figure 2.6), compounds that resemble colchicine and bind to
the colchicin domain on tubulin, have undergone extensive dev lopment as
antivascular agents. ZD6126 is a phosphate prodrug of the tubulin-binding agent
N-acetyl olchinol. Profound disruption of the tumor blood v ssel network has been
noted in a wide variety of preclinical tumor models. The observed effects include
vascular shutdown, and reduce tumor blood flow. Histologic assessment has
revealed central tumor necrosis extending to within a few cell layers from the tumor
margins [188]. Following treatment, a ring of viable tumor cells is invariably found on
the tumorperiphery [189]. Since the residual tumor tissue can serve as a foundation for
tumor regrowth, the vascular disrupting agent could be combined with other treat-
ment options so that the entire tumor cell population can be completely eradicated.
Several studies involving the use of ZD6126 in conjunction with conventional
chemotherapeutic agents led to enhanced responses in a wide variety of tumor
models [188]. Each phase I clinical trial reported similar toxicity profiles, including
anemia, constipation, and fatigue [190]. It is noteworthy that this toxicity profile is
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Fig. 2.6 Chemical structures of colchicines and ZD6126.
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Although	   its	   toxicity	   precluded	   further	   clinical	   development,	   sporadic	  
reports	  of	  tumor	  vascular	  damage	  induced	  by	  related	  compounds,	  such	  as	  
podophyllotoxin,	   continued	   to	   emerge.	   Since	   the	   late	   1990s,	   the	  
combretastatins	   and	   N-­‐acetylcolchinol-­‐O-­‐phosphate	   (ZD6126,	   24,	   Figure	  
1.6),	   compounds	   that	   resemble	   colchicine	   and	   bind	   to	   the	   colchicine	  
domain	  on	  tubulin,	  have	  undergone	  extensive	  development	  as	  antivascular	  
agents.	   ZD6126	   is	   a	   phosphate	   prodrug	   of	   the	   tubulin-­‐binding	   agent	   N-­‐
acetylcolchinol.	  Profound	  disruption	  of	  the	  tumor	  blood	  vessel	  network	  has	  
been	   noted	   in	   a	   wide	   variety	   of	   preclinical	   tumor	  models.	   The	   observed	  
effects	   include	   vascular	   shutdown,	   and	   reduced	   tumor	   blood	   flow.	  
Histologic	   assessment	   has	   revealed	   central	   tumor	   necrosis	   extending	   to	  
within	   a	   few	   cell	   layers	   from	   the	   tumor	  margins.	   Following	   treatment,	   a	  
ring	  of	  viable	  tumor	  cells	  is	  invariably	  found	  on	  the	  tumor	  periphery.	  Since	  
the	   residual	   tumor	   tissue	   can	   serve	   as	   a	   foundation	   for	   tumor	   regrowth,	  
the	   vascular	   disrupting	   agent	   could	   be	   combined	   with	   other	   treatment	  
options	   so	   that	   the	   entire	   tumor	   cell	   population	   can	   be	   completely	  
eradicated.35	  	  
	  
1.1.3.6	  	  
Ukrain	  
	  
Ukrain	   (NSC-­‐631570)	   has	   been	   described	   by	   Novicky	   Pharma	   (Vienna,	  
Austria)	  as	  a	  semisynthetic	  compound	  derived	  from	  Chelidonium	  majus	  L.,	  
which	   contains	   a	   range	   of	   alkaloids,	   most	   notably	   chelidonine.	   Ukrain	  
consists	   of	   one	   molecule	   of	   thiophosphoric	   acid	   conjugated	   to	   three	  
molecules	   of	   chelidonine.	   A	   mass-­‐spectrometric	   analysis	   of	   Ukrain	  
components	   failed	   to	   demonstrate	   the	   presence	   of	   the	   semisynthetic	  
thiothepa	   derivative.	   Instead,	   analysis	   of	   the	   pharmaceutical	   preparation	  
Ukrain	   revealed	   well-­‐known	   alkaloids	   from	   Chelidonium	  majus,	   including	  
chelidonine,	   chelerythrine,	   sanguinarine,	   protopine,	   and	   allocryptopine.	  
Since	   1990,	   preclinical	   investigations	   have	   pointed	   to	   the	   promising	  
antineoplastic	   activity	   of	   Ukrain.36-­‐38	   These	   studies	   suggested	   that	  Ukrain	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exerts	   selective	   cytotoxic	   effects	   on	   tumor	   cells	   without	   adverse	   side	  
effects	  on	  normal	  cells	  and	  tissues.	  However,	  observations	  on	  the	  selective	  
cytotoxicity	  of	  Ukrain	  are	  still	  subject	  to	  controversy.39	  
	  
1.1.3	  	  
Alkaloids	  used	  for	  MDR	  reversal	  
	  
1.1.3.1	  	  
Cinchona	  alkaloids	  
	  
Cinchona	   alkaloids	   isolated	   from	   the	   bark	   of	   several	   species	   of	   cinchona	  
trees	  have	  been	  extensively	  studied	  for	  their	  antimalarial	  properties	  [197].	  
Later,	  quinine	  (25)	  and	  cinchonine	  (26)	  (Figure	  1.6)	  were	  shown	  to	  have	  a	  
potential	  use	  in	  reversing	  multidrug	  resistance	  in	  cancer	  patients,	  and	  are	  
considered	  as	  first-­‐generation	  blockers.	   In	  addition	  to	  their	  known	  role	  as	  
inhibitors	   of	   Pgp,	   these	   chemomodulators	   have	   been	   suggested	   to	   have	  
intracellular	  protein	  targets	  that	  may	  be	  involved	  in	  drug	  distribution.40-­‐42	  
	  
could be used safely in combination with various chemotherapeutic agents,
including mitoxantrone, vincristine, adriamycin, or paclitaxel for the treatment
of clinically resistant acute leukemias, advanced breast cancer, or non-Hodgkin’s
lymphomas [201–203]. Phase III clinical trials in patients with acute leukemia
showedmodest results [204,205]. In preclinical studies, cinchoninewas reported to
be more efficient than quinine as an anti-MDR agent [200,206]. A Phase I trial
showed that cinchonine in combination with doxorubicin, vinblastine, cyclopho-
sphamide, and methylprednisolone could be safely administered in patients with
malignant lymphoid diseases and an MDR reversing activity was identified in the
serum from every patient [207]. The development of third-generation drugs, which
are highly specific for Pgp and which seem to have only modest effects on drug
clearance, include dofequidar fumarate, tariquidar, zosuquidar, and laniquidar,
which are in phase I/II trials and show promise for future treatment.
2.4.2
Dofequidar Fumarate (MS-209)
MS-209 (27, Figure 2.7), a quinoline derivative, was developed specifically as a
selective Pgp inhibitor [208]. MS-209 alone has no antitumor activity and did not
show serious toxicity at doses up to 2000 mg/kg. In preclinical models, MS-209
enhanced the antitumor effects of anticancer agents including adriamycin, vincris-
tine, paclitaxel, and docetaxel in multidrug-resistant tumor cell lines [209]. It also
enhanced the efficacy of anticancer agents against cancer cells sensitive to anticancer
agents. MS-209 in combination with adriamycin wasmore effective than adriamycin
alone against transplanted murine tumors, multidrug-resistant murine tumors, and
human tumors transplanted to nudemice [210]. Aphase I trial designed to determine
the safety and tolerability of MS-209 when given in combination with docetaxel
showed no significant differences in docetaxel-induced nadir neutrophil and platelet
counts in the absence or presence of MS-209 [211]. A clinical trial including MS-209
in combination with cyclophosphamide, doxorubicin, and fluorouracil therapy for
patients with advanced or recurrent breast cancer showed promising efficacy in
patients who had not received prior therapy [212]. By March 2003, phase II trials in
breast and NSCLC had been initiated [213].
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Fig. 2.7 Chemical structures of cinchona alkaloids and MS-209.
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1.1.3.2	  
	  Dofequidar	  Fumarate	  (MS-­‐209)	  
	  
MS-­‐209	  (27,	  Figure	  1.6),	  a	  quin line	  deriv tive,	  wa 	  develop d	  specifically	  
as	  a	  selective	  Pgp	   inhib tor	   [208].	  MS-­‐209	  alone	  has	  no	  antitumor	  activity	  
and	  did	  not	  show	  serious	  toxicity	   t	  doses	  up	  to	  2000	  mg/kg.	  In	  preclinical	  
models,	   MS-­‐209	   enhanced	   the	   antitumor	   effects	   of	   anticancer	   agents	  
including	   adr amycin,	   vincristine,	   paclitaxel,	   and	   docetaxel	   in	   multidrug-­‐
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resistant	  tumor	  cell	  lines.	  It	  also	  enhanced	  the	  efficacy	  of	  anticancer	  agents	  
against	  cancer	  cells	  sensitive	  to	  anticancer	  agents.	  MS-­‐209	  in	  combination	  
with	  adriamycin	  was	  more	  effective	  than	  adriamycin	  alone	  against	  	  
transplanted	   murine	   tumors,	   multidrug-­‐resistant	   murine	   tumors,	   and	  
human	  tumors	  transplanted	  to	  nude	  mice.43	  
	  
1.1.4	  
References	  
	  
1.	  Roberts,	  M.F.	  and	  Wink,	  M.	   (1998)	  Alkaloids	  –	  Biochemistry,	  Ecological	  
Functions	  and	  Medical	  Applications,	  Plenum	  Press,	  New	  York.	  
2.	  Wink,	  M.,	  The	  Alkaloids:	  Chemistry	  and	  Biology,	  1995,	  43,	  Academic	  
Press,	  San	  Diego,	  1–118.	  
3.	  Wink,	  M.,	  Schmeller,	  T.,	  Latz-­‐Bruning,B.,	  Journal	  of	  Chemical	  Ecology,	  
1964,	  24,	  1881–1937.	  
4.	  Wink,	  M.	  Phytochemistry,	  2003,	  64,	  3–19.	  
5.	  Wink,	  M.	  and	  Schimmer,	  O.	  (1999)	  Modes	  of	  action	  of	  defensive	  
secondary	  metabolites.	  In	  Wink	  M.	  (ed.):	  Function	  of	  Plant	  Secondary	  
Metabolites	  and	  Their	  Exploitation	  in	  Biotechnology,	  Vol.	  3	  Sheffield	  
Academic	  Press	  and	  CRC	  Press, Annual	  Plant	  Reviews,	  17–133.	  
6.	  Brown,	  K.S.	  and	  Trigo,	  J.L.	  (1995)	  The	  ecological	  activity	  of	  alkaloids.	  
Cordell	  G.	  (ed.):	  The	  Alkaloids,	  Vol.	  47	  Academic	  Press,	  San	  Diego,	  	  227–354	  
7.	  Pezzuto,	  J.	  M.	  Biochemical	  Pharmacology,	  1997,	  53,	  121–133.	  
8.	  Cragg,	  G.	  M.,	  Newman,	  D.	  J.,	  Snader,	  K.	  M.	  Journal	  of	  Natural	  Products,	  
1997,	  60,	  52–60.	  
9.	  Beck,	  W.	  T.	  (1980)	  Biochemical	  Pharmacology,	  29,	  2333–2337.	  
10.	  Chan,	  S.	  Y.,	  Worth,	  R.,	  Ochs,	   S.	   (1980)	   Journal	  of	  Neurobiology,	  1997,	  
11,	  251–264.	  
11.	  Fellous,	  A.,	  Ohayon,	  R.,	  Vacassin,	  T.,	  Binet,	  S.,	  Lataste,	  H.,	  Krikorian,	  A.,	  
Couzinier,	  J.	  P.,	  Meininger,	  V.	  28	  Lobert,	  S.,	  Ingram,	  J.	  W.,	  Hill,	  B.	  T.,	  Correia,	  
J.	  J.	  Molecular	  Pharmacology,1998,	  53,	  908–915.	  
12.	  Eyre,	  D.,	  Harrison,	  J.,	  Lythgoe,	  B.,	  Journal	  of	  Chemical	  Society,	  1967,	  6,	  
 13 
452–462.	  
13.	  Wani,	  M.	  C.,	  Taylor,	  H.	  L.,	  Wall,	  M.	  E.,	  Coggon,	  P.,	  McPhail,	  A.	  T.,	  Journal	  
of	  the	  American	  Chemical	  Society,	  1971,	  93,	  2325–2327.	  
14.	   Suffness,	  M.	   (1995)	   Taxol:	   Science	   and	   Applications,	   CRC	   Press,	   Boca	  
Raton,	  FL.	  
15.	   Kingston,	   D.	   G.,	   Hawkins,	   D.	   R.,	   Ovington,	   L.,	   Journal	   of	   Natural	  
Products,	  1982,	  45,	  466–470.	  	  
16.	   Kingston,	   D.	   G.,	   Hawkins,	   D.	   R.,	   Ovington,	   L.,	   Journal	   of	   Natural	  
Products,	  1982,	  45,	  466–470.	  
17.	  Nicolaou,	  K.	  C.,	  Yang,	  Z.,	  Liu,	  J.	  J.,	  Ueno,	  H.,	  Nantermet,	  P.	  G.,	  Guy,	  R.	  K.,	  
Claiborne,	  C.	  F.,	  Renaud,	  J.,	  Couladouros,	  E.	  A.,	  Paulvannan,	  K.,	  Sorensen,	  E.	  
J.	  	  Nature,	  1994,	  367,	  630–634.	  
18.	   Baum,	   S.	   G.,	   Wittner,	   M.,	   Nadler,	   J.	   P.,	   Horwitz,	   S.	   B.,	   Dennis,	   J.	   E.,	  
Schiff,	   P.	   B.,	   Tanowitz,	   H.	   B	   Proceedings	   of	   the	   National	   Academy	   of	  
Sciences	  of	  the	  United	  States	  of	  America,	  1994,	  78,	  4571–4575.	  
19.	  Letourneau,	  P.	  C.	  and	  Ressler,	  A.	  H.,	  The	  Journal	  of	  Cell	  Biology,	  1994,	  
98,	  1355–1362.	  
20.	  Roytta,	  M.,	  Laine,	  K.	  M.,	  Harkonen,	  P.,	  Prostate,	  1987,	  11,	  95–106.	  
21.	  Verweij,	  J.,	  Journal	  of	  Clinical	  Oncology,	  2005,	  23,	  5420–5423.	  
22.	   Minuzzo,	   M.,	   Marchini,	   S.,	   Broggini,	   M.,	   Faircloth,	   G.,	   D’Incalci,	   M.,	  
Mantovani,	   R.,	   Proceedings	   of	   the	   National	   Academy	   of	   Sciences	   of	   the	  
United	  States	  of	  America,	  2000,	  97,	  6780–6784.	  
23.	   van	   Kesteren,	   C.,	   de	   Vooght,	  M.	  M.,	   Lopez-­‐Lazaro,	   L.,	  Mathot,	   R.	   A.,	  
Schellens,	   J.	   H.,	   Jimeno,	   J.	  M.,	   Beijnen,	   J.	   H.,	   Anticancer	  Drugs,	  2000,	  14,	  
487–502.	  
24.	   Seynaeve,	   C.	   M.,	   Kazanietz,	   M.	   G.,	   Blumberg,	   P.	   M.,	   Sausville,	   E.	   A.,	  
Worland,	  P.	  J.,	  Molecular	  Pharmacology,	  1994,	  45,	  1207–1214.	  
25.Hotte,	  S.	  J.,	  Oza,	  A.,	  Winquist,	  E.	  W.,	  Moore,	  M.,	  Chen,	  E.	  X.,	  Brown,	  S.,	  
Pond,	  G.	  R.,	  Dancey,	  J.	  E.,	  Hirte,	  H.	  W.,	  Annals	  of	  Oncology,	  2006,	  17,	  334–
340.	  
26.	  Kortmansky,	  J.,	  Shah,	  M.	  A.,	  Kaubisch,	  A.,	  Weyerbacher,	  A.,	  Yi,	  S.,	  Tong,	  
W.,	  Sowers,	  R.,	  Gonen,	  M.,	  O’Reilly,	  E.,	  Kemeny,	  N.,	  Ilson,	  D.	  I.,	  Saltz,	  L.	  B.,	  
 14 
Maki,	   R.	   G.,	   Kelsen,	   D.	   P.,	   Schwartz,	   G.	   K.,	   Journal	   of	   Clinical	   Oncology,	  
2005,	  23,	  1875–1884.	  	  
27.	   Jurayj,	   J.,	   Haugwitz,	   R.	   D.,	   Varma,	   R.	   K.,	   Paull,	   K.	   D.,	   Barrett,	   J.	   F.,	  
Cushman,	  M.,	  Journal	  of	  Medicinal	  Chemistry,1994,	  	  37,	  2190–2197.	  
28.	   Kohn,	   K.	   W.,	   Waring,	   M.	   J.,	   Glaubiger,	   D.,	   Friedman,	   C.	   A.,	   Cancer	  
Research,	  1995,	  35,	  71–76.	  
29.	  Froelich-­‐Ammon,	  S.	   J.,	  Patchan,	  M.	  W.,	  Osheroff,	  N.,	  Thompson,	  R.	  B.,	  
The	  Journal	  of	  Biological	  Chemistry,	  1995,	  270,	  14998–15004.	  
30.	  Macdonald,	  P.	  L.	  and	  Robertson,	  A.	  V.,	  	  Australian	  Journal	  of	  Chemistry,	  
1966,	  19,	  275–281.	  
31.	  Scarffe,	  J.	  H.,	  Beaumont,	  A.	  R.,	  Crowther,	  D.,	  Cancer	  Treatment	  Report,	  
1983,	  67,	  93–94.	  
32.	  David-­‐Cordonnier,	  M.	  H.,	   Laine,	  W.,	  Kouach,	  M.,	  Briand,	  G.,	  Vezin,	  H.,	  
Gaslonde,	  T.,	  Michel,	  S.,	  Doan	  Thi	  Mai,	  H.,	  Tillequin,	  F.,	  Koch,	  M.,	  Leonce,	  S.,	  
Pierre,	  A.,	  Bailly,	  C.,	  Bioorganic	  and	  Medicinal	  Chemistry,	  1994,	  12,	  23–29.	  
33.	   Boyland,	   E.	   and	  Boyland,	  M.	   E.,	   Biochemistry	   Journal,	  1937,	  31,	   454–	  
460.	  
34.	  Seed,	  L.,	  Slaughter,	  D.	  P.,	  Limarzi,	  L.	  R.,	  Surgery,	  1940,	  	  7,	  696–709.	  
35Siemann,	   D.	   W.	   and	   Rojiani,	   A.	   M.,	   International	   Journal	   of	   Radiation	  
Oncology,	  Biology,	  Physics,	  2002,	  53,	  164–171.	  
36.	  Habermehl,	  D.,	  Kammerer,	  B.,	  Handrick,	  R.,	  Eldh,	  T.,	  Gruber,	  C.,	  Cordes,	  
N.,	  Daniel,	  P.	  T.,	  Plasswilm,	  L.,	  Bamberg,	  M.,	  Belka,	  C.,	  Jendrossek,	  V.,	  BMC	  
Cancer,	  2006,	  6,	  14.	  
37.	  Hohenwarter,	  O.,	  Strutzenberger,	  K.,	  Katinger,	  H.,	  Liepins,	  A.,	  Nowicky,	  
J.	  W.,	   	  Drugs	  under	  Experimental	  and	  Clinical	  Research,	  1992,	  18	   (Suppl.),	  
1–4.	  
38.	  Cordes,	  N.,	  Plasswilm,	  L.,	  Bamberg,	  M.,	  Rodemann,	  H.	  P.,	  International	  
Journal	  of	  Radiation	  Biology,	  2002,	  78,	  17–27.	  
39.	  Ernst,	  E.	  and	  Schmidt,	  K.,	  BMC	  Cancer,	  2005,	  5,	  69.	  
40.	  Lehnert,	  M.,	  Dalton,	  W.	  S.,	  Roe,	  D.,	  Emerson,	  S.,	  Salmon,	  S.	  E.,	  Blood,	  
1991,	  77,	  348–354.	  
41.	   Bennis,	   S.,	   Ichas,	   F.,	   Robert,	   J.,	   International	   Journal	   of	   Cancer,	  1995,	  
 15 
62,	  283–290.	  
42.	  Genne,	  P.,	  Duchamp,	  O.,	  Solary,	  E.,	  Magnette,	  J.,	  Belon,	  J.	  P.,	  Chauffert,	  
B.,	  	  Anticancer	  Drug	  Design,	  1995,	  10,	  103–118.	  
43.	   Dieras,	   V.,	   Bonneterre,	   J.,	   Laurence,	   V.,	   Degardin,	   M.,	   Pierga,	   J.	   Y.,	  
Bonneterre,	  M.	  E.,	  Marreaud,	  S.,	  Lacombe,	  D.,	  Fumoleau,	  P.,	  Clinical	  Cancer	  
Research,	  1995,	  11,	  6256–	  6260.	  
 16 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.2	  
Topoisomerases	  and	  their	  inhibitors	  
	  
DNA	  topoisomerases	  are	  marvelous	  molecular	  machines	  that	  manage	  the	  
topological	  state	  of	  the	  DNA	  in	  the	  cell.	  These	  enzymes	  accomplish	  this	  feat	  
by	  either	  passing	  one	  strand	  of	   the	  DNA	  through	  a	  break	   in	  the	  opposing	  
strand	  (type	  I	  subfamily)	  or	  by	  passing	  a	  region	  of	  duplex	  from	  the	  same	  or	  
a	   different	  molecule	   through	   a	   double-­‐stranded	   gap	   generated	   in	   a	   DNA	  
(type	   II	   subfamily).	   Besides	   altering	   the	   supercoiling	   of	   a	   closed	   DNA	  
domain,	   the	   strand	  passing	  activities	  of	   topoisomerases	   can	  promote	   the	  
catenation	   and	   decatenation	   of	   circular	   DNAs	   or	   the	   disentanglement	   of	  
intertwined	   linear	   chromosomes.	   The	   fundamental	   need	   for	  
topoisomerases	  derives	  from	  the	  double	  helical	  structure	  of	  DNA.	  For	  most	  
processes	   that	   must	   access	   the	   information	   stored	   in	   the	   DNA,	   the	   two	  
strands	  of	  the	  helix	  must	  separate	  either	  temporarily,	  as	  in	  transcription	  or	  
recombination,	   or	   permanently,	   as	   in	   replication.	   The	   circular	   nature	   of	  
bacterial	   chromosomes	   and	   the	   large	   size	   of	   eukaryotic	   DNA	   molecules	  
preclude	   a	   simple	  winding	   solution	   to	  many	   of	   the	   topological	   problems	  
that	  accompany	  the	  DNA	  transactions	  that	  occur	  in	  the	  cell.1	  Thus,	  during	  
DNA	   replication,	   the	   two	   strands	   of	   the	   DNA	   must	   become	   completely	  
unlinked	   by	   topoisomerases,	   and	   during	   transcription,	   the	   translocating	  
RNA	  polymerase	  generates	   supercoiling	   tension	   in	   the	  DNA	   that	  must	  be	  
relaxed.1,2	   The	   association	   of	   DNA	   with	   histones	   and	   other	   proteins	  
introduces	   supercoiling	   that	   requires	   relaxation	   by	   topoisomerases.	   The	  
immense	  interest	  in	  topoisomerases	  in	  recent	  years	  derives	  not	  only	  from	  
the	   recognition	   of	   their	   crucial	   role	   in	  managing	   DNA	   topology,	   but	   also	  
from	   two	   major	   advances	   in	   the	   field.	   First,	   a	   wide	   variety	   of	  
topoisomerase-­‐targeted	   drugs	   have	   been	   identified,	   many	   of	   which	  
generate	  cytotoxic	  lesions	  by	  trapping	  the	  enzymes	  in	  covalent	  complexes	  
on	  the	  DNA.	  These	  topoisomerase	  poisons	  include	  both	  antimicrobials	  and	  
anticancer	  chemotherapeutics,	  some	  of	  which	  are	  currently	  in	  widespread	  
clinical	  use.	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DNA	  cleavage	  by	  all	  topoisomerases	  is	  accompanied	  by	  the	  formation	  of	  a	  
transient	  phosphodiester	  bond	  between	  a	   tyrosine	   residue	   in	   the	  protein	  
and	  one	  of	  the	  ends	  of	  the	  broken	  strand.	  DNA	  topology	  can	  be	  modified	  
during	   the	   lifetime	   of	   the	   covalent	   intermediate,	   and	   the	   enzyme	   is	  
released	   as	   the	   DNA	   is	   religated.	   Those	   enzymes	   that	   cleave	   only	   one	  
strand	  of	  the	  DNA	  are	  defined	  as	  type	  I	  and	  are	  further	  classified	  as	  either	  
type	  IA	  subfamily	  members	  if	  the	  protein	  link	  is	  to	  a	  5ʹ′	  phosphate	  (formerly	  
called	  type	  I-­‐5ʹ′)	  or	  type	  IB	  subfamily	  members	  if	  the	  protein	  is	  attached	  to	  a	  
3ʹ′	  phosphate	  (formerly	  called	  type	  I-­‐3ʹ′).	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Tab	  2.1	  
	  
Topoisomerases	  that	  cleave	  both	  strands	  to	  generate	  a	  staggered	  double-­‐
strand	   break	   are	   grouped	   together	   in	   the	   type	   II	   subfamily	   of	  
topoisomerases.	  Further	  division	  of	   the	  subfamilies	   is	  based	  on	  structural	  
considerations.	  Table	  2.1	  lists	  representatives	  of	  the	  various	  subfamilies	  of	  
both	  prokaryotic	  and	  eukaryotic	  topoisomerases.3	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TABLE 1 Classification of Topoisomerases
Subfamily Subunit Size(s)
Topoisomerasea type structure (aa)b
Eubacterial DNA topoisomerase I (E. coli) IA Monomer 865
Eubacterial DNA topoisomerase III (E. coli) IA Monomer 653
Yeast DNA topoisomerase III (S. cerevisiae) IA Monomer 656
Mammalian DNA topoisomerase IIIα (human) IA Monomer 1001
Mammalian DNA topoisomerase IIIβ (human) IA Monomer 862
Eubacterial and archaeal reverse DNA gyrase IA Monomer 1247
(Sulfolobus acidocaldarius)
Eubacterial reverse gyrase (Methanopyrus IA Heterodimer A, 358
kandleri)c B, 1221
Eukaryotic DNA topoisomerase I (human) IB Monomer 765
Poxvirus DNA topoisomerase (vaccinia) IB Monomer 314
Hyperthermophilic eubacterial DNA IB Monomer —e
topoisomerase V (Methanopyrus kandleri)d
Eubacterial DNA gyrase (E. coli) IIA A2B2 hetero- GyrA, 875
tetramer GyrB, 804
Eubacterial DNA topoisomerase IV (E. coli) IIA C2E2 hetero- ParC, 752
tetramer ParE, 630
Yeast DNA topoisomerase II (S. cerevisiae) IIA Homodimer 1428
Mammalian DNA topoisomerase IIα (human) IIA Homodimer 1531
Mammalian DNA topoisomerase IIβ (human) IIA Homodimer 1626
Archaeal DNA topoisomerase VI (Sulfolobus IIB A2B2 hetero- A, 389
shibatae) tetramer B, 530
aThe source of the most extensively studied family member is given in parentheses. The top portion of the table lists
the type I topoisomerases; the bottom portion the type II enzymes.
bThe subunit sizes are those corresponding to the most extensively studied family member.
cIncluded as the only known reverse gyrase with a heterodimeric structure.
dOnly known representative at present. Probably present in other hyperthermophilic eubacteria.
eGene not yet cloned; purified protein has a molecular size of 110 kDa.
prokaryotic domains of life, theMethanopyrus kandleri reverse gyrase is included
in the table because it is the only known example of a heterodimeric type IA en-
zyme (21). The availability of complete genome sequences for many bacteria and
yeast indicates that no additional homologues of the known enzymes are likely
to be discovered. It remains to be seen whether new and distinct subclasses of
topoisomerases will be identified in the future.
Besides those topoisomerases listed in Table 1, a number of viral or plasmid-
encoded topoisomerases have been described through the years. Thus, in addition
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Like	   the	   yeasts,	   all	   higher	   eukaryotes	   contain	   a	   single	   topoisomerase	   I	  
enzyme	   that	   plays	   a	   major	   role	   in	   supporting	   fork	   movement	   during	  
replication	  and	  in	  relaxing	  transcription	  related	  supercoils.	  Topoisomerase	  I	  
is	   indispensable	   during	   development	   and	   probably	   also	   during	   cell	  
division.4,5	   The	   realization	   that	   chromosome	   condensation	   during	  mitosis	  
involves	   the	   generation	  of	   right-­‐handed	   solenoidal	   supercoils	   by	   proteins	  
belonging	  to	   the	  SMC	  family	   6	  means	  that	   topoisomerase	   I	  would	  also	  be	  
required	   at	   this	   stage	   of	   the	   cell	   cycle	   to	   relax	   compensatory	   negative	  
supercoils.	  	  
	  
1.2.1	  	  
Human	  DNA	  Topoisomerase	  I	  
	  
This	  section	  mainly	  focuses	  on	  the	  properties	  and	  structure	  of	  human	  DNA	  
topoisomerase	  I,	  the	  best	  studied	  of	  the	  cellular	  type	  IB	  enzymes.	  Based	  on	  
sequence	  comparisons,	  it	  is	  likely	  that	  most	  features	  described	  here	  for	  the	  
human	   enzyme	   apply	   to	   the	   cellular	   topoisomerases	   I	   from	   other	  
eukaryotic	  species	  as	  well.	  
Structure	   Based	   on	   conservation	   of	   sequence,	   sensitivity	   to	   limited	  
proteolysis,	   hydrodynamic	   properties,	   and	   fragment	   reconstitution	  
experiments,	   the	   91-­‐kDa	   human	   topoisomerase	   I	   protein	   has	   been	  
subdivided	  into	  four	  distinct	  domains	  7,8	  	  (Figure	  2.1).	  	  
	  
	  
	  
	  
	  
Fig	  2.1	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Figure 4 Domain structure of human topoisomerase I. Human topoisomerase I comprises
an N-terminal domain (open box), a core domain (gray box), a linker domain (diagonally
striped box), and a C-terminal domain (black box). The domain boundaries are based on
sequence alignments, limited proteolysis studies, and the crystal structures of the protein.
The solution of the crystal structure led to the division of the core domain into three
subdomains (see Figure 5). The properties of the four domains are summarized in the
lower portion of the figure.
T-antigen, certain transcription factors, p53, and theWRN protein (113–124). The
N-terminal domain is followed by a highly conserved, 421 amino acid core domain
that contains all of the catalytic residues except the active site tyrosine (125). A
protease-sensitive and poorly conserved linker domain comprising 77 amino acids
connects the core domain to the 53 amino acid C-terminal domain. An active form
of the enzyme can be reconstituted by mixing together fragments corresponding
approximately to the core domain (residues 175 to 659) and the C-terminal domain
(residues 713 to 765), and thus the linker is dispensable for relaxation activity in
vitro. The active site Tyr723 is found within the C-terminal domain.
The crystal structures of several forms of the human enzyme with both non-
covalently and covalently bound DNA have been determined (125–128). These
co-crystal structures represent the only examples to date of a topoisomerase con-
taining bound DNA. Two views of the structure of human topoisomerase I non-
covalently complexed with a 22 base pair DNA are shown in Figure 5. Although
the crystals were grown with an N-terminal truncated active form of the protein
missing the first 174 amino acids, the X-ray density was only interpretable be-
ginning at residue 215, and thus the entire N-terminal domain is missing from
the structure (see Figure 4). Recently the crystal structure of another form of the
protein extends the structure back to amino acid residue 203 (not shown) (126).
The bi-lobed protein clamps tightly around the DNA with contacts between the
protein and the DNA phosphate backbone that extend over 14 base pairs. Most of
the contacts are clustered around the five base pairs upstream (−5 to −1) of the
cleavage site, which is defined as occurring between DNA residues −1 and +1.
The domain structure of the protein, including the subdivision of the core domain
into core subdomains I, II, and III, is shown by the color scheme in Figure 5. One
of the lobes of the protein comprises core subdomains I and II (yellow and blue)
and forms what has been referred to as the “cap” of the protein (125). The front
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The	  N-­‐terminal	  214	  aminoacids	  of	  the	  human	  enzyme	  are	  dispensable	  for	  
relaxation	  activity	   in	  vitro	  and	  constitute	  a	  hydrophilic,	  unstructured,	  and	  
highly	   protease-­‐sensitive	   region	   of	   the	   protein.	   Contained	   with	   the	   N-­‐
terminal	   domain	   are	   four	   nuclear	   localization	   signals	   and	   sites	   for	  
interaction	   with	   other	   cellular	   proteins,	   including	   such	   proteins	   as	  
nucleolin,	  SV40	  T-­‐antigen,	  certain	  transcription	  factors,	  p53,	  and	  the	  WRN	  
protein.	   The	   N-­‐terminal	   domain	   is	   followed	   by	   a	   highly	   conserved,	   421	  
amino	  acid	   core	  domain	   that	   contains	   all	   of	   the	   catalytic	   residues	  except	  
the	   active	   site	   tyrosine.	   A	   protease-­‐sensitive	   and	   poorly	   conserved	   linker	  
domain	   comprising	   77	   amino	   acids	   connects	   the	   core	   domain	   to	   the	   53	  
amino	   acid	   C-­‐terminal	   domain.	   An	   active	   form	   of	   the	   enzyme	   can	   be	  
reconstituted	  by	  mixing	   together	   fragments	   corresponding	   approximately	  
to	   the	   core	   domain	   (residues	   175	   to	   659)	   and	   the	   C-­‐terminal	   domain	  
(residues	   713	   to	   765),	   and	   thus	   the	   linker	   is	   dispensable	   for	   relaxation	  
activity	   in	   vitro.	   The	   active	   site	   Tyr723	   is	   found	   within	   the	   C-­‐terminal	  
domain.	  The	  crystal	  structures	  of	  several	  forms	  of	  the	  human	  enzyme	  with	  
both	   non-­‐	   covalently	   and	   covalently	   bound	   DNA	   have	   been	   determined.	  
These	   co-­‐crystal	   structures	   represent	   the	   only	   examples	   to	   date	   of	   a	  
topoisomerase	   containing	   bound	   DNA.	   Two	   views	   of	   the	   structure	   of	  
human	  topoisomerase	  I	  non-­‐covalently	  complexed	  with	  a	  22	  base	  pair	  DNA	  
are	   shown	   in	   Figure	   2.2.	   Although	   the	   crystals	   were	   grown	   with	   an	   N-­‐
terminal	   truncated	   active	   form	   of	   the	   protein	   missing	   the	   first	   174	  
aminoacids,	   the	  X-­‐ray	  density	  was	  only	   interpretable	  beginning	  at	  residue	  
215,	  and	  thus	   the	  entire	  N-­‐terminal	  domain	   is	  missing	   from	  the	  structure	  
(see	   Figure	   2.1).	   Recently	   the	   crystal	   structure	   of	   another	   form	   of	   the	  
protein	  extends	  the	  structure	  back	  to	  amino	  acid	  residue	  203.	  The	  bi-­‐lobed	  
protein	  clamps	  tightly	  around	  the	  DNA	  with	  contacts	  between	  the	  protein	  
and	  the	  DNA	  phosphate	  backbone	  that	  extend	  over	  14	  base	  pairs.	  Most	  of	  
the	  contacts	  are	  clustered	  around	  the	  five	  base	  pairs	  upstream	  (−5	  to	  −1)	  
of	   the	  cleavage	  site,	  which	   is	  defined	  as	  occurring	  between	  DNA	  residues	  
−1	  and	  +1.	  The	  domain	  structure	  of	   the	  protein,	   including	  the	  subdivision	  
of	  the	  core	  domain	  into	  core	  subdomains	  I,	  II,	  and	  III,	  is	  shown	  by	  the	  color	  
 20 
scheme	   in	   Figure	   2.2.	   One	   of	   the	   lobes	   of	   the	   protein	   comprises	   core	  
subdomains	  I	  and	  II	  (yellow	  and	  blue)	  and	  forms	  what	  has	  been	  referred	  to	  
as	  the	  “cap”	  of	  the	  protein.	  The	  front	  end	  of	  the	  cap	  consists	  of	  a	  pair	  of	  
long	  α-­‐helices	  in	  a	  V-­‐shaped	  configuration	  that	  had	  been	  seen	  earlier	  in	  the	  
structure	  of	   a	   26-­‐kDa	  N-­‐terminal	   fragment	  of	   yeast	   topoisomerase	   I.	   The	  
other	   lobe	   forms	   a	   base	   that	   cradles	   the	   DNA	   and	   consists	   of	   core	  
subdomain	  III	  (red)	  and	  the	  C-­‐terminal	  domain	  (green).9-­‐13	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Fig	  2.2	  
This	   second	   lobe	   is	   connected	   to	   the	   cap	   by	   a	   long	   α-­‐helix	   labeled	   the	  
“connector”	  in	  Figure	  2.2a.	  On	  the	  side	  opposite	  to	  this	  α-­‐helix	  are	  a	  pair	  of	  
opposing	   loops	  called	   the	  “lips”	   that	   interact	  via	   six	  amino	  acids	  and	  one	  
salt	   bridge	   to	   connect	   the	   cap	   to	   the	   base	   of	   the	   protein.	   Opening	   and	  
closing	  of	  the	  protein	  clamp	  during	  DNA	  binding	  and	  release	  must	  involve	  
the	  breaking	  of	  this	  interaction	  between	  the	  lips	  and	  the	  lifting	  of	  the	  cap	  
away	  from	  the	  base	  as	  shown	  by	  the	  opposing	  arrows	  in	  Figure	  2.2b.	  The	  
hinge	   for	   this	  movement	  may	   be	   located	   at	   the	   top	   of	   the	   connector	   α-­‐
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helix	  as	  shown	  in	  Figure	  2.2b	  (putative	  hinge).13	  	  The	  dispensable	  77	  amino	  
acid	   linker	   domain	   (orange)	   is	   a	   coiled-­‐coil	   structure	   that	   protrudes	  
conspicuously	  from	  the	  base	  of	  the	  protein.	  Despite	  the	  clustering	  of	  basic	  
amino	  acids	  on	  the	  DNA	  proximal	  sides	  of	  both	  the	  linker	  and	  the	  V-­‐shaped	  
α-­‐helices	  of	  the	  cap,	  neither	  region	  of	  the	  protein	  is	  in	  direct	  contact	  with	  
the	   DNA	   in	   the	   structure.	   Although	   it	   was	   necessary	   to	   inactivate	   the	  
enzyme	   by	   replacing	   the	   active	   site	   Tyr723	  with	   phenylalanine	   to	   obtain	  
crystals,	   by	   modeling	   a	   tyrosine	   in	   place	   of	   the	   phenylalanine	   in	   the	  
structure,	  it	  can	  be	  seen	  that	  the	  tyrosine	  side	  chain	  is	  buried	  between	  core	  
subdomain	   III	   and	   the	   C-­‐terminal	   domain	   and	   is	   close	   to	   the	   scissile	  
phosphate	  (Figure	  2.2a).	  
Despite	   very	   little	   sequence	   homology,	   most	   of	   core	   subdomain	   III	   of	  
human	   topoisomerase	   I	   (residues	   440–614)	   superimposes	   structurally	   on	  
the	  catalytic	  core	  region	  of	  a	  family	  of	  tyrosine	  recombinases	  that	  includes	  
bacteriophages	  HP1	  and	  λ	   integrases,	  and	  E.	   coli	  XerD	  and	  bacteriophage	  
P1	   Cre	   recombinases.12-­‐13	   In	   addition,	   a	   region	   near	   the	   active	   site	   of	  
human	   topoisomerase	   I	   (residues	   717–724)	   appears	   to	   correspond	  
structurally	  to	  the	  active	  site	  region	  of	  the	  recombinases.	  In	  retrospect,	  this	  
structural	   similarity	   is	   not	   surprising	   in	   view	   of	   the	   many	   biochemical	  
properties	  shared	  by	  the	  two	  classes	  of	  enzymes,	  including	  a	  lack	  of	  Mg(II)	  
dependence	   and	   the	   formation	   of	   a	   covalent	   intermediate	   involving	  
attachment	  of	  the	  enzyme	  to	  the	  3ʹ′	  phosphate	  of	  the	  cleaved	  strand.	  Most	  
strikingly,	  the	  architecture	  of	  the	  active	  sites	  for	  the	  tyrosine	  recombinases	  
are	   very	   similar	   to	  what	   is	   found	   for	  human	   topoisomerase	   I.14	   Thus,	   the	  
tyrosine	   recombinases	   and	   type	   IB	   topoisomerases	   possess	   functional	  
cores	  that	  use	  the	  same	  chemistry	  to	  carry	  out	  cleavage	  and	  religation.	  The	  
two	   classes	   of	   enzymes	   are	   distinguishable	   by	   what	   occurs	   during	   the	  
lifetime	   of	   the	   cleaved	   intermediate.	   The	   topoisomerases	   permit	  
topological	   changes	   in	   the	   DNA	   and	   restore	   the	   original	   DNA	   linkage,	  
whereas	   the	   recombinases	   promote	   strand	   exchange	   and	   join	   the	   DNA	  
ends	  to	  new	  partners.15	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Substrate	  Specificity	   The	  substrate	  specificity	  of	  eukaryotic	  
	  topoisomerases	  I	  has	  been	  characterized	  at	  both	  the	  nucleotide	  sequence	  
level	  and	  at	  the	  level	  of	  DNA	  tertiary	  structure.	  By	  mapping	  cleavage	  sites	  
using	  detergent	  to	  trap	  the	  covalent	  complex,15,16	  the	  enzymes	  were	  found	  
to	  nick	   the	  DNA	  with	   a	   preference	   for	   a	   combination	  of	   nucleotides	   that	  
extends	   from	  positions	  −4	   to	  −1.	  The	  preferred	  nucleotides	   in	   the	  scissile	  
strand	   are	   5ʹ′-­‐(A/T)(G/C)(A/T)T-­‐3ʹ′	  with	   the	   enzyme	   covalently	   attached	   to	  
the	   −1	   T	   residue.	  Occasionally	   a	   C	   residue	   is	   found	   at	   the	   −1	   position.	   A	  
particularly	   strong	   cleavage	   site	   for	   all	   eukaryotic	   topoisomerases	   I	   was	  
identified	  by	  Westergaard	  and	  his	  colleagues	  in	  the	  rDNA	  repeats	  found	  in	  
Tetrahymena	   pyriformis,17	   and	   this	   sequence,	   which	   has	   a	   T	   at	   the	   −1	  
position,	   formed	   the	   basis	   for	   designing	   the	   22	   base	   pair	   oligonucleotide	  
used	  in	  the	  crystallographic	  studies	  .15	  
The	   only	   base-­‐specific	   contact	   between	   the	   protein	   and	   the	   DNA	   in	   the	  
crystal	   structures	   involves	  a	  hydrogen-­‐bond	  between	  Lys532	  and	   the	  O-­‐2	  
atom	   of	   the	   strongly	   preferred	   thymine	   base	   located	   at	   the	   −1	   position.	  
This	   base-­‐specific	   contact	  would	   seem	   to	   provide	   a	   good	   explanation	   for	  
the	   preference	   of	   a	   thymine	   at	   this	   location.	   The	   presence	   of	   a	   carbonyl	  
oxygen	  at	  the	  same	  position	   in	  a	  cytosine	  base,	  which	   is	  also	  tolerated	  at	  
this	  position,	  would	  be	  consistent	  with	  this	  conclusion.	  However,	  replacing	  
Lys532	   with	   an	   alanine	   drastically	   reduces	   the	   activity	   of	   the	   enzyme	  
without	   detectably	   changing	   the	   cleavage	   specificity.	   Apparently	   other	  
protein-­‐DNA	   interactions	   in	   addition	   to	   the	   Lys532	   contact	   with	   the	   −1	  
base	  play	  an	  important	  role	  in	  cleavage	  site	  selection.	  Thus,	  the	  structural	  
basis	  for	  the	  weak	  nucleotide	  sequence	  preference	  of	  the	  enzyme	  remains	  
elusive.	  
A	   number	   of	   studies	   have	   indicated	   that	   eukaryotic	   topoisomerase	   I	  
prefers	   supercoiled	  over	   relaxed	  plasmid	  DNAs	  as	   substrates,16,17	   and	   the	  
use	  of	  a	  mutant	  form	  of	  the	  protein	  with	  phenylalanine	  instead	  of	  tyrosine	  
at	  the	  active	  site	  (Y723F)	  showed	  that	  the	  enzyme	  has	  a	  strong	  preference	  
for	  binding	  to	  supercoiled	  DNA	  over	  relaxed	  DNA.18	  This	  binding	  property	  
was	   localized	   to	   the	   core	   domain	   by	   showing	   that	   a	   fragment	   including	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amino	   acid	   residues	   175	   to	   659	   exhibited	   the	   same	   preference	   for	  
supercoils.	   Since	   the	   enzyme	   preferentially	   binds	   to	   supercoils	   of	   either	  
sign,	   it	  seems	   likely	  that	  the	  structural	   feature	  recognized	   in	  the	  DNA	  is	  a	  
node	   where	   two	   duplexes	   cross.	   Indeed,	   topoisomerase	   I	   has	   been	  
observed	   to	   associate	   with	   nodes	   by	   electron	   microscopy.18,19	   The	  
association	  of	  human	  topoisomerase	  I	  with	  a	  node	  would	  appear	  to	  require	  
two	   DNA	   binding	   sites	   on	   the	   protein.	   One	   way	   to	   accommodate	   this	  
requirement	   would	   be	   for	   the	   enzyme	   to	   dimerize	   upon	   binding	   DNA.3	  
Although	  there	  is	  no	  evidence	  for	  dimerization,	  this	  possibility	  has	  not	  been	  
ruled	  out.	  An	  alternative	  hypothesis	   is	   suggested	  by	   the	  crystal	   structure.	  
The	   three-­‐dimensional	   structure	   of	   core	   subdomain	   II	   was	   found	   to	  
superimpose	   on	   the	   structure	   of	   the	   human	   Oct-­‐1	   POU	   homeodomain.	  
Since	  Oct-­‐1	  belongs	  to	  a	  family	  of	  transcription	  factors	  that	  specifically	  bind	  
DNA	  ,	  this	  homeodomain-­‐like	  region	  could	  represent	  a	  second	  DNA	  binding	  
site	   on	   topoisomerase	   I.	   However	   the	   residues	   in	   Oct-­‐1	   that	   confer	  
sequence	   specificity	   are	   not	   conserved	   in	   core	   subdomain	   II,	   so	   if	   this	  
region	  of	   human	   topoisomerase	   I	   does	  bind	  DNA,	   it	  would	   seem	   to	  be	   a	  
low-­‐	   affinity,	   nonspecific	   interaction.	   Further	   experimentation	   will	   be	  
required	  to	  test	  this	  hypothesis.	  
Mechanism	  of	  Catalysis	  Nucleophilic	   attack	  by	   the	  O-­‐4	  oxygen	  of	   Tyr723	  
on	   the	   scissile	   phosphate	   breaks	   the	   DNA	   strand	   to	   generate	   a	  
phosphodiester	  link	  between	  the	  tyrosine	  and	  the	  3ʹ′	  phosphate,	  releasing	  a	  
5ʹ′	  hydroxyl.	  Two	  different	  orientations	  of	  key	  active	  site	  residues	  in	  relation	  
to	   the	   scissile	   phosphate	   were	   observed	   in	   the	   crystal	   structures,	  
suggesting	   the	   interesting	   possibility	   that	   two	   distinct	   stages	   along	   the	  
catalytic	  pathway	  have	  been	  observed.	  In	  noncovalent	  complexes	  in	  which	  
the	  DNA	  contains	  a	  thymine	  at	  the	  −1	  position	  (−1T	  structure)	  ,	  Arg488	  and	  
Arg590	  appear	  to	  hydrogen	  bond	  with	  one	  of	  the	  nonbridging	  oxygens	  of	  
the	   scissile	   phosphate	   while	   His632	   is	   hydrogen-­‐bonded	   to	   the	   other	  
nonbridging	   oxygen.	   In	   a	   structure	   where	   the	   −1	   thymine	   has	   been	  
replaced	  with	  cytosine	  (−1C	  structure),	  the	  phosphate	  group	  has	  rotated	  by	  
75°	  relative	  to	  its	  position	  in	  the	  −1T	  structure,	  leaving	  Arg488	  and	  His632	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hydrogen-­‐bonded	   to	   the	  same	   two	  nonbridging	  oxygens,	  but	  now	  Lys532	  
rather	  than	  Arg590	  is	  hydrogen-­‐bonded	  to	  a	  nonbridging	  oxygen.	  This	  −1C	  
configuration	  is	  shown	  in	  Figure	  6	  where	  it	  can	  be	  seen	  that	  Lys532	  is	  also	  
hydrogen-­‐bonded	   to	   the	   carbonyl	  O-­‐2	  oxygen	  of	   the	  −1	   cytosine	  base.	   In	  
either	   orientation,	   it	   appears	   that	   Tyr723	   is	   perfectly	   aligned	   for	  
nucleophilic	   attack	   and	   that	   a	   triad	   of	   basic	   amino	   acids	   is	   positioned	   to	  
stabilize	   the	   pentavalent	   transition	   state	   through	   interactions	   with	   the	  
nonbridging	  oxygens	  of	  the	  scissile	  phosphate.	  
Although	   it	   has	   been	   hypothesized	   that	   the	   nucleophilic	   O-­‐4	   oxygen	   of	  
Tyr723	  could	  be	  activated	  by	  the	  proximity	  of	  a	  general	  base,	  none	  of	  the	  
structures	  revealed	  an	  amino	  acid	  close	  enough	  to	  the	  tyrosine	  to	  play	  this	  
role.	   However,	   a	   water	   molecule	   has	   been	   found	   hydrogen-­‐bonded	   to	  
Arg590	  that	  is	  only	  2.3	  Å	  from	  the	  O-­‐4	  oxygen	  (not	  shown	  in	  Figure	  2.3)	  and	  
therefore	  is	  in	  a	  position	  to	  act	  as	  a	  specific	  base	  and	  accept	  the	  proton	  as	  
catalysis	   proceeds.	   There	   are	   two	   reasons	   for	   suspecting	   that	   the	   −1C	  
structure	   represents	   a	   more	   advanced	   stage	   in	   catalysis	   than	   the	   −1T	  
structure.	   First,	   the	   orientation	   of	   the	   amino	   acid	   side	   chains	   in	   the	  
structure	  of	  the	  covalent	  complex	  that	  is	  produced	  on	  cleavage	  is	  the	  same	  
as	  that	  observed	  in	  the	  −1C	  structure.	  Second,	  after	  the	  75°	  reorientation	  
of	  the	  phosphate	  group	  on	  going	  from	  the	  −1T	  to	  the	  −1C	  structure,	  Arg590	  
is	   no	   longer	   within	   hydrogen-­‐bonding	   distance	   of	   either	   non-­‐bridging	  
oxygen	   but	   is	   now	   brought	   into	   close	   proximity	   to	   the	   Tyr723	   hydroxyl	  
.Hence,analogous	   to	   the	   situation	   described	   above	   for	   Arg321	   of	   E.	   coli	  
topoisomerase	   I,	   Arg590	   could	   facilitate	   nucleophilic	   attack	   by	   stabilizing	  
the	   phenolate	   anion.	   Furthermore,	   a	   direct	   role	   for	   Lys532	   in	   transition-­‐
state	   stabilization	   is	   consistent	   with	   the	   large	   effect	   on	   the	   rates	   of	  
cleavage	   observed	   for	   the	   K532A	   mutation	   in	   the	   human	   enzyme	   (H	  
Interthal,	   J	   Champoux,	   unpublished)	   and	   the	   corresponding	   K167A	  
mutation	  in	  vaccinia	  topoisomerase	  .20	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It	   was	   originally	   proposed	   that	   His632,	   in	   addition	   to	   stabilizing	   the	  
transition	   state	   through	   its	   interaction	  with	   a	   nonbridging	   oxygen,	  might	  
also	  act	  as	  a	  general	  acid	  to	  protonate	  the	  leaving	  5	  oxygen	  in	  the	  cleavage	  
reaction.	  The	  findings	  that	  His632	  can	  be	  replaced	  by	  glutamine	  with	  only	  a	  
modest	  reduction	  in	  activity	  and	  that	  the	  H632Q	  mutation	  has	  the	  same	  pH	  
profile	  as	  the	  wild-­‐type	  enzyme	  rule	  out	  the	  possibility	  that	  His632	  acts	  as	  a	  
general	  acid.20	  A	  similar	  conclusion	  has	  been	  reached	  concerning	  the	  role	  
of	   the	   corresponding	   His265	   of	   vaccinia	   topoisomerase.	   Recent	   results	  
indicate	   that	   Lys167	   of	   vaccinia	   topoisomerase	   and	   the	   corresponding	  
Lys532	   in	   the	   human	   enzyme	   function	   instead	   as	   general	   acids	   to	  
protonate	   the	   leaving	   5ʹ′	   oxygen	   during	   cleavage.	   The	   distance	   of	   Lys532	  
from	   the	   5ʹ′oxygen(∼4	   Å	   )	   in	   the	   human	   enzyme	   is	   compatible	   with	   this	  
suggestion	   and	   confirms	   that	   Lys532	   may	   very	   well	   play	   a	   key	   role	   in	  
catalysis	  by	  human	  topoisomerase	   I.	   In	  principle,	  DNA	  religation	  could	  be	  
mechanistically	  just	  the	  reverse	  of	  the	  cleavage	  reaction	  and	  the	  proximity	  
of	  most	   of	   the	   same	   amino	   acids	   to	   the	   scissile	   phosphate	   in	   the	   crystal	  
structure	   of	   the	   covalent	   complex	   is	   compatible	   with	   this	   possibility.	  
However,	   the	   observation	   that	   the	   critical	   active	   site	   residue	   His632	   is	  
within	   a	   disordered	   region	   in	   the	   structure	   of	   the	   covalent	   complex	  	  
suggests	   that	   there	   could	   be	   some	  mechanistic	   differences	   between	   the	  
cleavage	   and	   religation	   reactions.	   Although	   the	   close	   proximity	   of	   the	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Figure 6 Stereoview of the amino acid side chains in the active site of human topoi-
somerase I. The three-dimensional relationship between the side chains of the active site
residues Tyr723, Arg488, Arg590, His632, and Lys532 and the scissile phosphate is shown
for the structure containing a cytosine at the −1 position in the DNA (−1Cyt) (pdb entry
1EJ9). Hydrogen bonds are shown as dashed green lines; other distances as dashed black
lines. Bond distances are indicated in angstroms. Figure was generated with Swiss-Pdb
Viewer software (v. 3.51) in combination with POV-Ray for Windows (v. 3.1).
s ructure, Arg590 is no l nger within hydrog n-bonding distance of either non-
bridging oxygen but is now brought into close proximity to the Tyr723 hydroxyl
(2.4 A˚) (Figure 6). Hence, analogous to the situation described above for Arg321
of E. coli topoisomerase I, Arg590 could facilitate nucleophilic attack by stabiliz-
ing the phenolate anion. Furthermore, a direct role for Lys532 in transition-state
stabilization is consistent with the large effect on the rates of cleavage observed for
the K532Amutation in the human enzyme (H Interthal, J Champoux, unpublished)
and the corresponding K167A mutation in vaccinia topoisomerase (144).
It was originally proposed that His632, in addition to stabilizing the transi-
tion state through its interaction with a nonbridging oxygen, might also act as a
general acid to protonate the leaving 5￿ oxygen in the cleavage reaction (127).
The findings that His632 can be replaced by glutamine with only a m dest reduc-
tion in activity and that the H632Q mutation has the same pH profile as the wild-
type enzyme r le out the possibility that His632 acts as gen ral acid (144a).
A similar conclusion has been reached concerning the role of the corresponding
His265 of vaccinia topoisomerase (145–147). Recent results indicate that Lys167
of vaccinia topoisomerase and the corresponding Lys532 in the human enzyme
function instead as general acids to protonate the leaving 5￿ oxygen during cleavage
(148 and H Interthal, J Champoux, in preparation). The distance of Lys532 from
the 5￿ oxygen (∼4 A˚) in the human enzyme is compatible with this suggestion
and confirms that Lys532 may very well play a key role in catalysis by human
topoisomerase I.
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attacking	  5	  oxygen	  nucleophile	  to	  the	  scissile	  phosphate	  likely	  contributes	  
significantly	   to	   the	   rate	   of	   religation,	   other	   nucleophiles	   such	   as	   water,	  
hydrogen	  peroxide,	  and	  certain	  alcohols	  can	  replace	  the	  5	  	  hydroxyl	  under	  
some	   conditions.20,21	   Similar	   results	   have	   been	   reported	   for	   the	   vaccinia	  
topoisomerase	  where	  there	   is	  also	  the	  suggestion	  that	  after	  mutating	  the	  
active	   site	   tyrosine	   to	   histidine	   or	   glutamine,	   water	   may	   be	   able	   to	  
participate	  in	  the	  cleavage	  reaction.	  These	  results	   indicate	  that	  the	  key	  to	  
catalysis	  is	  the	  proper	  three-­‐dimensional	  organization	  of	  the	  side	  chains	  of	  
the	   active	   site	   residues	   around	   the	   scissile	   phosphate,	   leaving	   some	  
flexibility	  with	  respect	  to	  the	  nature	  of	  the	  attacking	  nucleophiles.21	  
Mechanism	  of	  DNA	  Relaxation	  A	  schematic	  of	  one	  possible	  model	  for	  DNA	  
relaxation	  is	  shown	  in	  Figure	  2.4.	  the	  spatial	  arrangement	  of	  the	  DNA	  in	  the	  
co-­‐crystal	  structure	  of	  human	  topoisomerase	  I	  renders	  unlikely	  an	  enzyme-­‐
bridging	  model	   for	  DNA	  relaxation	  analogous	   to	  what	  has	  been	  proposed	  
for	  E.	  coli	  topoisomerase	  I.	  Instead,	  it	  appears	  that	  once	  the	  DNA	  has	  been	  
cleaved,	   the	   helical	   duplex	   downstream	   of	   the	   cleavage	   site	   rotates	   to	  
relieve	  any	   torsional	   stress	  within	   the	   substrate	  DNA.	  Attempts	   to	  model	  
this	   rotation	   within	   the	   confines	   of	   the	   hollow	   interior	   of	   the	   protein	  
indicate	   that	   if	   the	   protein	   were	   to	   remain	   clamped	   around	   the	   DNA	   as	  
shown	   in	   Figure	   2.3,	   the	   rotating	   DNA	  would	   likely	   contact	   and	   perhaps	  
shift	  the	  position	  of	  both	  the	  cap	  and	  the	  linker.	  Thus,	  the	  term	  “controlled	  
rotation”	   was	   coined	   to	   indicate	   that	   these	   structural	   domains	   of	   the	  
protein	   likely	   hinder	   or	   impede	   the	   rotation	   reaction.	   An	   alternative	  
hypothesis	   is	   diagrammed	   in	   Figure	   2.4,	   where	   it	   is	   proposed	   that	   once	  
cleavage	   has	   occurred	   (Figure	   2.4d	   ),	   the	   enzyme	   opens	   up	   to	   allow	  
rotation	   and	   perhaps	   assumes	   a	   conformation	   approximating	   that	  
proposed	  for	  the	  DNA-­‐free	  form	  of	  the	  enzyme	  (Figure	  2.4a).	  In	  this	  model,	  
there	  may	   be	   little	   or	   no	   hindrance	   to	  DNA	   rotation	   (Figure	   2.4e).	   These	  
two	  models	  differ	  mainly	  in	  the	  extent	  to	  which	  the	  DNA	  interacts	  with	  the	  
cap	   and	   linker	   elements	   of	   the	   structure	   during	   rotation.	   Either	   model	  
could	  accommodate	  multiple	  rotation	  events	  before	  religation	  of	  the	  DNA.	  
Although	  the	  number	  of	  rotations	  per	  cleavage	  is	  not	  known	  for	  the	  human	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enyzme,	  the	  vaccinia	  topoisomerase	  appears	  to	  allow,	  on	  the	  average,	  five	  
rotations	  for	  each	  nicking-­‐closing	  cycle.22	  
	  
	  
	  
	  
	  
	  
	  
	  
Fig	  2.4	  
	  1.2.2	  
	  Human	  DNA	  Topoisomerase	  II	  
	  
The	  following	  properties	  are	  shared	  by	  all	  type	  II	  topoisomerases16:	  (a)	  The	  
dimeric	  enzymes	  bind	  duplex	  DNA	  and	  cleave	  the	  opposing	  strands	  with	  a	  
four-­‐base	  stagger	  (topoisomerase	  VI	  may	  generate	  a	  two-­‐base	  stagger).	  (b)	  
Cleavage	  involves	  covalent	  attachment	  of	  each	  subunit	  of	  the	  dimer	  to	  the	  
5ʹ′	  end	  of	   the	  DNA	  through	  a	  phosphotyrosine	  bond.	   (c)	  A	  conformational	  
change	  pulls	   the	   two	  ends	  of	   the	   cleaved	  duplex	  DNA	  apart	   to	   create	  an	  
opening	   in	  what	   is	   referred	   to	  as	   the	  gated	  or	  G-­‐segment	  DNA.	  A	  second	  
region	  of	  duplex	  DNA	  from	  either	  the	  same	  molecule	  (relaxation,	  knotting	  
or	   unknotting)	   or	   a	   different	   molecule	   (catenation	   or	   decatenation),	  
referred	   to	   as	   the	   transported	  or	   T-­‐segment,	   is	   passed	   through	   the	  open	  
DNA	  gate.	  This	  feature	  of	  the	  reaction	  explains	  why	  the	   linking	  number	   is	  
changed	   in	   steps	   of	   two	   when	   the	   supercoiling	   of	   a	   circular	   DNA	   is	  
changed.22	  (d)	  The	  reactions	  require	  Mg(II),	  and	  ATP	  hydrolysis	  is	  required	  
for	  enzyme	  turnover	  and	  rapid	  kinetics,	  although	  one	  cycle	  of	  relaxation	  or	  
decatenation/catenation	  can	  occur	  in	  the	  presence	  of	  the	  nonhydrolyzable	  
P1: FUM
May 8, 2001 17:48 Annual Reviews AR131-12
396 CHAMPOUX
Figure 7 A possible mechanism of DNA relaxation by human topoisomerase I. The
enzyme is viewed looking down the axis of the bound DNA. The enzyme is modeled into
an open configuration for DNA binding by allowing upward movement at the hinge point
identified in Figure 5b. Upon binding the DNA (a and b), the closed form of the enzyme
catalyzes cleavage of the scissile strand (c and d ). In this model, rotation of the DNA is
proposed to occur in the open conformation of the enzyme (e), although the protein may
not be as open as depicted here (see text). The cleaved DNA rotates about a series of bonds
in the intact strand (e); the gray transparent circle depicts the approximate cross section
circumscribed by the rotating DNA (127, 128). Multiple rotations are possible before the
steps are reversed, and the DNA is either cleaved again or released.
the polarity of attachment to the cleaved strand clearly place the viral enzyme
in the type IB subfamily. Interestingly, the vaccinia enzyme is more sequence-
specific than the cellular enzyme with a pentanucleotide recognition sequence of
5￿-(T/C)CCTT-3￿. The recognition site specificity and the observation that the
vaccinia enzyme can resolve Holliday junctions (154, 155) indicate an overlap in
function with the related tyrosine recombinases and suggest that the viral topoiso-
merase may have multiple functions during the infection.
Structurally, vaccinia topoisomerase appears to be a pared-down cellular topoi-
somerase I (128). The crystal structures of two fragments that constitute virtually
the entire vaccinia topoisomerase have been determined (156, 157). These two
fragments correspond to the amino-terminal domain (amino acids 1–77) and the
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analog	   of	   ATP,	   ADPNP	   (5ʹ′-­‐adenylyl-­‐β,γ-­‐imidodiphosphate).	   (e)	   The	   crystal	  
structures	   of	   several	   members,	   including	   the	   structurally	   distinct	  
topoisomerase	   VI,	   reveal	   that	   the	   active	   site	   tyrosines	   are	   situated	   in	   a	  
helix-­‐turn-­‐helix	  (HTH)	  motif	  found	  within	  a	  domain	  that	  strongly	  resembles	  
the	  DNA	  binding	  region	  of	  the	  E.	  coli	  catabolite	  activator	  protein	  (CAP).	  In	  
addition,	  acidic	  residues	  within	  a	  Rossmann	  fold	  on	  the	  opposing	  protomer	  
appear	   to	   collaborate	   with	   the	   HTH	   region	   of	   the	   CAP-­‐like	   domain	   to	  
assemble	   the	   active	   site	   for	   catalysis	   and	   may	   be	   involved	   in	   metal	   ion	  
binding	   in	   some	  cases.23	   This	   fold	  has	   also	  been	   referred	   to	   as	   a	   “toprim	  
motif”	  because	  it	   is	  found	  in	  DNA	  primases	  as	  well	  as	  the	  topoisomerases	  
and	  also	   in	  a	  number	  of	  other	  enzymes	  that	  catalyze	  phosphotransfers	  or	  
hydrolyze	   phosphodiester	   bonds.	   Interestingly,	   both	   the	   CAP-­‐like	   domain	  
and	   the	   Rossmann/toprim	   fold	   of	   the	   type	   II	   enzymes	   are	   shared	   by	   the	  
type	   IA,	  but	  not	   the	   type	   IB,	   subfamily	  of	   topoisomerases.	   (f)	  As	  with	   the	  
type	   I	   enzymes,	   a	   highly	   conserved	   arginine	   residue	   is	   implicated	   in	  
catalysis	  by	  its	  close	  proximity	  to	  the	  active	  site	  tyrosine.24	  
Several	  characteristics	  distinguish	  individual	  members	  of	  the	  type	  II	  family.	  
All	  of	  the	  type	  II	  enzymes	  from	  both	  prokaryotic	  domains	  of	  life	  described	  
to	  date	  contain	  two	  different	  subunits	  and	  are	  therefore	  heterotetrameric	  
in	  structure,	  whereas	  the	  eukaryotic	  enzymes	  are	  homodimers	  (Table	  2.1).	  
Among	  all	  of	   the	  known	  type	   II	  enzymes,	  DNA	  gyrase	  stands	  alone	  as	  the	  
only	  enzyme	  capable	  of	  using	  the	  energy	  from	  ATP	  hydrolysis	  to	  introduce	  
negative	  supercoils	  into	  the	  DNA.	  Finally,	  different	  members	  of	  the	  type	  II	  
family	  can	  be	  distinguished	  by	  their	  relative	  proficiency	  at	  DNA	  relaxation	  
versus	  decatenation	   (or	  catenation),	  and	   this	  property	   likely	   reflects	   their	  
specialized	  roles	  in	  the	  cell.25	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1.2.3	  
	  Topoisomerase	  –	  Targeted	  anticancer	  drugs	  
	  
Topo	  I	  and	  II	  inhibitors	  are	  two	  promising	  new	  classes	  of	  anticancer	  agents3	  
whose	  mechanism	  of	  action	   involves	  covalent	  binding	  to	  double-­‐stranded	  
DNA	   and	   subsequent	   interference	   with	   the	   DNA	   breakage-­‐resealing	  
process.	   Both	   inhibitor	   types	   form	   a	   cleavable	   complex	   by	   covalently	  
binding	   to	   DNA-­‐topo	   I	   or	   II;	   this	   binding	   still	   permits	   uncoiling	   of	   the	  
double-­‐stranded	  DNA	  but	  prevents	  its	  subsequent	  resealing.	  The	  advancing	  
replication	   then	   is	   halted	   within	   the	   topoisomerase-­‐DNA	   complex	   stage,	  
resulting	  in	  unsealed	  DNA	  breakage	  and	  eventual	  cell	  death.	  
	  
1.2.3.1	  
	  Topoisomerase	  I	  inhibitors	  
	  
Topo	   I	   is	   a	   monomeric	   protein	   that	   breaks	   single	   strands	   of	   DNA	   by	  
cleaving	   a	   phosphodiester	   bond,	   then	   covalently	   binds	   to	   the	   DNA	   3’-­‐
phosphoryl	  end	  via	  a	  phosphotyrosine	   linkage.	   In	  general,	  topo	  I	  enzymes	  
catalyze	   the	   removal	   of	   negative	   superhelical	   DNA	   twists,	   which	   is	   a	  
thermodynamically	  favorable	  reaction.26	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All	   cells	   appear	   to	   contain	   at	   least	   one	   type	   I	   and	   one	   type	   II	  
topoisomerase.	   However,	   the	   levels	   of	   topo	   I	   in	   tumor	   specimens	   are	  
higher	   than	   that	   in	   normal	   tissues,	   making	   inhibition	   of	   this	   enzyme	   an	  
attractive	   target	   for	   anticancer	   agents.	   Surgical	   specimens	   from	   patients	  
with	   colon	   cancer	   have	   a	   14-­‐	   to	   16-­‐fold	   increase	   in	   topo	   I	   levels	   in	   the	  
malignant	  cells	  as	  compared	  with	  adjacent	  normal	  tissues.	  
Topo	  I	  inhibitors	  can	  be	  grouped	  into	  two	  main	  classes	  (a)	  topo	  I	  poisions,	  
and	   (b)	   topo	   I	   suppressors.	   Both	   inhibit	   topo	   I	   catalytic	   activity	   (DNA	  
relaxation).	   While	   topo	   I	   poisions	   trap	   cleavage	   complees,	   topo	   I	  
suppressors	  do	  not.	  Topo	  I	  poisons	  kill	  cells	  by	  trapping	  cleavage	  complexes	  
rather	  than	  inhibiting	  catalytic	  activity.27,	  28	  
 
 
Camptotecin	  and	  analogues	  
	  
See	  chapter	  3.	  
	  
	  Benzophenanthridine	  Alkaloids	  	  
	  
N
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Nitidine Chelerythrine Isofagaridine 	  
	  
Three	   strongly	   topo	   I	   inhibitory	   principles,	   nitidine	   ,	   chelerythrine	   	   and	   a	  
new	   alkaloid	   isofagaridine	   were	   identified	   from	   a	   methanol	   extract	   of	  
Zanthoxylum	  nitidum	  by	  Fang	  et	  al.29	  At	  167	  or	  500	  mM	  for	  30	  min.	  nitidine	  
and	   isofagaridine,	   completely	   inhibited	   pSP64	  DNA	   relaxation	   induced	  by	  
2.2	   ng	   of	   calf	   thymus	   DNA	   topo	   I.	   Nitidine	   and	   isofagaridine	   were	   also	  
effective	   at	   50	   mM,	   while	   	   chelerythrine,	   gave	   partial	   inhibition	   at	   this	  
concentration.	   These	   results	   compared	   favorably	  with	   those	  obtained	   for	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camptothecin,	   which	   inhibited4	   relaxation	   partially	   at	   167	   mM	   and	  
completely	  at	  500	  mM.	  
N
CH3
NH2
OCH3
OCH3
H3CO
	  
In	   	   2005,	   Clement	   et	   al30	   reported	   11-­‐substituted	   6-­‐aminobenzo	  
[c]phenanthridine	   derivatives,	   among	   them	   the	   above	   compound	   shows	  
good	  activity	  in	  vitro	  as	  well	  as	  in	  vivo.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Indolocarbazole	  Derivatives	  
	  
A	   	   indolocarbazole	   antitumor	   antibiotic,	   BE-­‐13793C	   isolated	   31	   from	   the	  
culture	   broth	   of	   the	   actinomycete	   strain	   Streptoverticillium	   mobaraense	  
has	   topoisomerase	   inhibitory	   activity.	   BE-­‐13793C	   strongly	   inhibited	   both	  
topo	   I	   and	   topo	   II	   and	   inhibited	   the	   growth	   of	   doxorubicin-­‐resistant	   or	  
vincristine-­‐resistant	  P388	  murine	  leukemia	  cell	  lines,	  as	  well	  as	  their	  parent	  
P388	  cell	  line.	   	  Compound	  ED-­‐110	  is	  a	  new	  semisynthetic	  antitumor	  agent	  
derived	  from	  BE-­‐13793C	  by	  glucosylation.32	  Exposing	  P388	  cells	  to	  ED-­‐110	  
caused	   typical	   topoisomerase	   toxicity,	   i.e.,	   formation	   of	   cleavable	  
complexes,	  inhibition	  of	  nucleotide	  synthesis	  rather	  than	  protein	  synthesis,	  
and	  cell	  cycle	  arrest	  in	  G2.	  
N N
N
HO OHR2H
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BE-13793C: R1=R2=H
ED:R1=H. R2=D-glucose
NB-506:R1==NHCHO, R2=D-glucose
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N
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KT6006:R=OH 	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KT6006	   	   and	   KT6528	   ,	   synthetic	   antitumor	   derivatives	   of	   the	  
indolocarbazole	   antibiotic	   K252a,	   were	   potent	   inducers	   of	   a	   topo	   I	  
cleavable	  complex.33	  A	  fluoroindolo[2,3-­‐a]carbazole	  	  BMS-­‐250749:1	  shows	  
a	   broad	   spectrum	   antitumour	   activity	   34	   comparable	   to	   that	   of	   the	  
marketed	  CPT-­‐11.	  
	  
	  	  Indenoisoquinolines	  	  
	  
Indenoisoquinoline	   (NSC314622),	   an	   unexpected	   transformation	   product	  
during	  the	  synthesis	  of	  	  nitidine	  chloride,	  was	  reported	  by	  Cushman	  et	  a	  l35	  
to	   induce	  DNA	  cleavage	   in	   the	  presence	  of	   topI.	   Its	  cleavage	  site	  was	  not	  
the	   same	   as	   that	   observed	   in	   camptothecin.	   In	   	   2003,	   Cushman	   et.	   al	  
reported	  that	  N-­‐substitution	  by	  3-­‐aminopropyl	  substituents	  induced	  potent	  
topoisomerase	   inhibitor	   activity.	   On	   the	   basis	   of	   these	   results,	   the	  	  
substituents	   on	   the	   heterocyclic	   lactam	   as	   given	   below,	   showed	   greater	  
activity	  than	  the	  parent	  indenoisoquinoline	  (NSC314622).36,37 
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Phenanthridines	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Synthetic	   phenanthridine	   derivatives	   such	   as	   5H-­‐8,9-­‐dimethoxy-­‐5-­‐(2-­‐N,N-­‐
dimethylaminoethyl)-­‐2,3-­‐methylenedioxydibenzo[c,h][1,6]naphthyridin-­‐6-­‐
one,	   (A),	   and	   11H-­‐	   2,3-­‐dimethoxy-­‐5-­‐(2-­‐N,N-­‐dimethylaminoethyl)-­‐8,9-­‐
methylenedioxy-­‐5,6,11-­‐triazachrysen-­‐12-­‐one	   (B)	   can	   exhibit	   potent	   TOP1-­‐
targeting	  activity	  and	  pronounced	  cytotoxicity..	  Potent	  antitumor	  activity38	  
was	  observed	  for	  (A)	  administered	  orally	  and	  parenterally	  to	  athymic	  nude	  
mice	  bearing	  the	  human	  tumor	  xenograft,	  MDAMB-­‐435.	  
	  
Flavones	  	  
	  
O
OOH
HO
R2' R3'
R4'
R3
Quercetin: R3= R3'= R4'= OH, R2=H
Acacetin: R3= R2'= R3''= OH, R4'=OCH3
Apigenin: R3= R2'= R3''= H, R4'=OH
Kaempferol: R2'= R3''= H, R3 = R4'=OH
Morin: R3= R2'= R4'= H, R3'= H 	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Quercetin	  and	  the	  related	  natural	  flavones,	  acacetin,	  apigenin,	  kaempferol,	  
and	   morin	   inhibit	   topo	   I-­‐catalyzed	   DNA	   religation.39.	   	   In	   contrast	   to	  
camptothecin	   these	   compounds	   do	   not	   act	   directly	   on	   the	   catalytic	  
intermediate	   and	   also	   do	   not	   interfere	   with	   DNA	   cleavage.	   However,	   a	  
ternary	   complex	   with	   topo	   I	   and	   DNA	   is	   formed	   during	   the	   cleavage	  
reaction	  that	  inhibits	  the	  following	  DNA	  religation	  step.	  
	  
Shikonin	  Analogs	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The	   antineoplastic	   benzoquinone	   Shikonin	   isolated	   from	   the	   root	   of	  
Lithospermum	   erythrorhizon	   (Boraginaceae),	   exhibited	   strong	   cytotoxicity	  
against	  L1210	  cells.	   	  Ahn	  et	  al.	  reported	  that	  shikonin	  and	  some	  synthetic	  
19-­‐acylshikonins40	  are	  potent	   inhibitors	  of	  DNA	  topo	  I.	   In	  general,	  analogs	  
with	  shorter	  acyl	  groups	  (C2–C6)	  were	  more	  potent	  than	  those	  with	  longer	  
acyl	   chains	   (C7–C20).	   While	   halogen	   substitution	   at	   C-­‐2	   of	   the	   acetyl	  
moiety	   failed	   to	   increase	   the	   inhibitory	   potency,	   placing	  double	  bonds	   in	  
the	  acyl	  group	  (C5–C7)	  augmented	  the	  potency	  remarkably.	  	  
	  	  
β-­‐Lapachone	  
	  
β-­‐Lapachone	   is	  obtained	  by	  simple	  sulfuric	  acid	  oxidation	  of	   the	  naturally	  
occurring	  lapachol41	  	  which	  is	  isolated	  from	  Tabebuia	  avellanedae	  growing	  
mainly	   in	   Brazil.	   This	   compound	   inhibits	   topo	   I	   mediated	   DNA	   cleavage	  
through	  direct	  interaction	  with	  topo	  I	  rather	  than	  DNA	  substrate.	  
 35 
O
O
O
O
O
OH
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  β-­‐Lapachone	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Lapachol	  
The	   direct	   interaction	   of	   β-­‐Lapachone	   with	   topo	   I	   may	   not	   affect	   the	  
assembly	   of	   the	   enzyme-­‐DNA	   complex	   but	   does	   inhibit	   the	   formation	   of	  
cleavable	  complex.	  
	  
	  1.2.3.3	  	  
	  Topoisomerase	  II	  inhibitors	  
	  
The	  level	  of	  topo	  II	  in	  normal	  cells	  is	  cell	  cycle-­‐dependent	  and	  is	  controlled	  
by	   the	   topo	   II	   gene,	   probably	   through	   a	   post-­‐translation	   regulation	  
mechanism.42	   	  Topo	   II	  activity	   is	   low	   in	  G0	  phase,	   is	  higher	   in	  cell	  division	  
phase,	   and	   reaches	   a	   maximum	   during	   S	   phase.43	   Topo	   II	   activity	   also	  
parallels	  the	  rate	  of	  cell	  proliferation;	  it	  is	  high	  in	  rapidly	  growing	  cells	  and	  
lower	  in	  slowly	  growing	  cells.	  The	  half	  life	  of	  topo	  II	  activity	  in	  tumor	  cells	  
(chicken	   hepatoma	   cells)	   is	   4-­‐fold	   longer	   than	   that	   in	   the	   corresponding	  
normal	  cells	  (chicken	  embryo	  fibroblasts).	  
Topo	   II-­‐targeted	   anticancer	   drugs	   achieve	   their	   selectivity	   for	   rapidly	  
proliferating	   cancer	   cells	   over	  normal	   cells	   from	   this	   correlation	  between	  
topo	   II	   activity	   and	   cell	   proliferation.	   Topo	   II	   inhibitors	   can	   be	   roughly	  
classified	   into	   two	   groups:	   intercalators	   and	   nonintercalators.	  
Nonintercalator	   topo	   II	   inhibitors	   include	   epipodophyllotoxins,	   such	   as	  
etoposide,	   and	   some	   isoflavones,	   such	   as	   genistein.	   Intercalator	   topo	   II	  
inhibitors	   are	   structurally	   diverse	   and	   usually	   have	   planar	   aromatic	   ring	  
systems	  that	  can	  fill	   in	  (intercalate)	  between	  DNA	  base	  pairs	  and	  obstruct	  
normal	  DNA	  functions.	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Etoposide	  and	  its	  analogs	  
	  
	  Etoposide	   (VP16,)	   and	   teniposide	   (VM26,)	   are	   two	   successful	   anticancer	  
analogs	   developed	   from	   the	   anticancer	   lignan	   podophyllotoxin,	   which	   is	  
isolated	  from	  Podophyllum	  peltatum	  or	  P.	  emodii	  (Berberidaceae).	  
	  
	  
	  Etoposide–like	   compounds	   are	   potent	   irreversible	   inhibitors	   of	   DNA	  
topoisomerase	  II	  and	  their	  action	  is	  based	  on	  the	  formation	  of	  nucleic	  acid	  
drug	   enzyme	   complex,	   which	   induces	   single-­‐	   and	   double-­‐	   stranded	   DNA	  
breaks	   as	   the	   intial	   step	   in	   a	   series	   of	   biochemical	   transformations	   that	  
eventually	  lead	  to	  cell	  death.	  
In	   order	   to	   overcome	   the	   limitations	   of	   these	   compounds	   with	   better	  
anitumour	  activity,	  many	   structural	  modifications44	   	   have	  been	  perfomed	  
on	  the	  cyclolignan	  skeleton.	  
	  
	  Anthracyclines	  
	  
The	   anthracyclines	   are	   classical	   anticancer	   antibiotics	   and	   include	  
doxorubicin	   (Adriamycin)	   and	   daunorubicin.	   These	   predominant	   topo	   II	  
inhibitors	   have	   been	   used	   in	   the	   treatment	   of	   various	   tumors	   for	   many	  
years.	   Doxorubicin,	   a	   standard	   anticancer	   drug,	   is	   widely	   used	   against	  
leukemia,	   advanced	   urothelial,	   and	   other	   tumors.	   Antracyclines	   are	  
intercalated	  in	  DNA	  due	  to	  their	  planar	  cyclic	  system.	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Doxorubicin R= OH 
Daunorubicin R = H 	  
Menogaril 	  
Menogaril,	   a	   new	   anthracycline	   agent,	   possesses	   weak	   double-­‐helix	  
unwinding	   activity.	   This	   anthracycline	   is	   for	   treatment	   of	   many	   tumors	  
including	  leukemia45	  and	  malignant	  mesothelioma.	  Due	  to	  the	  side	  effects	  
of	   doxorubicin	   ,	   such	  as	  myelosuppression	  and	   irreversible	   cardiotoxicity,	  
pirarubicin	  was	  recently	  developed46	  	  
	  
Anthrapyrazoles	  (Mitoxantrone	  Analogs)	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New	   DNA	   topo	   II	   inhibitory	   anthrapyrazoles	   structurally	   related	   to	  
mitoxantrone	  were	  designed	  to	  suppress	  the	  redox	  reductions	  responsible	  
for	   cardiac	   toxicity.	   e.g.	  DuP	  941	   (Losoxantrone)	   and	  DuP	  937.	   These	   are	  
potent	   topo	   II	   inhibitors	  closely	   related	   to	  mitoxantrone.	  Anthrapyrazoles	  
are	   unlikely	   to	   produce	   free	   radicals	   and	   might	   be	   useful	   in	   the	   same	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indications	  as	  mitoxantrone,	  especially	   for	  patients	  with	   cardiac	   risks	  and	  
for	  pediatric	  patients.47	  	  	  	  
	  
	  	  Azaanthracene-­‐9,10-­‐diones	  
	  
N
O
O
O
O
N
N
OH
N
N
OH
H
H
H
H
N
O
O
O
O
N
N
OH
N
N
OH
H
H
H
H
1-Azaanthracene-9-10-dione 2-Azaanthracene-9-10-dione 	  
	  
Zwelling	  et	  al.48	  	  examined	  the	  activities	  of	  two	  novel	  aza-­‐anthracene-­‐9,10-­‐
diones,	  1-­‐aza	  and	  2-­‐aza-­‐anthracene-­‐9-­‐10-­‐diones	  in	  HL-­‐60	  human	  leukemia	  
cell	  lines	  containing	  topo	  II	  with	  different	  sensitivities	  to	  other	  intercalating	  
agents.	  Both	  aza	  compound	  induced,	  topo	  II-­‐mediated	  DNA	  cross-­‐linking	  in	  
the	   cells	   revealed	   resistance	   and	   sensitivity	   patterns	   paralleling	   the	  
cytotoxicity	  results.	  
	  
Thioxanthones	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Some	   new	   4-­‐aminomethylthioxanthones	   are	   active	   against49	   the	   murine	  
tumor	  Panc	  03.	   	  The	  methanesulfonamide	  analog	  SR	  233377	  (WIN	  33377)	  	  
is	  also	  a	  potent	  topo	  II	  inhibitor	  with	  a	  EC50	  value	  of	  3.0	  μM.	  Derivatives	  A,	  
B	   which	   	   incorporate	   a	   pyrazole	   ring	   at	   the	   1-­‐	   and	   9-­‐position	   of	   the	  
thioxanthones50	  showed	  more	  topo	  II	  inhibition	  than	  WIN	  33377.	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Acridone	  and	  Related	  Acridine	  Derivatives	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NHSO2CH3
OCH3
Amsacrine 	  
(i), 1' -NHMe
(ii), 1' -NHSO2Me, 3' = OMe
(iii), 1' - NHSO2Me, 3' = OMe, 3,6-diNH2
(iv), 1' - SO2NH2, 3-NH2
(v), 1' -SO2NH2, 3,6-diNH2
(vi), 1' - NH2 , 3,6-diNH2
(vii), 1'-N(Me)Et
(viii), 1'-NHhexyl
	  
	  
Naturally	   occurring	   acridone	   alkaloids	   and	   related	   synthetic	   derivatives51	  
possess	   many	   biological	   activities	   including	   antitumor,	   antiparasitic,	   and	  
antiviral	   properties.	   	   9-­‐Anilinoacridines	   derivatives	   (	   I	   –	   viii	   )	   inhibit	   both	  
the	  growth	  of	   Jurkat	   leukemia	   cells	   and	  activity	  of	  human	  DNA	   topo	   II	   in	  
vitro52.	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Y
CONH(CH2)2N(CH3)2
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CONH(CH2)2N(CH3)2N
(ix): A : X = N, Y = CONH2
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A B 	  
	   	   	   	   	   	   	   	   	   	   	  
Antitumor	   intercalators	   acridine-­‐4-­‐carboxamide	   (A)	   and	   2-­‐(4-­‐
pyridyl)quinoline-­‐8-­‐carboxamide	  (B)	  are	  structurally	  related	  to	  the	  topo	  II-­‐
targeted	   drug	   amsacrine.	   	   These	   tricyclic	   carboxamides	   (ix	   –xiii	   )	   induce	  
DNA	   lesions	   (which	  reflects	  stabilization	  of	   topo	   II	  cleavage	  complexes)	   in	  
mouse	  fibrosarcoma	  cells	  (line	  935.1).53	  The	  topo	  II	  inhibitory	  mechanisms	  
by	   these	   tricyclic	   carboxamides	   differ	   from	   the	   classical	   trapping	   of	  
topoisomerase	  in	  covalent	  cleavage	  complex.	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  Pyridoacridine	  Alkaloids	  
	  
Several	   new	   pyridoacridine	   alkaloids,	   dehydrokuanoniamine	   B	   (i),	  
shermilamine	   C	   (ii),	   and	   bystodytin	   J	   (iii),	   and	   the	   known	   compounds	  
cystodytin	   A	   (iv),	   kuanoniamine	  D	   (v),	   shermilamine	   B	   (vi),	  were	   isolated	  
from	  the	  Fijian	  Cystodytes	  sp.	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  These	  pyridoacridines	  probably	   inhibit	   cellular	  proliferation	  by	  disrupting	  
topo	   II	   function	   subsequent	   to	   intercalation.	   In	   incorporation	   studies,	  
pyridoacridines	   disrupted	   DNA	   and	   RNA	   synthesis	   with	   little	   effect	   on	  
protein	  synthesis.	  These	  results	  are	  consistent	  with	  those	  for	  known	  DNA	  
intercalators.	  	  
	  
N
N
H
H R
OH
CF3CO2-
+
Styelsamines A -D
A , R= CH(OH)CH2NH3  CF3CO2
B, R= (CH2)2NHAc
C, R= CHO
D, R = (CH2)2NH3 CF3CO2
+ _
+ _
	  
	  
A	  series	  of	  new	  alkaloids,	  styelsamines	  A-­‐D	  (a-­‐d),	  have	  been	  isolated	  from	  
the	  Indonesian	  Ascidian,	  Eusynstyela	  latericius,	  which	  inhibit	  human	  colon	  
HCT-­‐116	  cells	  in	  vitro54	  in	  the	  1-­‐100	  µM	  range.	  	  
	  
Elsamicin	  and	  Other	  Coumarin-­‐Related	  Antitumor	  Agents	  
	  
Elsamicin	  	  is	  structurally	  related	  to	  the	  anticancer	  compounds	  chartreusin	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These	   compounds	   induced,	   to	   a	   different	   extent,	   DNA	   breakage	   in	   the	  
human	   lung	  adenocarcinoma	  A549	  cell	   line.55	   In	  addition	  all	  either	  bound	  
to	  or	  intercalated	  into	  DNA.	  
	  
	  1,4-­‐Dihydroquinoline	  Derivatives	  
	  
The	   antibacterial	   properties	   of	   the	   quinolines	   have	   been	   known	   for	   over	  
three	   decades.	   A	   3-­‐quinolinecarboxylic	   acid	   derivative	   (WIN	   57294),	   a	  
reported	   potent	   inhibitor	   of	   bacterial	   DNA	   gyrase,	   was	   found	   to	   be	  
interactive	  with	  mammalian	  topo	  II	  by	  Wentland	  et	  al56.	  	  
The	   7-­‐(4-­‐hydroxyphenyl)	   analog	   (CP-­‐115,953)	   was	   6-­‐fold	   more	   potent	  
(EC50	  =	  1.2	  mM)	  than	  WIN	  57294	  
N
N
H3C
CH3
F
F
COOH
O
1
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HO
	  
.	  
Mono-­‐	  and	  Bis-­‐naphthalimide	  Analogs	  
	  
Amonafide	   and	   its	   analogs	   interfere	  with	   the	   breakage-­‐rejoining	   reaction	  
of	  purified	  mammalian	  DNA	  topo	  II	  by	  stabilizing	  a	  reversible	  enzyme-­‐DNA	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cleavable	   complex.	   In	   contrast	   to	   other	   topo	   II-­‐active	   antitumor	   drugs,	  
Amonafide	  induces	  specific	  DNA	  cleavage	  at	  a	  single	  major	  site	  on	  pBR322	  
DNA.	  This	  strong	  site	  specificity	  may	  allow	  detailed	  characterization	  of	  the	  
intercalator-­‐stabilized,	  topo	  II-­‐DNA	  cleavable	  complex57	  	  
A	  dimethylaminoethyl	  group	  was	  the	  best	  N2	  substitution,	  and	  the	  4-­‐,	  5-­‐,	  7-­‐
,	   and	   9-­‐amino	   derivatives58	   showed	   significantly	   higher	   potency	   than	   the	  
unsubstituted	  parent	  compound,	  Azonafide.	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To	   increase	   binding	   capacity	   to	   DNA	   and	   improve	   the	   therapeutic	  
properties	  of	  Aminofide	  and	  Azonafide	  two	  naphthalimides	  were	  joined	  by	  
polyamine	  linkers.59	  	  
	  
	  Ellipticine	  Analogs	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Ellipticine	   is	   an	   antitumor	   alkaloid	   isolated	   from	   Ochrosia	   elliptica.60	   	   It	  
inhibits	  topo	  II	  and	  shows	  anticancer	  activity	  in	  several	  animal	  and	  human	  
tumor	  systems.	  
Compound	  (DHE)	  and	  Retelliptine	  are	  more	  cytotoxic	   than	  Ellipticine,	   this	  
increased	   cytotoxicity	   was	   not	   accompanied	   by	   greater	   amount	   of	   DNA	  
strand	   breakage	   or	   protein–DNA	   cross-­‐linking.	   The	   single	   strand	   breaks	  
caused	  by	  both	  compounds	  were	  protein	  associated	  and	  could	  result	  from	  
double	  strand	  breaks.	  The	  DNA	  damage	  therefore	  was	  consistent	  with	  topo	  
II	  inhibition.61	  	  
	  	  
γ-­‐Carbolines	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γ-­‐Carbolines	  are	   tricyclic	  aromatic	  compounds	   ,	   they	   intercalate	   into	  DNA	  
base	  pairs	  and	  exhibit	  significant	  cytotoxic	  and	  antitumor	  activities62.	  These	  
two	  most	  cytotoxic	  γ-­‐carbolines	  are	  also	  the	  most	  efficient	  stabilizers	  of	  the	  
DNA-­‐topo	  II	  covalent	  cleavable	  complex.	  
	  
Benzonaphthofuran-­‐6,11-­‐diones	  
	  
O
O
O
HO
O(CH2)2NC2H5.HCl
	  
	  
Based	   on	   the	   “2-­‐phenylnaphthalene-­‐type”	   structural	   pattern	   hypothesis,	  
Liu	   et	   al.	   designed	   and	   synthesized	   a	   series	   of	   benzonaphthofuran-­‐6,11-­‐
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diones.	   In	   vitro	   inhibitory	   action	   was	   evaluated	   against	   the	   growth	   of	  
various	   human	   tumors	   and	   drug-­‐stimulated	   topo	   II-­‐mediated	   DNA	  
cleavages.63	  	  
	  
	  Aurintricarboxylic	  Acid	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Aurintricarboxylic acid (ATA) 	  
	  
Aurintricarboxylic	   acid	   (ATA)	   is	   a	   polyanionic,	   polyaromatic	   compound	  
derived	  from	  aurin,	  a	  triphenylmethane	  dye.	  Aurintricarboxylic	  acid	  inhibits	  
apoptotic	  cell	  death	  induced	  by	  a	  variety	  of	  factors	  in	  various	  cell	  types.	  It	  
is	  a	  potent	   inhibitor	  of	  the	  nuclear	  enzyme	  DNA	  topo	  II.64	  This	  compound	  
effects	  on	  DNA-­‐protein	  complex	  formation	  in	  living	  cells	  may	  result	  from	  a	  
direct	  interaction	  with	  topo	  II.	  It	  prevents	  the	  binding	  of	  topo	  II	  to	  DNA	  and	  
inhibits	  topo	  II-­‐catalyzed	  ATP	  hydrolysis.	  65	  	  	  
	  
	  Coumarins	  and	  Derivatives	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Columbianadin,	   5-­‐methoxylpsoralen,	   psoralen,	   and	   acetylumbelliferone	  
were	  isolated	  from	  the	  roots	  of	  Seseli	  mairei	  Wolff	  66	  to	  significantly	  inhibit	  
DNA	   topo	   II	   activity.	   4-­‐hydroxymethyl-­‐4’,5’-­‐benzopsoraien	   appeared	   to	  
inhibit	  mammalian	  topo	  II	  activity	   in	  vitro,	   in	  both	  the	  catenation	  and	  the	  
deactivations	  assays.	  
	  
	  Bis-­‐dioxopiperazines	  (Dexrazoxane	  Analogs)	  
	  
Bis-­‐dioxopiperazines	   are	   recently	   developed	   novel	   antitumor	   agents.	   The	  
parent	   bis(2,6-­‐dioxopiperazine),	   ICRF-­‐154,	   and	   its	   derivatives,	   ICRF-­‐159,	  
ICRF-­‐193,	  and	  MST-­‐16,	  all	  inhibit	  mammalian	  type	  II	  DNA	  topoisomerase67.	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ICRF	   -­‐154	  and	   related	  compounds	  are	   specific	   inhibitors	  of	   topo	   II	  with	  a	  
unique	   mode	   of	   action:	   i.e.,	   they	   interfere	   with	   some	   step(s)	   before	  
formation	   of	   the	   intermediate	   cleavable	   complex	   in	   the	   catalytic	   cycle.	  
Thus,	   bis-­‐dioxopiperazines	   are	   quite	   distinct	   from	   previously	   known	  
cleavable	  complex-­‐forming	  type	  topo	  II-­‐targeting	  antitumor	  agents	  such	  as	  
acridines,	  anthracyclines,	  and	  epipodophyllotoxins.68	  
	  
Netropsin	  and	  Its	  Dimers.	  	  
	  
Lown	   et	   al	   69	   synthesized	   a	   group	   of	   oligopeptides	   that	   are	   structurally	  
related	   to	   the	   natural	   antiviral	   antitumor	   antibiotics	   netropsin	   	   and	  
distamycin.	  Polymethylene	  bridges	  [(CH2)n,	  n	  =	  1	  and	  6–8]	  link	  two	  units	  of	  
and	   markedly	   enhance	   both	   antitumor	   and	   antivaccinia	   virus	   activity,	  
relative	  to	  the	  parent	  compounds	  .	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Both	   parent	   compounds	   and	   their	   dimers	   inhibit	   the	   catalytic	   activity	   of	  
isolated	   topo	   II	  and	   interfere	  with	   stabilization	  of	  both	   topo	   II	  and	   topo	   I	  
cleavable	  complexes	  in	  nuclei.	  70	  
	  
Cyclic	  Depsipeptides	  
	  
BE-­‐22179,	   a	   novel	   cyclic	   depsipeptide	   antibiotic,	   was	   isolated	   from	   the	  
culture	   broth	   of	   Streptomyces	   sp.	   A22179	   and	   showed	   potent	   antitumor	  
activity	  against	  various	  tumor	  cell	  lines	  both	  in	  vitro	  and	  in	  vivo	  71	  
BE-22179 	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Compound	  BE-­‐22179	   inhibited	   the	  DNA-­‐relaxing	  activity	  of	   L1210	   topo	   II,	  	  
also	   showed	   DNA-­‐intercalating	   ability	   (DNA	   unwinding).	   The	   structure	   of	  
BE-­‐22179	  	  contains	  two	  3-­‐hydroxyquinoline	  moieties	  and	  is	  quite	  novel	  for	  
a	  topo	  II	  inhibitor.	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The	   makaluvamines	   A–F,	   makaluvone,	   discorhabdin	   A,	   and	   damirone	   B	  
were	   isolated	   from	  a	   sponge	  of	   the	  genus	  Zyzzya	  by	   following	  bioactivity	  
against	  the	  human	  colon	  carcinoma	  cell	  line	  (HCT	  116).72	  These	  compounds	  
are	  considerably	  cytotoxic	  and	  may	  act	   through	   inhibition	  of	  DNA	  topo	   II.	  
The	   compounds	   show	   enhanced	   toxicity	   toward	   a	   topo	   II-­‐cleavable	  
complex-­‐sensitive	   cell	   line,	   and	   they	   inhibit	   topo	   II	   decatenation	   of	  
kinetoplast	   DNA	   in	   vitro.	   Like	   amsacrine,	   makaluvamine	   C	   	   and	  
makaluvamine	  A	   	  produced	  protein-­‐linked	  DNA	  double-­‐strand	  breaks	   in	  a	  
dose-­‐dependent	  fashion.	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Benzophenazine	  Derivative	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NC-­‐190,	   a	   novel	   benzophenazine	   derivative,	   is	   a	   potent	   antitumor	  
compound.	   Compound	   NC-­‐190	   inhibited	   the	   DNA	   strand-­‐passing	   and	  
decatenation	  activity	  of	  DNA	  topo	  II,73	  but	  only	  weakly	  inhibited	  DNA	  topo	  
I.	  In	  a	  topo	  II-­‐dependent	  DNA	  cleavage	  assay,	  NC-­‐190	  	  inhibited	  the	  enzyme	  
activity	  by	  stabilizing	  a	  topo	  II-­‐DNA	  cleavable	  complex.	  
	  
Fostriecin	  and	  Its	  Analogs	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Fostriecin R1 = H, R2 = PO3_ ,   R3 = H, R4 = OH
PD113271 R1 = OH, R2 = PO3
_ ,   R3 = H, R4 = OH
PD114631 R1 = H, R2 = H ,   R3 = H, R4 = OH
PD116425  R1 = OH, R2 = PO3
_ ,   R3 = H, R4 = OH	  
	  
Fostriecin	   (phosphotrienin,	   FST)	   is	   a	  new	  antitumor	  antibiotic,	  derivatives	  
being	   developed	   as	   anticancer	   agents	   based	   on	   their	   marked	   activity	   in	  
murine	  leukemias.	  	  
Fostriecin	   	  and	  some	  of	  its	  analogs	  inhibit	  the	  catalytic	  activity	  of	  partially	  
purified	  topo	  II	  74	  
	  
	  Isocolchicine	  
	  
Colchicine	  (i)	  ,	  a	  major	  alkaloid	  present	  in	  Colchicum	  autumnale,	  has	  been	  
extensively	  investigated,	  and	  the	  principal	  biological	  action	  of	  this	  drug	  as	  a	  
microtubule	   spindle	   toxin	   is	   well	   established.	   Recently,	   some	  
 49 
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(vi) R = NHCOCH3
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Furthermore,	   (ii)	  and	   (iii)	   inhibited	  topo	   II	  activity	  and	  were	  2-­‐fold	  and	  7-­‐
fold	   more	   potent	   than	   etoposide.	   Isocolchicine	   analogs	   (iv)	   to	   (vii)	  
completely	  inhibited	  topo	  II-­‐dependent	  DNA	  unknotting.	  
	  
	  Isoflavones	  
	  
O
OOH
HO R
OH
Genistein: R = H
Orobol : R = OH
	  
Two	   isoflavones,	   genistein	   and	   orobol,	   induced	   mammalian	   topo	   II	   DNA	  
cleavage	   in	   vitro	   with	   activities	   comparable	   to	   those	   of	   amsacrine	   and	  
etoposide	  .	  
	  
	  Streptonigrin	  
	  
Streptonigrin	   is	   a	   nonintercalative	   antitumor	   antibiotic	   produced	   by	  
Streptomyces	  sp.	  S-­‐224	  and	  S-­‐502.	  Streptonigrin	   induces	  mammalian	  topo	  
II	  dependent	  DNA	  cleavage	  in	  vitro.	  76	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Streptonigrin 	  
	  
Streptonigrin77	   stimulated	   unique	   intensity	   patterns	   of	   topo	   II-­‐mediated	  
DNA	   that	   were	   not	   similar	   to	   those	   of	   doxorubicin,	   VM-­‐26,	   amsacrine,	  
genistein	   ,	  and	  mitoxantrone.	  Streptonigrin	  may	  bind	  to	  DNA	  like	  a	  minor	  
groove	   binder,	   and	   its	   pharmacophore,	   which	   is	   possibly	   different	   from	  
other	   topo	   II	   inhibitors,	   may	   be	   an	   important	   determinant	   of	   its	   unique	  
sequence	  position	  specificity.	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2	  
Aim	  of	  the	  work	  
	  
This	  Ph.D.	  work	  was	  carried	  out	  as	  a	  part	  of	  a	  project	  focusing	  
on	   the	   search	   of	   new	   naturally	   derived	   topoisomerase	   I	  
inhibitors	  as	  potential	  antitumor	  compounds.	  Topoisomerase	  
I	   is	   the	   target	   of	   anticancer	   drug	   campthotecin	   (CPT).	   First	  
generation	   analogues	   of	   CPT	   are	   already	   approved	   as	  
anticancer	  agents	  in	  human	  therapy,	  and	  several	  second	  and	  
third	   generation	   derivatives	   are	   well	   advanced	   in	   clinical	  
trials.	   Nevertheless,	   identification	   of	   new	   campthotecins	   or	  
alternative	   molecular	   scaffolds	   endowed	   with	   similar	  
properties	   is	   highly	   desirable	   because	   CPT	   derivatives	   were	  
shown	  to	  be	  clinically	  problematic,	  above	  all	   for	  the	  instable	  
α-­‐hydroxy	   lactone	   moiety.	   Aim	   of	   this	   research	   is	   the	  
synthesis	  of	  new	  CPT	  derivatives,	  in	  an	  effort	  to	  decrease	  the	  
toxicity	   and	   improve	   the	   E	   ring	   stability	   of	   the	   natural	  
alkaloid.	   At	   the	   same	   time,	   the	   search	   of	   new	   scaffolds	  
showing	   topoisomerase	   I	   inhibitory	   activity	   was	   developed.	  
Attention	   focuses	   on	   a	   new	   class	   of	  marine	   alkaloids	   called	  
lamellarins	   that	   have	   been	   recently	   studied	   as	   Topo	   I	  
inhibitors.	   In	   this	   Ph.D.	   work	   new	   lamellarin	   analogues	   are	  
designed	   and	   synthesized.	  Molecular	  models	   of	   the	   ternary	  
complex	  formed	  between	  the	  DNA-­‐Topo	  I	  ensemble	  and	  new	  
derivatives	  have	  been	  built	  to	  optimize	  the	  scaffold	  structure.	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3	  
Synthesis	  of	  new	  cytotoxic	  E-­‐ring	  modified	  
camptothecins	  
	  
3.1	  	  
Introduction	  
	  
Camptothecin	   (CPT,	  1)	   is	   a	  natural	   compound	   isolated	   for	   the	   first	   time	   1	  
from	  the	  wood	  of	  Camptotheca	  acuminata	  Decne	  (Nyssaceae),	  a	  deciduous	  
plant	  (xi	  shu,	  happy	  tree)	  of	  Southeastern	  China,	  but	  produced	  also	  by	  the	  
Indian	  icacinacea	  Nothapodytes	  foetida	  (Wight)	  Sleumer	  (formerly	  Mappia	  
foetida	  Miers)	   2,	   and	   by	   some	   other	   plants	   3,	   the	   two	   former	   being	   the	  
major	  sources	  of	  the	  compound.	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Although	  CPT	  is	  not	  basic,	   it	  certainly	  belongs	  to	  the	  alkaloid	  family,	  as	  its	  
structure	   clearly	   shows	   the	   derivation	   from	   the	   main	   precursors	   of	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monoterpenoid	   indole	   alkaloids,	   tryptamine	   and	   secologanin.	   The	   well-­‐
known	  intermediate	  of	  this	  pathway,	  strictosamide,	  has	  been	  shown	  to	  be	  
a	   precursor	   of	   CPT,	   by	   incorporation	   of	   a	   radiolabeled	   sample.4	   The	  
subsequent	   steps	   in	   the	   rearrangement	   of	   the	   indole	   to	   the	   quinoline	  
nucleus	  most	  probably	   involve	  oxidation	  and	   recyclization	  of	   the	  C	  and	  D	  
rings,	  oxidation	  of	  the	  D	  ring	  and	  removal	  of	  the	  C-­‐21	  glucose	  moiety,	  and	  
oxidation	  of	  ring	  E.	  In	  agreement	  with	  this	  hypothesis	  is	  the	  isolation	  of	  3-­‐
(S)-­‐	   and	   3-­‐(R)	   deoxypumiloside	   and	   3-­‐(S)-­‐pumiloside	   from	   Ophiorrhiza	  
pumila,	  another	  plant	  producing	  CPT.	  (See	  ref.	  [3]	  for	  a	  detailed	  review	  of	  
CPT	  biosynthesis.)	  (Scheme	  3.1).	  13C	  NMR	  studies	  have	  established	  that	  the	  
secologanin	   moiety	   is	   formed	   via	   the	   plastidic	   nonmevalonate	   (MEP)	  
pathway,5	   but	   details	   of	   the	   last	   steps	   of	   the	   biosynthesis	   remain	  
hypothetical.	  
	  
	  
Scheme	  3.1	  
	  
Camptothecin	  was	  discovered	  during	  a	  program	  of	  screening	  plant	  extracts	  
for	  antitumor	  activity,	  launched	  by	  NCI	  in	  1955.	  The	  unusual	  activity	  of	  the	  
extracts	   of	   Camptotheca	   acuminata	   against	   some	   leukemia	   cellular	   lines	  
prompted	   a	   study	   of	   the	   components,	   which	   led	   to	   the	   bioguided	  
fractionation,	  isolation,	  and	  structural	  elucidation	  of	  CPT	  in	  1966.	  1	  As	  soon	  
as	  sufficient	  material	  became	  available,	   further	   in	  vitro	  and	   in	  vivo	  assays	  
were	  conducted,	  culminating	  in	  Phase	  I	  and	  II	  clinical	  trials	  in	  1970–1972	  .6	  
Owing	  to	  its	  extremely	  low	  solubility	  in	  water,	  CPT	  had	  to	  be	  administered	  
as	  the	  sodium	  salt	  of	  the	  hydroxycarboxylic	  acid	  2	  (Scheme	  3.2).	  However,	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shifting	   of	   the	   equilibrium	   toward	   the	   lactone	   form	   in	   tissutal	  
compartments	  with	  acid	  pH	  caused	  precipitation	  of	  crystals	  of	  CPT,	  which	  
caused	   severe	   hemorrhagic	   cystitis.	   This	   effect,	   together	   with	   other	  
toxicities,	  led	  to	  the	  termination	  of	  clinical	  trials	  in	  1972.	  
Interest	   in	   possible	   applications	   of	   CPT	   declined.	   However,	   renewed	  
interest	  in	  CPT	  emerged	  when,	  as	  a	  result	  of	  a	  cooperative	  effort	  between	  
Johns	  Hopkins	  University	  and	  SKB,	  it	  was	  found	  that	  DNA	  damage,	  which	  is	  
the	  main	   reason	   for	   the	   antitumor	   activity,	   was	   due	   to	   inhibition	   of	   the	  
ubiquitous	  nuclear	  enzyme	  topoisomerase	  I.7	  Elucidation	  of	  the	  mechanism	  
of	  action	  of	  CPT	  and,	  therefore,	  of	  a	  definite	  biological	   target	  at	  which	  to	  
aim	  new	  drugs	  gave	  rise	  to	  a	  fresh	  wave	  of	  research	  aimed	  at	  finding	  new	  
more	  active	  and	   less	  toxic	  camptothecin	  derivatives.	  This	   is	  clearly	  shown	  
by	   the	   sharp	   increase	   in	   the	   number	   of	   publications	   and	   patents	   that	  
followed	  Liu’s	  paper.	   To	  avoid	   the	  problems	  encountered	  with	  CPT	   itself,	  
the	   introduction	   of	   functional	   groups	   able	   to	   make	   the	   compounds	  
sufficiently	  water	   soluble	   to	  allow	   intravenous	  administration	  was	  a	  main	  
issue.	  
The	   results	   of	   this	   effort	   were	   a	   detailed	   pattern	   of	   structure–activity	  
relationships	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Scheme	  3.2	  
	  
and	  the	  production	  of	  two	  compounds,	  topotecan	  3	  and	  irinotecan	  4,9	  	  
which	  were	   approved	   for	   clinical	   use	   in	   1996,	   the	  main	   indications	  being	  
ovarian	  and	  small-­‐cell	  lung	  cancer	  for	  the	  former	  and	  metastatic	  colorectal	  
cancer	   for	   the	   latter.	   Irinotecan	   is	   a	   water-­‐soluble	   prodrug	   of	   the	   active	  
compound	  SN-­‐38	   5	   (Figure	  3.2).	   Several	   reviews	  of	   this	  phase	  of	   research	  
have	  been	  published.	  10–12	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Together	  with	  the	  synthesis	  and	  screening	  of	  new	  derivatives	  and	  analogs,	  
research	   continued	   unabated	   to	   unveil	   the	   details	   of	   the	   mechanism	   of	  
action	  of	  CPT	  at	  the	  molecular	   level.	  The	  decade	  1995–2005	  brought	  new	  
exciting	  results	  and	  some	  changes	  in	  the	  perspective	  of	  research	  in	  the	  CPT	  
field.13	  
	  
Fig	  3.1	  
	  
Camptothecin	   acts	   by	   forming	   a	   reversible	   ternary	   complex	   (‘‘cleavable	  
complex’’)	  with	  DNA	  and	  topoisomerase	  I,	  preventing	  the	  religation	  of	  the	  
DNA	   strand	   cut	   by	   topoisomerase	   to	   allow	   relaxation,	   and	   thus	   inducing	  
apoptosis.14	  The	  X-­‐ray	  structure	  of	  crystals	  of	  such	  a	  complex	  of	  a	  22-­‐base	  
DNA	   fragment	  with	   topoisomerase	   I	   and	   topotecan	   has	   been	   reported,15	  
and	  molecular	  models	  of	  the	  interaction	  have	  been	  proposed.16–18	  This	  kind	  
of	   information	  should	  be	  of	  help	   in	  designing	  new	  active	  compounds,	  but	  
so	  far	  no	  breakthrough	  substance	  seems	  to	  have	  been	  obtained	  on	  such	  a	  
basis,	  and	  discussion	  on	  which	  feature	  of	  ring	  E	  of	  camptothecin	  is	  essential	  
for	  activity	  is	  still	  lively.19	  
Over	   the	   years,	   the	   feature	   of	   interest	   for	   pharmacologists	   in	  
camptothecins	   has	   progressively	   shifted,	   so	   that	   water	   solubility	   is	   no	  
longer	  an	  essential	  requisite.	  Lipophilic	  compounds	  have	  the	  advantage	  of	  
compartmentation	  in	  tissues,	  thus	  assuring	  the	  stabilization	  and	  enhanced	  
persistence	  of	  the	  active	  lactone	  form,	  and	  allowing	  oral	  administration	  of	  
the	  drug,	  with	  increased	  compliance	  by	  the	  patients.	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Fig	  3.2	  
	  
A	  seminal	  paper	  in	  this	  respect	  was	  published	  by	  Burke	  in	  1993,	  20	  and	  now	  
this	   trend	   is	   largely	   accepted.21	   These	   changes	   had	   important	  
consequences	  in	  the	  design	  and	  synthesis	  of	  new	  analogs.	  In	  fact	  a	  series	  of	  
lipophilic	  analogs	  of	  CPT	  are	  in	  preclinical	  development	  at	  the	  time	  of	  	  
writing	  (2010)	  (Figure	  3.3).	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  3.2	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Another	  aspect	  of	  the	  progress	  toward	  the	  development	  of	  a	  camptothecin	  
drug	   candidate	   concerns	   the	   study	   of	   proper	   formulations,	   such	   as	  
liposomes,22	  and	  the	  finding	  of	  innovative	  drug	  delivery	  systems.23	  
For	   the	   synthesis	   of	   a	   new	   camptothecin	   derivative,	   the	   first	   choice	   is	  
between	   a	   semisynthesis	   starting	   from	   the	   natural	   compound	   CPT,	   or	   a	  
total	   synthesis.	   Camptothecin	   is	   a	   chiral	   compound,	   with	   only	   one	  
asymmetric	   center,	   carbon	   20,	   the	   active	   compounds	   possessing	   the	  
natural	   configuration	   (S).	   A	   semisynthesis	   has	   the	   advantages	   of	   starting	  
from	   a	   compound	   that	   possesses	   all	   the	   necessary	   structural	   features,	  
including	  the	  required	  20-­‐(S)	  configuration.	  The	  drawbacks	  of	  this	  approach	  
can	  be	  the	  limited	  reactivity	  of	  the	  quinoline	  nucleus	  and	  the	  sensitivity	  of	  
the	   lactone	   ring.	   For	   the	   development	   of	   a	   drug,	   difficulties	   could	   derive	  
from	  the	  possible	  failure	  of	  an	  adequate	  and	  constant	  supply	  of	  the	  natural	  
material,	  and	  from	  an	  unpredictable	  pattern	  of	   impurities	   in	  the	  different	  
batches.	  Owing	  to	  the	  high	  potency	  of	  the	  drugs,	  doses	  are	  rather	  low,	  so	  
that	   the	   amount	   of	   camptothecin	   required	   has	   so	   far	   been	   within	   the	  
capacity	  of	  the	  Chinese	  and	  Indian	  producers,	  although	  some	  concern	  has	  
been	  raised	  on	  the	  conservation	  of	  Camptotheca	  acuminata,	  which	  grows	  
only	  in	  an	  area	  of	  China	  south	  of	  the	  Yangtze	  river.	  However,	  the	  plant	  has	  
been	  shown	  to	  grow	   in	  other	  areas	  of	   the	  world,	  and	  considerable	  effort	  
has	   already	   been	   spent	   toward	   the	   production	   of	   camptothecin	   by	   cell	  
cultures.3	   On	   the	   other	   hand,	   a	   total	   synthesis	   offers	   the	   possibility	   of	  
substitutions	   and	   structural	   modifications	   that	   depend	   only	   on	   the	  
manageability	   of	   the	   synthetic	   scheme,	   so	   enlarging	   the	   diversity	   of	   the	  
target	   compounds,	   and	   is	   free	   from	   the	   constraints	   indicated	   above.	  
However,	  an	  asymmetric	   synthesis	   is	   required,	  with	   several	   steps,	  and	  so	  
far	   most	   of	   the	   total	   syntheses	   appear	   too	   expensive.	   Actually,	   the	   two	  
drugs	  currently	  in	  clinical	  practice	  and	  most	  of	  the	  candidates	  presently	  in	  
an	   advanced	   stage	   of	   development	   are	   produced	   by	   semisynthesis.	   As	  
Figure	  3.2,	  3.3	  show,	  so	  far	  the	  most	  fruitful	  modifications	  of	  CPT	  to	  obtain	  
an	  active	  antitumor	  compound	  have	  been	  the	  introduction	  of	  substituents	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in	  positions	  7,9,	  and	  10.	  	  
	  	  	  
	  
Scheme	  3.3	  
	  
The	  electron-­‐deficient	  ring	  of	  quinoline	  is	  not	  very	  reactive	  to	  electrophilic	  
substitution,	   the	   preferred	   sites	   of	   attack	   being	   position	   5	   and	   9.24	  
Nitration	  of	  CPT	  (best	  yields	  70	  %)	  25	  gives	   in	  fact	  a	  mixture	  of	  12-­‐	  and	  9-­‐
nitrocamptothecin	  6.	  The	  latter	  is	  itself	  a	  compound	  (Rubitecan)	  endowed	  
with	  potent	  antitumor	  activity,	  26	  and	  is	  a	  precursor	  of	  many	  derivatives,	  as	  
it	   can	   be	   easily	   reduced	   to	   9-­‐amino-­‐CPT	   7,	   in	   turn	   convertible	   into	   9-­‐
hydroxy-­‐	   and	   9-­‐methoxycamptothecin,	   minor	   components	   of	   the	   plant	  
extract	  (Scheme	  3.3).	  
	  
	  
Scheme	  3.4	  
	  
The	   accessibility	   of	   position	   9	   becomes	  much	   higher	   when	   an	   activating	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group,	   such	   as	   an	   OH,	   is	   present	   in	   position	   10.	   Although	   10-­‐
hydroxycamptothecin	   8	   is	   available	   in	   small	   amounts	   from	   the	   plant	  
material,	  two	  efficient	  preparations	  of	  this	  compound	  were	  developed,	  via	  
catalytic	   reduction	   of	   CPT	   in	   acid	   medium	   to	   a	   tetrahydroquinoline,	  
followed	  by	  selective	  oxidation	  with	  lead	  tetraacetate,8	  or	  phenyliodonium	  
diacetate,27	   or	   via	   a	   photochemical	   rearrangement	   of	   camptothecin	   N-­‐
oxide.28	   Thus	   activated,	   the	   nucleus	   smoothly	   undergoes	   the	   Mannich	  
reaction	  to	  give	  topotecan	  3	  (Scheme	  3.4).	  
	  
	  
Scheme	  3.5	  
	  
The	   10-­‐hydroxy	   group	   can	   facilitate	   the	   alkylation	   of	   C-­‐9	   via	   a	   Claisen	  
rearrangement,	  as	   in	   the	  case	  of	  7-­‐ethyl-­‐10-­‐hydroxy-­‐CPT,29	  or	  nitration	   in	  
the	  same	  position,	  possibly	   followed	  by	  removal	  of	   the	  OH	  and	  reduction	  
of	   the	   nitro	   group	   by	   palladium-­‐catalyzed	   deoxygenation	   to	   give	   9-­‐
aminoCPT	   7,30	   another	   drug	   candidate	   (Scheme	   3.5).	   By	   contrast,	  
substitution	  in	  position	  7	  is	  much	  easier	  thanks	  to	  the	  well-­‐known	  Minisci	  
reaction,	   which	   involves	   a	   nucleophilic	   radical	   attack	   on	   a	   protonated	  
quinoline.31	   Moreover,	   due	   to	   the	   unavailability	   of	   position	   2	   of	   the	  
quinoline	   nucleus,	   the	   reaction	   shows	   complete	   regioselectivity.	   Minisci	  
alkylation	   with	   an	   ethyl	   radical	   produced	   in	   situ	   by	   decarbonylation	   of	  
propionaldehyde	   is	   a	   crucial	   step	   in	   the	   process	   of	   preparation	   of	  
irinotecan	  4	  (Scheme	  16.6),32	  whereas	  the	  same	  kind	  of	  reaction	  led	  to	  the	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semisynthesis	   (Scheme	   16.7)	   of	   gimatecan	   9,33	   silatecan	   10,34	   and	  
belotecan	   11.35	   This	   last	   compound	   entered	   clinical	   practice	   in	   Korea	   in	  
2005.	  
	  
	  
Scheme	  3.6	  
	  
As	   soon	   as	   the	   structure	   of	   camptothecin	  was	   published,	   the	   interest	   of	  
many	   chemists,	   including	   some	   famous	   names,	  was	   directed	   toward	   this	  
synthetic	   goal,	   encouraged	   by	   the	   relevance	   of	   the	   unusual	   antitumor	  
activity.	  Later,	  when	  the	  compound	  had	  lost	  its	  novelty	  value,	  such	  studies	  
were	   stimulated	   by	   the	   desire	   to	   achieve	   a	   process	   of	   production	   of	   the	  
drugs	  derived	  from	  CPT	  and	  the	  preparation	  of	  new	  derivatives.	  Although	  
at	  first	  sight	  the	  synthesis	  of	  CPT	  might	  not	  appear,	  by	  modern	  standards,	  a	  
difficult	  task,	  the	  array	  of	  functional	  groups	  on	  ring	  E,	  not	  easily	  compatible	  
with	  many	  synthetic	  procedures,	  has	  often	  required	  a	  number	  of	  steps	  and	  
some	   detours	   to	   overcome	   the	   difficulties	   of	   a	   total	   synthesis.	   In	   some	  
cases,	   the	   problem	   has	   been	   solved	   by	   the	   invention	   of	   new	   synthetic	  
methods,	  so	  that	  the	  approaches	  have	  led	  to	  the	  addition	  of	  new	  tools	  to	  
the	  arsenal	  of	  the	  synthetic	  organic	  chemist.	  The	  early	  syntheses	  have	  been	  
reviewed	  by	  Schultz38	   and	  Hutchinson.39	  Other	   reviews,	  more	  medicinally	  
oriented,	  have	  appeared.40	  One	  of	  the	  most	  recent	  and	  detailed,	  covering	  
work	  from	  1990	  onward,	  is	  that	  of	  Du.41	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3.2	  
Results	  and	  discussion	  
	  
One	  of	   the	  major	   limitations	  of	  CPT	  and	  analogues	   is	   the	   severe	   toxicity,	  
stemming	   in	   part	   from	   the	   instability	   of	   the	   α-­‐hydroxylactone	   E-­‐ring.	  
Moreover,	  the	  CPT	  carboxylate	  binds	  tightly	  to	  serum	  albumin,	  which	  limits	  
the	  fraction	  of	  drug	  in	  the	  active	  lactone	  form.	  
In	   early	   research,	   a	   number	   of	   E-­‐ring	   modified	   CPT	   analogues	   were	  
prepared.	   These	   studies	   showed	   that	   any	   change	   in	   the	   E-­‐ring,	   such	   as	  
deletion	  of	   the	  hydroxy	   group	  at	  C20	  position,	   ring	   contraction	   to	   a	   five-­‐
membered	  lactone,	  replacement	  of	  the	  lactone	  by	  a	  lactam,	  a	  thiolactone	  
or	  an	  imide,	  reduction	  of	  the	  lactone	  to	  lactol,	  synthesis	  of	  six-­‐member	  ring	  
or	   five-­‐member	   ring	   ethers	   gave	   essentially	   inactive	   compounds.	   These	  
results	   led	   to	   the	   conclusion	   that	   the	   intact	   six-­‐membered	   ring	   was	  
indispensable	  for	  antitumor	  activity.	  
However,	   further	   investigations	   demonstrated	   that	   other	   E-­‐ring	  modified	  
CPT	  analogues	  showed	  comparable	  or	  even	  better	  antitumor	  activity	  than	  
the	  parent	  compound.	  The	  first	  successful	  approach	  was	  to	  expand	  the	  α-­‐
hydroxylactone	  ring	  by	  an	  additional	  methylene,	  thereby	  generating	  seven	  
	  
	  
	  
	  
	  
	  
	  
Figure	  3.4	  
	  
membered	  α-­‐hydroxylactone	  E-­‐ring	  analogues,	  which	  are	  referred	  to	  as	  	  
homocamptothecins	   ,	   expectedly	   less	   prone	   to	   ring	   opening.	   HomoCPTs	  
were	   reported	   to	  exert	  potent	   inhibition	  of	  Topo	   I	   and	  elevated	   levels	  of	  
cytotoxicity,	   while	   showing	   enhanced	   stability	   and	   decreased	   protein	  
binding	   in	   human	   plasma.	   Their	   dehydrated	   conjugated	   ene-­‐lactone	  
1
Homocamptothecins	  
2
Lactone-­‐free	  CPT	  analogues	  
3
Aromatic	  E-­‐ring	  CPT	  
analogue	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analogues	   were	   only	   modestly	   active	   in	   the	   TopoI	   cleavage	   test.	   Other	  
successful	   approaches	   to	   the	   synthesis	   of	   stabile	   E-­‐ring	   CPT	   derivatives	  
were	   recently	   reported.	   Five-­‐membered	   lactone-­‐free	   CPT	   analogues,	  
appeared	  to	  be	  potent	  inhibitors	  of	  TopoI	  and	  showed	  interesting	  cytotoxic	  
activity.	   Aromatic	   E-­‐ring	   CPT	   analogues	   and	   the	   natural	  
pyrroloquinazolinoquinoline	   alkaloid	   luotonin	  A,	  were	   also	   found	   to	   have	  
significant	  in	  vitro	  cytotoxic	  activity	  (Figure	  3.4).	  
These	   results	   raise	   the	  possibility	   that	  novel	  E-­‐ring	  modified	  analogues	  of	  
CPT	  might	  retain	  or	  even	  possess	  enhanced	  antitumor	  activity.	  
The	  present	   study	  was	  undertaken	   to	  explore	  a	  new	  structural	   change	  at	  
the	  E-­‐ring,	  while	  keeping	  a	  lactone	  moiety	  in	  this	  portion	  of	  the	  molecule.	  
Thus,	  we	  designed	  derivatives	  with	  an	  ‘inverted’	  lactone	  ring	  (compounds	  9	  
and	  10,	  Figure	  3.5).	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In	   these	   compounds	   the	   lactone	   ring	   is	   expected	   to	   be	   more	   stable,	  
because	   the	   carbonyl	   group,	   lacking	   the	   activating	  α-­‐hydroxy	   substituent	  
typical	  of	  camptothecins,	  should	  be	  a	  weaker	  electrophile	  than	  the	  CPT	  α-­‐
hydroxylactone	  moiety	  (compare	  the	  HomoCPTs,	  see	  above).	  
Molecular	  modelling	  studies	  were	  performed	  to	  explore	  the	  binding	  mode	  
for	   the	   planned	   compounds	   to	   the	   covalent	   TopoI–DNA	   complex.	   This	  
study	   was	   based	   on	   the	   X-­‐ray	   crystal	   structure	   of	   a	   ternary	   complex	  
between	   a	   human	   TopoI	   construct	   covalently	   100	   attached	   to	   a	   DNA	  
duplex	  with	  bound	  Topotecan.	  For	  comparison	  purposes,	  the	  same	  docking	  
protocol	  used	   to	   study	   the	   complex	   containing	  Topotecan	  was	  applied	   in	  
the	   present	   work.	   The	   intercalation	   binding	   site	   was	   created	   by	  
conformational	   changes	   of	   the	   phosphodiester	   bond	   between	   the	   +1	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(upstream)	  and	  -1	  (downstream)	  base	  pairs	  of	  the	  uncleaved	  strand,	  which	  
effectively	   ‘open’	   the	   DNA	   duplex,	   with	   the	   evidence	   of	   only	   one	   direct	  
hydrogen	  bond	  between	  the	  Asp533	  residue	  of	  the	  enzyme	  and	  Topotecan	  
in	   both	   the	   carboxylate	   and	   lactone	  models.	   The	   comparative	   analysis	   of	  
the	   best	   poses	   obtained	   for	   compound	   9	   revealed	   that	   the	   molecule	  
formed	  base-­‐stacking	  interactions	  with	  both	  the	  and	  +1	  base	  pairs,	  with	  a	  
strong	  π-­‐π	  stacking	  between	  the	  C-­‐ring	  and	  guanosine	  at	  position	  +1	  of	  the	  
cleaved	  strand	   (+1G).	  The	   interactions	  between	  compound	  9	  and	  Topo	   I–
DNA	   complex	   are	   given	   in	   Figure	   3.6	   (together	   with	   the	   experimental	  
Topotecan	   conformation),	   where	   the	   interactions	   listed	   are	   hydrogen	  
bonds.	  	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  3.6	  
	  
For	   compound	   9,	   the	   hydrogen	   bond	   between	   the	   Asp533	   residue	   and	  
Topotecan	  is	  replaced	  by	  two	  strong	  hydrogen	  bond	  interactions	  between	  
the	  lactone	  ring	  oxygen	  atom	  and	  both	  the	  NH1	  and	  NH2	  hydrogen	  atoms	  
of	  Arg364	  (close	  to	  Asp533),	  equal	  to	  2.85	  Å	  and	  3.00	  Å,	  respectively.	  Thus,	  
compound	  9	  appears	  to	  make	  use	  of	  distinct	  sets	  of	  interactions	  to	  stabilize	  
the	   binding	   mode	   at	   the	   intercalation	   site	   in	   TopoI–DNA	   complex.	   The	  
promising	   binding	   provides	   structural	   support	   to	   synthesis	   of	   9	   and	  
analogues.	   Among	   them,	   compound	   10,	   bearing	   a	   methoxy	   group	   in	  
position	  10,	   showed	  a	  calculated	   free	  energy	   (9.12	  kcal/mol)	   close	   to	   the	  
value	  calculated	  for	  compound	  9	  (9.81	  kcal/mol).	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  Figure	  3.7	  
	  
As	  shown	  in	  Figure	  3.7,	  the	  ligand	  is	  placed	  in	  the	  TopoI–DNA	  complex	  in	  
almost	  the	  same	  orientation	  as	  Topotecan	  and	  compound	  9,	  but	  the	  
molecule	  is	  shifted	  towards	  the	  entrance	  of	  the	  binding	  site.	  Consequently,	  
the	  strong	  π-­‐π	  stacking	  interaction	  is	  now	  between	  the	  B-­‐ring	  and	  +1G.	  Due	  
to	  the	  new	  position	  of	  the	  ligand,	  compound	  10	  is	  connected	  to	  the	  Topo	  I–
DNA	  complex	  through	  two	  new	  hydrogen	  bonds	  between	  the	  heterocyclic	  
nitrogen	  of	  B-­‐ring	  and	  NH1	  Arg364	  (2.93	  Å)	  and	  N2	  of	  guanosine	  +1	  (2.78	  
Å).	  	  
The	   synthesis	  of	   compound	  9	  was	  performed	  using	  natural	   camptothecin	  
as	  a	  starting	  material.	  CPT	  was	  readily	  reduced	  with	  sodium	  borohydride	  to	  
the	  corresponding	  lactol	  11,	  whose	  1,2-­‐diol	  moiety	  was	  oxidatively	  cleaved	  
with	  periodic	   acid	   to	   give	   compound	  12.	   Attempts	   to	   catalytically	   reduce	  
the	   keto	   group	   failed,	   while	   treatment	   with	   sodium	   borohydride	   in	  
DCM/methanol	  gave	  compound	  13	   in	  good	  yield.	  The	  diol	  was	  disilylated	  
using	  TBDMSCl	   in	  DCM	  and	  selective	  primary	  desilylation	  was	  successfully	  
achieved	   using	   catalytic	   PTSA	   in	   methanol.	   To	   install	   the	   carboxylic	   acid	  
moiety	   in	   the	   right	  position	   for	   the	   subsequent	   lactonization,	  one-­‐carbon	  
homologation	  of	  the	  side	  chain	  at	  position	  8	  of	  compound	  15	  was	  required.	  
Thus,	   compound	   15	   was	   converted	   into	   the	   corresponding	   tosylate	   that	  
was	   immediately	   treated	   with	   sodium	   cyanide	   to	   furnish	   compound	   17.	  
Finally,	   deprotection	   of	   the	   hydroxyl	   group	   and	   simultaneous	   hydrolysis	  
and	  cyclization	  were	  achieved	  using	  HCl	  in	  ethanol	  (Scheme	  3.7).	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Scheme	  3.7	  
	  
Synthesis	  of	  compound	  9	   from	  natural	  camptothecin.	  Reagents	  and	  conditions:	   i	  NaBH4,	  
MeOH,	  rt,	  overnight;	  ii	  NaIO4,	  AcOH,	  rt,	  overnight;	  iii	  NaBH4,	  DCM/MeOH	  8:2,	  rt,	  40	  min;	  
iv	  TBDMSCl,	   imidazole,	  DMF,	  rt,	  24	  h;	  v	  PTSA,	  DCM/MeOH	  1:1,	  0	  °C	  then	  rt,	  1	  h;	  vi	  TsCl,	  
DMAP,	  DCM,	  0	  °C,	  24	  h;	  vii	  NaCN,	  DMSO,	  70	  °C,	  2	  h;	  viii	  HCl,	  EtOH,	  90	  °C,	  1.5	  h.	  
	  
The	   synthesis	   of	   the	   corresponding	   10-­‐methoxy	   derivative	   was	   achieved	  
following	   the	   same	   pathway	   described	   for	   compound	   9,	   starting	   from	  
natural	   10-­‐OH-­‐CPT.	   It	  was	   previously	   converted	   in	   10-­‐methoxy	   derivative	  
18	   according	   the	   procedure	   described	   in	   experimental	   methods.	   In	   this	  
case	  the	  oxidative	  cleavage	  with	  sodium	  periodate	  appeared	  troublesome.	  
Several	  attempts	  were	  performed	  but	  they	  all	  resulted	  unsuccessful,	  giving	  
complex	  and	  unseparable	  mixtures	  of	  products.	   Finally,	   it	  was	   found	   that	  
treatment	   of	   a	   DCM	   solution	   of	   compound	   15	   with	   silica-­‐gel	   supported	  
NaIO4	  afforded	  compound	  16	  in	  a	  satisfactory	  yield.	  The	  remaining	  steps	  to	  
get	  compound	  10	  were	  the	  same	  as	  described	  previously	  for	  compound	  9	  
(Scheme	  3.8).	  
Compounds	   9	   and	   10	   were	   tested	   for	   their	   antiproliferative	   activity	   on	  
human	  non-­‐small	   lung	  cancer	  cells	  H-­‐460	  (1	  h	  exposure),	  using	  Topotecan	  
as	  a	  reference	  compound	  (IC50	  =	  1.38	  ±	  0.95 µM).	  Both	  analogues	  9	  and	  10,	  	  
even	  if	  still	  in	  the	  racemic	  form,	  maintained	  a	  good	  cytotoxic	  activity,	  with	  
IC50	  less	  than	  10	  µM	  (IC50	  8.73	  and	  7.45	  µM,	  respectively).	  The	  results	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Scheme	  3.8	  
	  
Synthesis	   of	   compound	   10	   from	   10-­‐methoxycamptothecin.	   Reagents	   and	   conditions:	   i	   NaBH4,	  
MeOH,	   rt,	   2h;	   ii	   Silica	   gel-­‐supported	  NaIO4,	  DCM,	   rt,	   overnight;	   iii	  NaBH4,	  DCM/MeOH	  8:2,	   rt,	   40	  
min;	  iv	  TBDMSCl,	  imidazole,	  DMF,	  rt,	  24	  h;	  v	  PTSA,	  DCM/MeOH	  1:1,	  0	  °C	  then	  rt,	  1	  h;	  vi	  TsCl,	  DMAP,	  
DCM,	  0	  °C,	  24	  h;	  vii	  NaCN,	  DMSO,	  70	  °C,	  2	  h;	  viii	  HCl,	  EtOH,	  90	  °C,	  1.5	  h.	  
	  
suggest	  that	  the	  introduction	  of	  an	  ‘inverted	  lactone’	  moiety	  in	  ring	  E	  gives	  
compounds	   with	   retained	   antitumor	   activity,	   making	   them	   worthy	   of	  
further	  investigation.	  Work	  is	  currently	  in	  progress	  to	  evaluate	  the	  effect	  of	  
substituents	  and	  to	  study	  the	  Topoisomerase	   I	   inhibitory	  activity	  of	   these	  
new	  camptothecin	  analogues.	  
	  
3.3	  
Eperimental	  methods	  
	  
1HNMR	   spectra	   were	   recorded	   in	   CDCl3	   solutions	   (where	   not	   otherwise	  
stated)	  at	  room	  temperature	  on	  a	  Bruker	  AMX-­‐300	  spectrometer	  operating	  
at	  300	  MHz	   for	   1H	  and	  75	  MHz	   for	   13C.	  Chemical	   shifts	  are	   reported	  as	  δ	  
values	   in	   parts	   per	   million	   (ppm),	   and	   are	   indirectly	   referenced	   to	  
tetramethylsilane	  (TMS)	  via	  the	  solvent	  signal	  (7.26	  for	  1H,	  77.0	  for	  13C)	  in	  
CDCl3.	   Coupling	   constants	   (J)	   are	   given	   in	   Hz.	   Solvents	   were	   routinely	  
distilled	   prior	   to	   use;	   anhydrous	   tetrahydrofuran	   (THF)	   and	   ether	   (Et2O)	  
were	   obtained	   by	   distillation	   from	   sodium-­‐benzophenone	   ketyl;	   dry	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methylene	  chloride	  (CH2Cl2)	  and	  toluene	  were	  obtained	  by	  distillation	  from	  
CaCl2.	  All	  reactions	  requiring	  anhydrous	  conditions	  were	  performed	  under	  
a	   positive	   nitrogen	   flow,	   and	   glassware	   was	   oven-­‐dried.	   Isolation	   and	  
purification	   of	   the	   compounds	   were	   performed	   by	   flash	   column	  
chromatography	   on	   silica	   gel	   60	   (230-­‐400	   mesh);	   when	   necessary	  
deactivated	  silica	  gel	  was	  used.	  Analytical	  thin-­‐layer	  chromatography	  (TLC)	  
was	  conducted	  on	  Fluka	  TLC	  plates	  (silica	  gel	  60	  F254,	  aluminium	  foil),	  and	  
spots	   were	   visualized	   by	   UV	   light	   and/or	   by	   means	   of	   dyeing	   reagents.	  
Melting	   points	   were	   determined	   on	   a	   Stuart	   Scientific	   SMP3	   instrument	  
and	  are	  uncorrected.	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11.	  4-­‐Ethyl-­‐3,4-­‐dihydroxy-­‐1,3,4,12-­‐tetrahydro-­‐2-­‐oxa-­‐6,12a-­‐diaza-­‐
dibenzo[b,h]fluoren-­‐13-­‐one.	  
	  
N
N
O
O
OHOH 	  
C20H18N2O4
Mol. Wt.: 350,37 	  
	  
Camptothecin	  1	   (1g,	   2,87	  mmol)	  was	   dissolved	   in	  methanol	   (75	  mL)	   and	  
NaBH4	   (0,163	   g,	   4,30	   mmol)	   was	   added	   sequentially	   in	   10’	   at	   r.t.	   After	  
stirring	  overnight	  and	  evaporating	  the	  solvent,	  the	  mixture	  was	  poured	  in	  
water.	  AcOH	  solution	  was	  dropped	  until	  pH	  7	  and	  the	  solution	  was	  cooled	  
at	  0°C	  to	  facilitate	  the	  precipitation.	  The	  white	  solid	  was	  filtered	  and	  dried	  
(0,	  900	  g,	  90	  %).	  
	  
1H	  NMR	  (DMSO):	  8.70	  (1H,	  s),	  8.	  37	  (1H,	  s),	  8.10-­‐8.20	  (2H,	  m),	  7.89	  (1H,	  m),	  
7.75	  (1H,	  m),	  7.42	  (1H,	  s),	  5.20	  (2H,	  s),	  4.95	  (2H,	  m),	  4.50	  (2H,	  m),	  3.93	  (3H,	  
s),	  1.75	  (2H,	  m),	  0.90	  (3H,	  t,	  J=7.4).	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12.	  Formic	  acid	  9-­‐oxo-­‐7-­‐propionyl-­‐9,11-­‐dihydro-­‐indolizino[1,2-­‐b]quinolin-­‐
8-­‐ylmethyl	  ester	  
	  
N
N
O
O
O O
H
	  
C20H16N2O4
Mol. Wt.: 348,35 	  
	  
Compound	  11	  (0.895	  g,	  2.57	  mmol)	  was	  suspended	  in	  acetic	  acid	  (115	  mL)	  
at	   room	   temperature.	   To	   the	   suspension	  was	   added	   NaIO4	   (1.65	   g,	   7.71	  
mmol).	   The	   mixture	   reaction	   was	   stirred	   overnight	   and	   the	   solvent	   was	  
evaporated	   under	   vacuo.	  Water	   was	   added	   to	   the	   and	   the	   mixture	   was	  
extracted	   twice	   with	   dichloromethane.	   The	   combined	   organic	   layer	   was	  
dried	   over	   NaSO4	   and	   evaporated.	   The	   residue	   was	   purified	   by	   flash	  
chromatography	   (eluent	  dichloromethane:	  methanol,	   95:5)	   to	   afford	  12	   (	  
0.696	  g,	  78%).	  
	  
1H	  NMR	  (DMSO):	  8.70	  (1H,	  s),	  8.	  37	  (1H,	  s),	  8.10-­‐8.20	  (2H,	  m),	  7.89	  (1H,	  m),	  
7.75	  (1H,	  m),	  7.42	  (1H,	  s)	  5.30	  (2H,	  s),	  5.12	  (2H,	  s),	  2.90	  (2H,	  q,	  J=7.04	  Hz),	  
1.10	  (3H,	  t,	  J=7.04	  Hz).	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13.	  8-­‐Hydroxymethyl-­‐7-­‐(1-­‐hydroxy-­‐propyl)-­‐11H-­‐indolizino[1,2-­‐b]quinolin-­‐
9-­‐one	  
	  
N
N
OH
O
HO
C19H18N2O3
Mol. Wt.: 322,36 	  
	  
Compound	   2	   (0.690	   g,	   2	   mmol)	   was	   dissolved	   in	   dichloromethane-­‐
methanol	   	   (140	   mL,	   80:20).	   The	   solution	   was	   treated	   with	   NaBH4	   and	  
stirred	  at	  room	  temperature.	  After	  40’	  AcOH	  was	  dropped	  until	  pH	  7,	  the	  
solvent	   evaporated	   and	   the	   crude	   product	   purified	   by	   flash	  
chromatography	   	   (dichloromethane:	  methanol,	  9:1)	   to	  afford	  13	   (0.560	  g,	  
87%)	  
	  
1H	  NMR	  (DMSO):	  8.68	  (1H,	  s),	  8.10-­‐8.20	  (2H,	  m),	  7.83	  (1H,	  m),	  7.70	  (1H,	  m),	  
7.40	  (1H,	  s),	  5.42	  (1H,	  m),	  5.25	  (2H,	  s),	  4.80-­‐4.95	  (2H,	  m),	  4.48-­‐4.70	  (2H,	  m),	  
1.75	  (2H,	  m),	  0.98	  (3H,	  t,	  J=7.4	  Hz).	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14.	  8-­‐(tert-­‐Butyl-­‐dimethyl-­‐silanyloxymethyl)-­‐7-­‐[1-­‐(tert-­‐butyl-­‐dimethyl-­‐
silanyloxy)-­‐propyl]-­‐11H-­‐indolizino[1,2-­‐b]quinolin-­‐9-­‐one.	  
	  
N
N
OTBS
O
TBSO
C31H46N2O3Si2
Mol. Wt.: 550,88 	  
	  
A	  solution	  of	  compound	  13	  (0.555	  g,	  1.74	  mmol)	  in	  dry	  DMF	  (28	  mL)	  was	  
treated	  sequentially	  with	  imidazole	  (1.89	  g,	  2784	  mmol)	  and	  t-­‐butyl	  
chlorodimethylsilane	  (2.1	  g,	  13.92	  mmol)	  under	  nitrogen	  atmosphere	  and	  
stirred	  for	  24	  hours	  at	  room	  temperature.	  Solvent	  was	  evaporated	  and	  the	  
residue	  was	  dissolved	  in	  dichloromethane	  and	  washed	  with	  NaCl	  solution.	  
Organic	  layer	  was	  dried	  over	  NaSO4	  and	  evaporated	  under	  vacuo.	  The	  
crude	  product	  was	  purified	  by	  flash	  chromatography	  (dichloromethane:	  
methanol,	  9:1)	  to	  afford	  compound	  14	  (0.574	  g,	  70%).	  
	  
1H	  NMR	  (CDCl3):	  8.42	  (2H,	  m),	  7.82-­‐7.95	  (3H,	  m),	  7.62	  (1H,	  m),	  5.24	  (2H,	  s),	  
5.00-­‐5.10	  (	  2H,	  m),	  4.75	  (2H,	  m),	  1.82	  (2H,	  m),	  1.82	  	  (2H,	  m),	  1.10	  (3H,	  t,	  J=	  
7.4	  Hz),	  0.98	  (18H,	  s),	  0.10	  (12H,	  s)	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15.	  7-­‐[1-­‐(tert-­‐Butyl-­‐dimethyl-­‐silanyloxy)-­‐propyl]-­‐8-­‐hydroxymethyl-­‐11H-­‐
indolizino[1,2-­‐b]quinolin-­‐9-­‐one	  
	  
N
N
OH
O
TBSO
C25H32N2O3Si
Mol. Wt.: 436,62 	  
	  
A	  solution	  of	  14	   (0.570	  g,	  1.04	  mmol)	   in	  dichloromethane:	  methanol	  (100	  
mL,	   1:1)	  was	   cooled	   to	   0°C	   and	   treated	  with	   PTSA	   (0.179	   g,	   0.52	  mmol).	  
The	  cooling	  bath	  was	  removed	  and	  the	  reaction	  mixture	  allowed	  to	  warme	  
to	  room	  temperature.	  After	  1h	  a	  NaHCO3	  solution	  was	  added,	  the	  mixture	  
was	   concentrated	   under	   reduced	   pressure;	   dichloromethane	   was	   added	  
and	  washed	  with	  water	  and	  NaCl.	  The	  organic	  layer	  was	  dried	  on	  Na2SO4	  ,	  
evaporated	   and	   the	   crude	   product	   purified	   by	   flash	   chromatography	  
(dichloromethane	  :	  methanol,	  1:1)	  to	  afford	  product	  15	  (0.309	  g,	  68%).	  
	  
1H	  NMR	  (CDCl3):	  8.40	  (1H,	  s),	  8.30	  (1H,	  m),	  7.91	  (1H,	  m),	  7.85	  (1H,	  m),	  7.60-­‐
7.75	  (2H,	  m),	  5.27	  (2H,	  s),	  4.75-­‐4.90	  (3H,	  m),	  1.80	  (2H,	  m),	  1.10	  (3H,	  t,	  J=	  7.4	  
Hz),	  0.90	  (9H,	  s),	  0.15	  (3H,	  s),	  0.01	  (3H,	  s).	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16.	  Toluene-­‐4-­‐sulfonic	  acid	  7-­‐[1-­‐(tert-­‐butyl-­‐dimethyl-­‐silanyloxy)-­‐ethyl]-­‐9-­‐
oxo-­‐9,11-­‐dihydro-­‐indolizino[1,2-­‐b]quinolin-­‐8-­‐ylmethyl	  ester	  
	  
N
N
OTs
O
TBSO
C32H38N2O5SSi
Mol. Wt.: 590,81 	  
	  
To	   an	   ice-­‐cooled	   solution	   of	   compound	   15	   (0.303	   g,	   0.71	   mmol)	   in	   dry	  
dichloromethane	   (16	   mL)	   was	   added	   DMAP	   (0.564	   g,	   4.61	   mmol)	   and	  
successively	  TsCl	   (0.675	  g,	  3.55	  mmol)	  under	  nitrogen.	  After	  being	  stirred	  
for	   24h	   at	   0°C,	   the	   mixture	   was	   added	   with	   water	   and	   washed	   with	   a	  
NaHCO3	  solution.	  The	  organic	  layer	  was	  dried	  over	  Na2SO4	  and	  evaporated	  
affording	  crude	  product	  16,	  that	  was	  used	  for	  the	  next	  step	  without	  further	  
purification	  (0.459	  g).	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17.	  {7-­‐[1-­‐(tert-­‐Butyl-­‐dimethyl-­‐silanyloxy)-­‐propyl]-­‐9-­‐oxo-­‐9,11-­‐dihydro-­‐
indolizino[1,2-­‐b]quinolin-­‐8-­‐yl}-­‐acetonitrile.	  
	  
N
N
CN
O
TBSO
C26H31N3O2Si
Mol. Wt.: 445,63 	  
	  
To	  a	  solution	  of	  compound	  16	  (453	  mg)	  in	  DMSO	  (7	  mL)	  was	  added	  NaCN	  
(0057	   g,	   1.2	   mmol)	   and	   the	   mixture	   was	   heated	   at	   70°C	   for	   2	   h.	  	  
Dichloromethane	   was	   added	   and	   washed	   twice	   with	   NaCl	   solution.	   The	  
organic	   layer	  was	  dried	  over	  Na2SO4,	  evaporated	  under	   reduced	  pressure	  
and	  purified	  by	  flash	  chromatography	  (dichloromethane:methanol,	  98:2)	  to	  
afford	  product	  17	  (0.188	  g,).	  
	  
1H	  NMR	  (CDCl3):	  8.50	  (1H,	  s),	  8.40	  (1H,	  m),	  7.90	  (1H,	  m),	  7.82	  (1H,	  m),	  7.60-­‐
7.75	  (2H,	  m),	  5.30	  (2H,	  s),	  4.80	  (1H,	  m),	  3.95	  (2H,	  m),	  1.82	  (2H,	  m),	  1.00	  
(3H,	  t,	  J=	  7.4Hz),	  0.90	  (9H,	  s),	  0.90	  (9H,	  s),	  0.10	  (3H,	  s),	  -­‐0.1	  (3H,	  s).	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9.	  4-­‐Ethyl-­‐1,12-­‐dihydro-­‐4H-­‐3-­‐oxa-­‐6,12a-­‐diaza-­‐dibenzo[b,h]fluorene-­‐2,13-­‐
dione	  
	  
N
N
O
O
O
C20H16N2O3
Mol. Wt.: 332,35 	  
	  
Compound	  17	  (0.183	  g,	  0.42	  mmol)	  was	  suspended	  in	  ethanol	  (2	  mL),	  	  and	  	  
added	  with	  ethanol	  saturated	  with	  HCl	  (2	  mL)	  under	  stirring.	  The	  reaction	  
mixture	  was	  heated	  at	  90°C	  for	  1.5	  h,	  then	  AcOEt	  was	  added	  and	  washed	  
with	  a	  NaCl	  solution.	  The	  organic	  layer	  was	  dried	  over	  Na2SO4,	  evaporated	  
under	   reduced	   pressure,	   purified	   by	   flash	   chromatography	  
(dichloromethane:acetone,	   7:3)	   and	   crystallization	   from	   ethyl	   ether	   to	  
afford	  product	  8	  (0.04	  g,	  29%).	  Mp	  320	  °C	  
	  
1H	  NMR	  (DMSO):	  8.	  70	   (1H,	   s),	  8.10-­‐8.20	   (2H,	  m),	  7.86	   (1H,	  m),	  7.70	   (1H,	  
m),	   7.30	   (1H,	   s),	   5.58	   (1H,	  m),	   5.31	   (2H,	   s),	   3.68	   (2H,	  m),	   2.10	  9	   (2H,	  m),	  
1.10	  (3H,	  t,	  J=	  7.4	  Hz).	  
HRMS	  (ESI+)	  calcd	  for	  C20H16N2O3	  [M+Na]+	  355.10531:	  found	  .355.10612	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18.	  10-­‐methoxycamptothecin	  	  
	  
N
N
O
O
OOH
H3CO
C21H18N2O5
Mol. Wt.: 378,38 	  
	  
To	  a	   suspension	  of	  10-­‐OH-­‐camptothecin	   (1.70	  g,	  4.67mmol)	   in	  methanol-­‐
dioxane	   (350	   mL,	   1:1)	   was	   added	   dropwise	   a	   freshly	   distilled	   ethereal	  
solution	  of	  diazomethane	  	  until	  the	  starting	  material	  was	  dissolved	  giving	  a	  
yellow	  solution.	  The	  reaction	  mixture	  was	  stirred	  for	  2	  h.	  The	  solvent	  was	  
evaporated	  under	  reduced	  pressure	  to	  afford	  10-­‐methoxycamptothecin	  18	  
(1.77	  g,	  100%)	  as	  a	  yellow	  solid.	  Mp	  287	  °	  C	  
	  
1H	  NMR	  (DMSO):	  8.51	  (1H,	  s),	  8.00	  (1H,	  m),	  7.45-­‐7.55	  (2H,	  m),	  7.25	  (1H,	  s),	  
6.50	  (1H,	  s),	  5.50	  (2H,	  s),	  5.21	  (2H,	  s),	  4.00	  (3H,	  s),	  1.81	  (2H,	  m),	  0.80	  (3H,	  t,	  
J=	  7.4	  Hz).	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19.	  4-­‐Ethyl-­‐3,4-­‐dihydroxy-­‐9-­‐methoxy-­‐1,3,4,12-­‐tetrahydro-­‐2-­‐oxa-­‐6,12a-­‐
diaza-­‐dibenzo[b,h]fluoren-­‐13-­‐one.	  
	  
N
N
O
O
OHOH
H3CO
C21H20N2O5
Mol. Wt.: 380,39 	  
	  
10-­‐methoxycamptothecin	   (1.75	  g,	  4.6	  mmol)	  was	   suspended	   in	  methanol	  
(180	  mL).	  NaBH4	  (1.77g,	  4.67	  mmol)	  was	  added	  in	  portions	   in	  10’	  at	  room	  
temperature	  and	  the	  mixture	  was	  stirred	  for	  2	  h.	  Solvent	  was	  evaporated	  
under	   reduced	   pressure	   and	   the	   crude	   mixture	   was	   filtered	   over	   a	  
phosphate-­‐buffered	   silica	   pad	   (dichloromethane:methanol,	   7,5:	   2,5)	   to	  
affordi	  	  2	  (1.60	  g,	  90%).	  Mp	  300	  °	  C	  
	  
1H	  NMR	  (DMSO):	  8.50	  (1H,	  s),	  8.01	  (1H,	  m),	  7.49	  (2H,	  m),	  7.30	  (1H,	  s),	  6.70	  
(1H,	  d),	  5.20	  (2H,	  s),	  4.95	  (2H,	  m),	  4.50	  (2H,	  m),	  3.93	  (3H,	  s),	  1.75	  (2H,	  m),	  
0.90	  (3H,	  t,	  J=7.4).	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20.	  Formic	  acid	  2-­‐methoxy-­‐9-­‐oxo-­‐7-­‐propionyl-­‐9,11-­‐dihydro-­‐indolizino[1,2-­‐
b]quinolin-­‐8-­‐ylmethyl	  ester.	  
	  
N
N
O
O
O O
H
H3CO
C21H18N2O5
Mol. Wt.: 378,38 	  
	  
Compound	  19	  (1.55	  g,	  4.21	  mmol)	  was	  suspended	  in	  dichloromethane	  (150	  
mL)	  and	  silica	  supported	  NaIO4	  (8.42	  g,	  1.72	  g	  of	  NaIO4)	  was	  added	  at	  room	  
temperature.	  The	  reaction	  mixture	  was	  stirred	  for	  24	  h,	  filtered	  over	  a	  silica	  
pad	   (dichloromethane:methanol,	   8:2),	   affording	   a	   solution	   of	   compound	  
20,	  which	  was	  used	  for	  the	  next	  step	  without	  further	  purification.	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21.	  7-­‐(1-­‐Hydroxy-­‐ethyl)-­‐8-­‐hydroxymethyl-­‐2-­‐methoxy-­‐11H-­‐indolizino[1,2-­‐
b]quinolin-­‐9-­‐one.	  
	  
N
N
OH
O
HO
H3CO
C20H20N2O4
Mol. Wt.: 352,38 	  
	  
To	  the	  above	  solution	  of	  20	  was	  added	  NaBH4	  (0.318	  g,	  8.40	  mmol)	  in	  10’	  at	  
room	   temperature	   and	   the	   reaction	   mixture	   was	   stirred	   for	   30’.	   THE	  
Solvent	   was	   evaporated	   under	   reduced	   pressure	   and	   the	   crude	   product	  
was	  purified	  by	  filtration	  of	  its	  solution	  in	  (dichloromethane:methanol,	  8:2)	  
over	  a	  silica	  pad	  to	  afford	  compound	  21	  (1g).	  
	  
1H	  NMR	  (CDCl3):	  8.20	  (1H,	  s),	  8.12	  (1H,	  d,	  J=8.9	  Hz),	  7.60	  (1H,	  s),	  7.48	  (1H,	  d,	  
J=8.9	  Hz),	  7.12	  (1H,	  s),	  5.22	  (2H,	  s),	  5.95-­‐5.02	  (2H,	  m),	  4.70	  (1H,	  m),	  4.00	  
(3H,	  s),	  1.78	  (2H,	  m),	  0.98	  (3H,	  m).	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22.	  8-­‐(tert-­‐Butyl-­‐dimethyl-­‐silanyloxymethyl)-­‐7-­‐[1-­‐(tert-­‐butyl-­‐dimethyl-­‐
silanyloxy)-­‐propyl]-­‐2-­‐methoxy-­‐11H-­‐indolizino[1,2-­‐b]quinolin-­‐9-­‐one.	  
	  
N
N
OTBS
O
TBSO
H3CO
C32H48N2O4Si2
Mol. Wt.: 580,91 	  
	  
An	   ice-­‐cooled	   solution	  of	   compound	  22	   (0.995	  g,	   2.84	  mmol)	   in	  dry	  DMF	  
(100	  mL)	  was	  treated	  sequentially	  with	  imidazole	  (3.09	  g,	  45	  mmol)	  and	  t-­‐
butylchlorodimethylsilane	   (3.42	   g,	   23	   mmol)	   under	   nitrogen	   atmosphere	  
and	   stirred	   for	   24	   hours.	   The	   solid	   formed	   was	   isolated	   by	   filtration,	  
dissolved	   in	   dichloromethane	   and	   washed	   with	   water	   and	   NaCl.	   The	  
organic	  layer	  was	  dried	  over	  Na2SO4	  and	  evaporated	  under	  vacuo	  to	  afford	  
compound	  22	  (1.50	  g,	  96%).	  
	  
1H	  NMR	  (CDCl3):	  8.50	  (1H,	  s),	  8.00	  (1H,	  d,	  J=	  8.1	  Hz),	  7.41-­‐7.50	  (2H,	  m),	  7.20	  
(1H,	  s),	  5.21	  (2H,	  s),	  4.65-­‐4.95	  (3H,	  m),	  3.93	  (3H,	  s),	  1.75	  (2H,	  m),	  0.80-­‐1.05	  
(12H,s)	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23.	  7-­‐[1-­‐(tert-­‐Butyl-­‐dimethyl-­‐silanyloxy)-­‐propyl]-­‐8-­‐hydroxymethyl-­‐2-­‐
methoxy-­‐11H-­‐indolizino[1,2-­‐b]quinolin-­‐9-­‐one.	  
	  
N
N
OH
O
TBSO
H3CO
C26H34N2O4Si
Mol. Wt.: 466,64 	  
	  
A	  solution	  of	  22	  (1.45	  g,	  2.72	  mmol)	  in	  dichloromethane:methanol	  (80	  mL,	  
1:1)	  was	   cooled	   to	   0°C	  and	   treated	  with	  PTSA	   (0.234	   g,	   1.36	  mmol).	   The	  
cooling	   bath	  was	   removed	   and	   the	   reaction	  mixture	   allowed	   to	  warm	   to	  
room	   temperature.	   After	   1h	   a	   NaHCO3	   solution	   was	   added,	   the	   mixture	  
was	   concentrated	   under	   reduced	   pressure;	   dichloromethane	   was	   added	  
and	  washed	  with	  water	  and	  NaCl.	  The	  organic	  layer	  was	  dried	  over	  Na2SO4	  
and	  evaporated	  to	  afford	  product	  23	  (0.570	  g,	  45%).	  Mp	  200	  °	  C	  
	  
1H	  NMR	  (CDCl3):	  8.20	  (1H,	  s),	  8.11	  (1H,	  d,	  J=	  8.9	  Hz),	  7.10	  (1H,	  s),	  5.22	  (2H,	  
s),	   4.70-­‐4.90	   (3H,	  m),	   3.95	   (3H,	   s),	   1.80	   (2H,	  m),	   0.85-­‐1.10	   (12H,	  m),	   0.10	  
(3H,	  s),	  0.01	  (3H,	  s).	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24.	  Toluene-­‐4-­‐sulfonic	  acid	  7-­‐[1-­‐(tert-­‐butyl-­‐dimethyl-­‐silanyloxy)-­‐propyl]-­‐
2-­‐methoxy-­‐9-­‐oxo-­‐9,11-­‐dihydro-­‐indolizino[1,2-­‐b]quinolin-­‐8-­‐ylmethyl	  ester.	  
	  
N
N
OTs
O
TBSO
H3CO
C33H40N2O6SSi
Mol. Wt.: 620,83 	  
	  
To	   an	   ice-­‐cooled	   solution	   of	   compound	   23	   (0.470	   g,	   0.99	   mmol)	   in	   dry	  
dichloromethane	   (20	   mL)	   were	   added	   DMAP	   (0792	   g,	   6.49	   mmol),	   then	  
TsCl	  (0.949	  g,	  4.99	  mmol)	  under	  nitrogen.	  After	  being	  stirred	  for	  24h	  at	  0°C	  
the	  mixture	  was	  added	  w3ith	  water	  and	  washed	  with	  a	  NaHCO3	  solution.	  
The	  organic	   layer	  was	  dried	  over	  Na2SO4	  and	  evaporated	  affording	   crude	  
product	  24,	  which	  was	  used	  for	  the	  next	  step	  without	  further	  purification	  
(0.800	  g).	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25.	  {7-­‐[1-­‐(tert-­‐Butyl-­‐dimethyl-­‐silanyloxy)-­‐propyl]-­‐2-­‐methoxy-­‐9-­‐oxo-­‐9,11-­‐
dihydro-­‐indolizino[1,2-­‐b]quinolin-­‐8-­‐yl}-­‐acetonitrile.	  
	  
N
N
CN
O
TBSO
H3CO
C27H33N3O3Si
Mol. Wt.: 475,65 	  
	  
To	  a	  solution	  of	  crude	  compound	  24	  (0.800	  g)	  in	  DMSO	  (10	  mL)	  was	  added	  
NaCN	   (0.073	   g,	   1.49	  mmol)	   and	   the	  mixture	  was	  heated	   at	   50°C	   for	   2	  h.	  	  
Dichloromethane	   was	   added	   and	   washed	   twice	   with	   NaCl	   solution.	   The	  
organic	   layer	   was	   dried	   over	   Na2SO4,	   and	   evaporated	   under	   reduced	  
pressure	  to	  afford	  compound	  25	  (0.350	  g).	  Mp	  210	  °C.	  
	  
1H	  NMR	  (CDCl3):	  8.40	  (1H,	  s),	  8.12	  (1H,	  d,	  J=	  8.6	  Hz),	  7.50	  (1H,	  d,	  J=	  8.6	  Hz),	  
7.40	  (1H,	  s),	  7.18	  (1H,	  s),	  5.29	  (2H,	  s),	  4.75	  (1H,	  m),	  3.95	  (3H,	  s),	  3.90	  -­‐3.95	  
(2H,	  m),	  1.91	  (2H,	  m),	  1.10	  (3H,	  t,	  J=	  7.4	  Hz),	  0.90	  (9H,	  m),	  0.20	  (3H,	  s),	  0.01	  
(3H,	  s).	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10.	  4-­‐Ethyl-­‐9-­‐methoxy-­‐1,12-­‐dihydro-­‐4H-­‐3-­‐oxa-­‐6,12a-­‐diaza-­‐dibenzo	  
[b,h]fluorene-­‐2,13-­‐dione	  
	  
N
N
O
O
O
H3CO
C21H18N2O4
Mol. Wt.: 362,38 	  
	  
Compound	  8	   (0.100	  g,	  0.21mmol)	  was	  suspended	   in	  ethanol	   (1	  mL),	   then	  
ethanol	  saturated	  with	  HCl	  (1	  mL)	  was	  added	  	  under	  stirring.	  The	  reaction	  
mixture	  was	   heated	   at	   50°C	   for	   1.5	   h,	   then	   dichloromethane	  was	   added	  
and	   washed	   with	   a	   NaHCO3	   solution.	   The	   organic	   layer	   was	   dried	   over	  
Na2SO4,	   evaporated	   under	   reduced	   pressure,	   and	   purified	   by	   flash	  
chromatography	   (dichloromethane:	   acetone,	   7:	   3)	   to	   afford	   product	   10	  
(0.01	  g,	  13%).	  Mp	  278	  °	  C	  
	  
1H	  NMR	  (CDCl3):	  8.28	  (1H,	  s),	  8.10	  (1H,	  d,	  J=	  8.46	  Hz),	  7.50	  (1H,	  dd,	  J=8.46-­‐
1.47),	  7.19	  (1H,	  d,	  J=1.47),	  7.10	  (1H,	  s),	  5.41	  (1H,	  m),	  5.31	  (2H,	  s),	  4.00	  (3H,	  
s),	  3.89	  (1H,	  ab),	  3.62	  (1H,	  ab),	  2.10	  (2H,	  m),	  1.10	  (1H,	  d,	  J=1.47).	  
HRMS	  (ESI+)	  calcd	  for	  C21H18N2O4	  [M+H]+	  363.13393;	  found	  363.13426;	  
HRMS	  (ESI+)	  calcd	  for	  C21H18N2O4Na	  [M+Na]+	  385.15500;	  found	  385.11626	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4	  
Design	  and	  synthesis	  of	  new	  cytotoxic	  lamellarin	  D	  
analogues.	  
	  
4.1	  	  
Introduction	  
	  
Over	  100	  of	  the	  most	  important	  drugs	  in	  use	  today	  derive	  from	  terrestrial	  
organisms,	   either	   bacteria,	   fungi,	   or	   plants.1	   By	   contrast,	   the	   chemical	  
diversity	   of	  marine	   life,	  which	   is	   estimated	   to	   about	   two	  million	   species,	  
remains	   largely	   underexplored.2	   This	   exceptional	   reservoir	   represents	   a	  
vast	  chemical,	  structural,	  and	  biological	  diversity	  of	  molecules,	  often very 
distinct from those found in terrestrial natural compounds.	   The	  most	  
frequent	  marine	   species	   used	   as	   sources	   of	   bioactive	   drugs	   are	   sponges,	  
ascidians,	  mollusks,	  echinoderms,	  bryozoans,	  algae,	  and	  coelenterates	  (sea	  
whips,	  sea	  fans,	  and	  coral).3	  One of the first key bioactive molecules of 
marine origin was spongothymidine, initially extracted from the 
sponge Cryptotethia crypta and identified by Werner Bergmann, an 
organic chemist in the 1950s.4-6 This	   molecule	   is	   a	   nucleoside	   with	   a	  
modified	   sugar,	   which	   interferes	   with	   DNA	   replication	   and	   inhibits	   the	  
growth	  of	  some	  bacteria,	  viruses,	  and	  cancer	  cells.	  A	  few	  years	  later,	  Evans	  
and	   coworkers	   synthesized	   other	   ‘‘false’’	   nucleosides,	   including	  
arabinosylcytosine	  (Cytarabine	  or	  ara-­‐C)	  used	  mainly	   for	   the	  treatment	  of	  
acute	   leukemia	   and	   non-­‐Hodgkin’s	   lymphoma.7	   Cytarabine	   also	   displays	  
antiviral	   activities,	   of	   potential	   use	   for	   the	   treatment	   of	   herpes	   virus	  
infections.	   But	   during	   the	   following	   two	   decades,	   this	   field	   of	   research	  
implicating	   molecules	   of	   marine	   origin	   evolved	   relatively	   slowly,	   at	   least	  
compared	   to	   the	   huge	   efforts	   devoted	   to	   the	   identification	   of	   new	  
molecules	  from	  plants	  and	  microorganisms.	  The	  reason	  is	  that	  the	  marine	  
material	   was	   generally	   collected	   by	   hand,	   and	   in	   most	   cases	   only	   small	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quantities	   of	   the	   living	  material	   could	   be	   obtained.	   It	   was	   (and	   remains)	  
common	   to	   isolate	   less	   than	  one	  milligram	  of	  a	  bioactive	   substance	   from	  
one	   kilogram	   (when	   available)	   of	   the	   marine	   organism.	   But	   today,	  
extremely	  sensitive	  methods	  of	  NMR	  spectroscopy	  and	  mass	  spectrometry	  
combined	  with	  liquid	  chromatography	  (HPLC,	  UPLC)	  are	  routinely	  used	  for	  
the	  characterization	  of	  new	  drug	  structures.8	  Complex	  molecular	  structures	  
can	  be	  solved	  with	  much	  less	  that	  1	  mg	  of	  compounds,	  without	  too	  much	  
difficulty	   in	  most	   cases	   (although	   there	   are	   notorious	   exceptions).	   A	   few	  
drugs	  derived	  from	  the	  sea	  are	  being	  developed	  for	  their	  biological	  activity	  
in	  the	  field	  of	  inflammation	  (manoalide,	  pseudopterosins)	  and	  Alzheimer’s	  
disease	   (GTS-­‐21),	   to	   cite	   only	   two	   examples.9-­‐12	   The	   first	   totally	   marine-­‐
derived	  drug	  approved	  by	  the	  Food	  and	  Drug	  Administration	  was	  zicotinide	  
(Prialt,	   developed	   by	   Elan	   Pharmaceuticals)	   in	   December	   2004,	   for	   the	  
treatment	  of	  chronic	  and	  severe	  pain.13	  The	  field	  of	  cancer	  chemotherapy	  
has	   been	   also	  widely	   investigated	   using	  marine-­‐derived	  molecules.	  Many	  
natural	   products	   of	   marine	   origin	   are	   toxins	   and	   cytotoxic	   agents,	  
potentially	   useful	   to	   inhibit	   cancer	   cell	   proliferation.	  A	  handful	   of	  marine	  
compounds	  has	  reached	  phases	  II	  or	  III	  of	  clinical	  trials	  in	  oncology.	  This	  is	  
the	  case	  for	  certain	  dolastatin	  derivatives	  (soblidotin,	  tasitodin)	  as	  mitotic	  
inhibitors,14-­‐15	   bryostatin	   1,	   an	   activator	   of	   protein	   kinase	   C,16	  
ecteinascidin-­‐743,	   a	   powerful	   DNA	   alkylating	   drug,17	   neovastat,	   a	  
pleiotropic	   antiangiogenic	   agent,	   which	   prevents	   the	   binding	   of	   the	  
vascular	   endothelial	   growth	   factor	   (VEGF)	   to	   its	   receptors,	   inhibits	  
gelatinolytic	  and	  elastinolytic	  activities	  of	  matrix	  metallo-­‐proteinase	  MMP-­‐
2,	   MMP-­‐9,	   and	   MMP-­‐12,	   and	   promotes	   the	   activity	   of	   tissue-­‐type	  
plasminogen	   activator	   (t-­‐PA),18	   squalamine,	   another	   antiangiogenic	  
factor,20	   and	   kahalalide	   F,	   which	   alters	   the	   function	   of	   the	   lysosomal	  
membrane.	  These	  are	   just	  a	   few	  examples,	   there	  are	  many	  more	  marine-­‐
based	   molecules	   of	   therapeutic	   interest	   in	   the	   field	   of	   cancer	  
chemotherapy	  (see	  ref.	  21	  for	  a	  comprehensive	  survey).	  Ecteinascidin-­‐743	  
(ET-­‐743,	   Trabectidin,	   Yondelis1)	   is	   the	   most	   advanced	   marine	   natural	  
product	  in	  clinical	  development,	  with	  a	  clinical	  efficacy	  established	  for	  the	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treatment	  of	   soft-­‐tissue	  sarcoma.22	  This	  drug	  was	  originally	  developed	  by	  
PharmaMar	   (Madrid,	   Spain),	   now	   in	   codevelopment	   with	   Johnson	   &	  
Johnson	   (Ortho	   Biotech	   Products,	   NJ,	   USA).	   For	   more	   than	   10	   years,	  
chemists	   and	   pharmacologists	   at	   PharmaMar	   have	   focused	   on	   the	  
development	   of	   anticancer	   agents	   of	   marine	   origin	  
(www.pharmamar.com).	   In	   addition	   to	   ET-­‐743,	   the	   PharmaMar	   portfolio	  
includes,	   at	   the	   clinical	   level,	   aplidin,	   an	   apoptotic	   inducer	   originally	  
isolated	   from	  the	   tunicate	  Aplidium	  albicans,	  kahalalide	  F,	  a	  depsipeptide	  
isolated	   from	   the	   sea	   slug	   Elysia	   rufescens	   	   ES-­‐285,	   an	   aminoalcohol	  
isolated	   from	   the	   clam	  Mactromeris	  polynyma,	   Zalypsis,	   an	  analog	  of	   ET-­‐
743	   structurally	   related	   to	   the	   marine	   natural	   compound	   jorumycin	  
obtained	  from	  mollusks	  and,	  at	  the	  preclinical	  level,	  thiocoraline,	  variolins,	  
and	   the	   lamellarins,	  which	   represent	  original	   families	  of	   cytotoxic	  agents.	  
These	  last	  molecules,	  the	  lamellarins,	  have	  attracted	  interest	  owing	  to	  their	  
complex	  mechanism	  of	  action	  and	  structural	  originality	  (Figure	  4.1).	  
Lamellarins	  were	  originally	  extracted	   from	  a	  marine	  prosobranch	  mollusk	  
Lamellaria	   sp.	   and	   subsequently	   from	   primitive	   chordate	   ascidians	  
(tunicates).22-­‐23	  These	  ascidian	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species,	   known	   to	   produce	   many	   bioactive	   metabolites,	   likely	   represent	  
the	  original	  producer	  of	  lamellarins	  because	  these	  organisms	  are	  presumed	  
to	  be	  the	  dietary	  source	  of	  the	  Lamellaria	  mollusks.	  Lamellarins	  have	  been	  
isolated	   from	   different	   tunicates,	   including	   recently	   from	   the	   Indian	  
ascidian	   Didemnum	   obscurum.	   Ascidians	   are	   rich	   sources	   ofcytotoxic	  
compounds	   such	   as	   didemnin-­‐B,	   eudistomin-­‐C,	   lissoclinamides,	  
ascididemnin,	   eilatin	   and	   segolins,	   lukianols,	   polycitrins,	   and	   ningalins.	  
However,	   it	   may	   also	   be	   postulated	   that	   lamellarins	   are	   produced	   by	  
microorganisms	   symbiotic	   to	   the	   ascidians,	   since	   numerous	   natural	  
products	  from	  marine	  invertebrates	  have	  been	  demonstrated	  to	  originate	  
from	  symbiotic	  organisms,	   cyanobacteria	   in	  particular.	   To	  date,	  42	   lamel-­‐	  
larins	   (A–Z	   and	   a–z,	   including	   acetate	   and	   sulfate	   derivatives)	   have	   been	  
isolated.	   Lamellarins	   z,	   h,	   f,	   and	   x	   are	   the	   most	   recent	   members	   of	   the	  
family,	   having	   been	   isolated	   from	   the	   red	   colonial	   ascidian	   Didemnum	  
obscurum.24	  They	  can	  be	  divided	  into	  three	  groups	  characterized	  by	  (i)	  the	  
central	   ring	   pyrrole	   fused	   to	   adjacent	   rings	   having	   a	   single	   bond	   in	   the	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isoquinoline	  moiety	   at	  position	  5	  and	  6,	  or	   (ii)	   a	  double	  bond,	  or	   (iii)	   the	  
central	   ring	   pyrrole	   unfused	   to	   adjacent	   rings.	   Each	   series	   includes	  
derivatives	   in	   which	   the	   phenolic	   hydroxyl	   groups	   are	   substituted	   by	  
methoxy,	  sulfate,	  or	  acetate	  groups.	  Although,	  the	  exact	  ‘‘natural’’	  role	  of	  
lamellar-­‐	   ins	   in	   the	   ascidians	   is	   unknown,	  we	   can	   hypothesize	   that	   these	  
molecules	   participate	   in	   some	   forms	   of	   chemical	   communication	   or	  
defense	   mechanism	   (against	   predation	   or	   overgrowth	   by	   competing	  
species),	   as	   is	   the	   case	   for	   many	   other	   secondary	   metabolites.1,2	   In	   the	  
following	   sections,	   the	   different	   biological	   properties	   of	   lamellarins	   are	  
briefly	   summarized,	   including	   MDR	   modulation	   activities,	   antioxidant	  
properties,	  HIV	  integrase	  inhibition	  and	  cytotoxicity	  against	  tumor	  cells.	  
Multidrug	   resistance	   (MDR)	   is	   a	   term	   used	   to	   characterize	   the	   ability	   of	  
tumors	   to	   exhibit	   simultaneous	   resistance	   to	   various	   chemotherapeutic	  
agents.	  Different	  mechanisms	  can	  explain	  this	  behavior	  including	  alteration	  
of	   the	   activity	   of	   target	   enzymes	   (such	   as	   glutathione-­‐S	   transferase	   and	  
topoisomerases),	  changes	  in	  apoptotic	  processes,	  and/or,	  more	  frequently,	  
modification	   of	   drug	   efflux,	   implicating	   ABC	   transporters	   such	   as	   the	  
multidrug	  resistance-­‐associated	  protein	  (MRP)	  or	  P-­‐glycoprotein	  (Pgp).	  Pgp	  
proteins	   have	   been	   implicated	   in	   resistance	   to	   many	   chemotherapeutic	  
drugs	  such	  as	  doxorubicin,	  vincristine,	  etoposide,	  or	  taxol.	  In	  fact,	  in	  tumor	  
cells	  expressing	  Pgp,	  the	  efflux	  of	  a	  given	  anticancer	  drug	  increases	  across	  
the	   plasma	   membrane,	   thereby	   reducing	   the	   intracellular	   drug	  
concentration	  and	  hence	   its	  cytotoxicity.	  But	  Pgp	  activity	  can	  be	  reversed	  
by	  a	  few	  specific	  molecules,	  referred	  to	  as	  MDR	  modulators	  .	  For	  example,	  
the	  calcium	  channel	  blocker	  verapamil	  possesses	  this	  reversing	  capacity	  at	  
a	  concentration	  range	  from	  5	  mM	  to	  50	  mM.25	  Lamellarin	  I	  is	  also	  an	  MDR	  
modulator,	   directly	   inhibiting	   P-­‐glycoprotein-­‐mediated	   drug	   efflux	   at	  
nonlethal	   doses.	   In	   P388/schabel	   cells,	   lamellarin	   I	   is	   able	   to	   reverse	  
doxorubicin	   resistance	  at	  a	  concentration	  one-­‐tenth	  of	   that	  necessary	   for	  
verapamil.	  Other	  ‘‘sea	  world’’	  molecules	  are	  endowed	  with	  this	  property	  to	  
modulate	   MDR:	   discodermolide,	   pattelamide	   D,	   irciniasulphonic	   acid,	  
agosterol	  A,	  and	  ningalin	  B.26	  This	   last	  compound	  bears	  a	  close	  structural	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analogy	  with	  lamellarin	  T,	  which	  is	  also	  a	  modulator	  of	  multidrug	  resistance	  
in	   addition	   to	   its	   cytotoxic	   and	   antibacterial	   properties.	   Ningalin	   B	   was	  
recently	  incorporated	  with	  combretastatin	  A4-­‐like	  structures	  to	  design	  new	  
antimitotic	   agents.	   Combretastatin	   A-­‐4	   can	   easily	   isomerize	   to	   the	  
thermodynamically	   more	   stable	   trans	   isomer,	   with	   reduced	   antimitotic	  
activity.	  Its	  condensation	  with	  a	  lamellarin-­‐type	  moiety	  provides	  an	  original	  
approach	  to	  maintain	  the	  more	  potent	  cis	  configuration.27,28	  
Oxidant	  products	  are	  reactive	  species	  usually	  toxic	  to	  cells	  through	  lesions	  
caused	  to	  lipids,	  proteins,	  and	  DNA	  in	  particular.	  In	  cells,	  mitochondria	  are	  
the	   major	   source	   of	   oxidants.	   In	   fact,	   using	   oxygen	   to	   generate	   energy,	  
mitochondria	   naturally	   produce	   reactive	   oxygen	   species	   (ROS).	   To	   avoid	  
the	  toxic	  effects,	  cells	  have	  developed	  complex	  chemical	  and/or	  enzymatic	  
processes	   to	   prevent	   damage,	   including	   thioredoxin,	   the	   glutathione	  
system,	   superoxide	   dismutase,	   and	   catalase.	   When	   these	   protective	  
systems	   are	   deficient,	   an	   abnormal	   ROS	   production	   arises	   and	   produces	  
irreversible	   lesions	   potentially	   implicated	   in	   human	   pathologies	   such	   as	  
cancer,	   artheriosclerosis,	   or	   neurodegeneration.	   Antioxidants	   reduce	   the	  
rate	  of	  particular	  oxidation	  reactions	  and	  can	  help	  to	  protect	  against	  lethal	  
damage	  induced	  by	  ROS.	  Certain	  lamellarins	  such	  as	  lamellarins	  G,	  K,	  U,	  I,	  
and	   C-­‐diacetate	   have	   revealed	   mild	   antioxidant	   properties.	   Their	   effects	  
are	  fairly	  modest	  (with	  IC50	  above	  2	  μM)	  compared	  to	  reference	  drugs	  such	  
as	  Trolox	  and α-­‐tocopherol	  (IC50	  around	  50	  μM)	  but	  this	  property	  may	  be	  
enhanced	   upon	   adequate	   substitutions	   of	   the	  molecule.	   However,	   this	   is	  
certainly	   not	   the	   most	   advantageous	   property	   of	   the	   lamellarins,	   given	  
their	  significant	  cytotoxicity.29	  
AIDS	  remains	  a	  devastating	  disease,	  responsible	  for	  the	  death	  of	  millions	  of	  
humans,	   principally	   in	   central	   Africa.	   The	   prevalence	   of	   AIDS	   remains	  
extremely	  high	  and,	  despite	  the	  efficacy	  of	  the	  highly	  active	  antiretroviral	  
therapy	   (HAART)	   and	   the	   continuous	   development	   of	   chemotherapeutic	  
agents	  targeting	  HIV-­‐1	  reverse	  transcriptase	  and	  protease,	  newer	  effective	  
drugs	  are	  still	  eagerly	  awaited.	  HIV-­‐1	  integrase	  promotes	  the	  integration	  of	  
proviral	   DNA	   into	   the	   host	   cell	   chromosomal	   DNA.	   It	   constitutes	   an	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attractive	   target	   because	   no	   human	   cellular	   homolog	   for	   this	   enzyme	  
exists.	  Two	  major	  classes	  of	   integrase	   inhibitors	  have	  been	  described:	  the	  
catechol-­‐containing	  hydroxylated	  aromatics	   (L-­‐choric	   acid)	   and	   the	  diketo	  
acid-­‐containing	   aromatics	   (5CITEP,	   S-­‐1360).	   A	   few	   members	   of	   the	  
lamellarin	   family	   revealed	   integrase	   inhibition	   activities.	   Lamellarin	   A	   20	  
sulfate	   in	   vitro	   showed	   potent	   inhibition	   of	   HIV-­‐1	   integrase.	   This	  
compound,	  for	  which	  an	  efficient	  total	  synthesis	  has	  been	  reported,	  is	  able	  
to	  act	   at	   two	  different	   steps	  of	   the	   catalytic	   cycle,	   terminal	   cleavage	  and	  
strand	   transfer.	   Moreover,	   this	   compound	   inhibits	   viral	   replication	   in	  
cultured	   cells	   at	   nontoxic	   doses.	   Its	   sulfate	   group	   plays	   a	   critical	   role	  
because	   the	   analog	   lamellarin	   a	   is	   inactive	   against	   HIV-­‐1	   integrase.	   The	  
nonsulfated	   analog	   lamellarin	   H	   may	   also	   be	   of	   interest	   as	   an	   HIV-­‐1	  
integrase	   inhibitor	   (IC50	   1⁄4	   8	   μM)	   but	   unfortunately	   this	   compound	   is	  
markedly	   toxic	   to	   cells	   (LD50	   of	   5.7	   μM	   measured	   with	   Hela	   cells).	  
Nevertheless,	   the	   lamellarins	  have	  an	   intrinsic	  potential	   for	   the	   inhibition	  
of	   HIV-­‐1	   integrase.	   But	   so	   far	   this	   pharmacological	   activity	   has	   not	   been	  
thoroughly	  explored.30-­‐33	  
The	   most	   common	   properties	   of	   the	   lamellarins	   are	   their	   cytotoxic	  
activities	   and	   in	   particular	   their	   capacity	   to	   inhibit	   the	   proliferation	   of	  
cancer	   cells.	   This	   activity	   is	   usually	   easy	   to	  measure	   and	   a	   large	  panel	   of	  
tumor	   cells	   can	   be	   cultivated	   in	   vitro	   without	   much	   difficulty.	   Different	  
levels	   of	   activity	   corresponding	   to	   a	   lethal	   or	   a	   growth	   inhibition	   activity	  
(cytotoxic	   versus	   cytostatic)	   have	   been	   reported	   in	   the	   literature	   with	  
different	  cell	  lines.	  A	  representative	  selection	  of	  these	  values	  is	  collated	  in	  
Table	   4.1.	   Although	   comparison	   cannot	   strictly	   be	   made,	   because	   of	  
distinct	   experimental	   conditions	   from	   one	   study	   to	   another,	   it	   is	  
nevertheless	   obvious	   that	   the	   majority	   of	   lamellarins	   are	   considerably	  
cytotoxic,	  with	  IC50	  (or	  LD50)	  values	  in	  the	  nanomolar	  to	  micromolar	  range,	  
depending	   on	   the	   experimental	   conditions	   and	   the	   nature	   of	   the	  
compounds.	  A	  noticeable	  exception	  is	  that	  of	  the	  sulfated	  lamellarins	  (A,	  U,	  
and	  V)	  which	  are	  not	  cytotoxic,	  presumably	  owing	  to	  reduced	  cell	  uptake.	  
Lamellarin	  D	  (Lam-­‐D)	  is	  one	  of	  the	  most	  cytotoxic	  compounds	  of	  the	  family.	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Its	   broad	   spectrum	   of	   toxicity	   to	   numerous	   tumor	   cell	   lines	   (Table	   4.1)	  
makes	   it	   a	   solid	   lead	   for	   the	   design	   of	   synthetic	   analogs.	   Different	  
procedures	   have	   been	   reported	   for	   the	   total	   synthesis	   of	   Lam-­‐D	   and	  
related	  lamellarins,	  thus	  opening	  a	  route	  to	  the	  rational	  design	  of	  a	  variety	  
of	   analogs.	   In	   the	   Lam-­‐D	   series,	   precise	   structure–activity	   relationships	  
have	  been	  delineated.	  Compounds	  possessing	  hydroxyl	  groups	  at	  both	  the	  
C-­‐8	   and	   C-­‐20	   positions	   are	   more	   cytotoxic	   than	   other	   Lam-­‐D	   analogs,	  
whereas	  the	  OH	  at	  C-­‐14	  and	  methoxy	  groups	  at	  C-­‐13	  and	  C-­‐21	  seem	  to	  be	  
less	   important	   to	  maintaining	   the	   cytotoxic	   potential.34	   These	   structure–
activity	   relationships	   (Figure	   4.2)	   have	   been	   extended	   to	   delineate	   the	  
importance	  of	  the	  lactone	  of	  Lam-­‐D	  in	  the	  cytotoxicity.	  Most	  of	  the	  Lam-­‐D	  
derivatives	  with	  an	  open	   lactone	   ring	  were	   found	   to	  be	   considerably	   less	  
cytotoxic	   than	  Lam-­‐D,	  except	  when	  a	   lactonization	  potential	   is	  preserved.	  
In	   this	  case,	  a	  marked	  toxicity	   toward	  A-­‐549	   lung	  carcinoma,	  HT-­‐29	  colon	  
carcinoma,	  and	  MDA-­‐MD-­‐231	  breast	  adenocarcinoma	  cells	  was	  maintained	  
.35	  The	  mode	  of	  action	  of	  these	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Tab	  4.1	  
lactone-­‐free	   derivatives	   of	   Lam-­‐D	   is,	   however,	   unknown	   at	   present.	   It	  
remains	   to	   be	   determined	   whether	   these	   cytotoxic	   derivatives	   can	  
preserve	  an	  inhibitory	  activity	  against	  topoisomerase	  I,	  which	  is	  considered	  
the	  privileged	  (but	  not	  unique)	  target	  of	  Lam-­‐D.	  It	  is	  only	  since	  2002	  that	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the	  molecular	  mechanism	   of	   action	   of	   cytotoxic	   lamellarins,	   in	   particular	  
Lam-­‐D,	  has	  been	  investigated,	  essentially	  in	  our	  laboratory.36	  
	  
4.1.1	  
	  Topoisomerase	  I	  Inhibition	  
	  
The	   non-­‐CPT	   topoisomerase	   I	   poisons	   with	   potent	   activities	   include	  
different	   indenoisoquinolines	   such	   as	   MJ-­‐III-­‐65,	   certain	   glycosyl	  
indolocarbazoles	   such	   as	   NB-­‐506	   and	   edotecarin	   (formerly	   J-­‐107088	   and	  
ED-­‐749)	  	  and	  lamellarin	  D	  which	  was	  identified	  as	  a	  potent	  topoisomerase	  I	  
poison	  in	  2003.35	  Lam-­‐D	  binds	  relatively	  weakly	  to	  DNA,	  presumably	  via	  the	  
insertion	  of	   its	  planar	  pentacyclic	   chromophore	  between	  DNA	  base	  pairs.	  
Intercalation	   of	   the	   flat	   chromophore	   between	   two	   adjacent	   base	   pairs	  
exposes	   the	   perpendicular	   methoxyphenol	   moiety	   toward	   the	   major	  
groove	  of	  DNA	  where	  the	  enzyme	  can	  be	  trapped.37	  This	  DNA	  interaction,	  
although	   relatively	   weak,	   provides	   the	   necessary	   anchorage	   for	  
stabilization	  of	  the	  enzyme–DNA	  complex.	  Inhibition	  of	  topoisomerase	  I	  by	  
Lam-­‐D	   has	   been	   demonstrated	   by	   a	   variety	   of	   approaches,	   both	   in	   vitro	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using	   recombinant	   enzymes	   and	  model	   DNA	   substrates	   and	   in	   a	   cellular	  
context	   using	   immunoblot	   assays	   to	   detect	   the	   drug-­‐stabilized	  
topoisomerase	   I–DNA	   complexes	   in	   cells.	   The	   key	   discovery	   that	  
topoisomerase	  I	  was	  a	  major	  target	  for	  Lam-­‐D	  has	  opened	  the	  door	  to	  the	  
determination	  of	   structure–function	   relationships	   and	   the	   rational	   design	  
of	  lamellarin	  analogs	  of	  pharmaceutical	  interest.	  The	  double	  bond	  between	  
carbons	   5	   and	   6	   in	   the	   quinoline	   B-­‐ring	   is	   a	   crucial	   element	   for	  
topoisomerase	   I	   inhibition.	   This	   C-­‐51⁄4C-­‐6	   double	   bond	   confers	   a	   planar	  
structure	  on	  the	  molecule	  and	  when	  this	  double	  bond	  is	  lacking	  (as	  in	  Lam-­‐
K,	  for	  example)	  the	  planar	  conformation	  no	  longer	  exists	  and	  the	  drug	  loses	  
its	   capacity	   to	   interfere	   with	   topoisomerase	   I.	   This	   was	   clearly	  
demonstrated	  using	   the	   synthetic	   compound	   Lam-­‐501,	  which	  only	  differs	  
from	  Lam-­‐D	  in	  the	  absence	  of	  the	  C-­‐51⁄4C-­‐6	  double	  bond.	  This	  compound	  
showed	   no	   inhibition	   of	   topoisomerase	   I,	   and	   its	   cytotoxicity	   was	  
considerably	   reduced.36	   Additional	   structure–function	   relationships	   have	  
been	   delineated,	   thanks	   to	   the	   synthesis	   of	   different	   series	   of	   Lam-­‐D	  
derivatives.	   In	   particular,	   using	   Lam-­‐D	   analogs	   with	   distinct	   OMe/OH	  
substitution	  on	  the	  core	  structure,	  it	  was	  demonstrated	  that	  the	  8-­‐OH	  and	  
the	   20-­‐OH	   are	   crucial	   for	   topoisomerase	   I	   inhibition	   and	   in	  most	   cases	   a	  
direct	  link	  could	  be	  established	  between	  enzyme	  inhibition	  and	  cytotoxicity	  
.37	  The	  use	  of	  cancer	  cell	  lines	  with	  topoisomerase	  I	  mutated	  genes	  has	  also	  
contributed	  to	  the	  characterization	  of	  topoisomerase	   I	  as	  the	  main	  target	  
for	  Lam-­‐D	  and	  related	  analogs.	  It	  is	  thus	  not	  surprising	  to	  understand	  why	  
Lam-­‐H,	  which	   is	   structurally	   close	   to	  Lam-­‐D,	  has	  also	  been	   identified	  as	  a	  
topoisomerase	   inhibitor.	   Lam-­‐H	   was	   previously	   shown	   to	   inhibit	  
topoisomerase	  I	  from	  the	  Molluscum	  contagiosum	  virus	  (MCV).	  
In	   terms	   of	   efficacy,	   Lam-­‐D	   is	   less	   efficient	   than	   CPT	   in	   inhibiting	  
topoisomerase	   I	   (IC50	   of	   0.42	   versus	   0.087	   μM,	   respectively).36	   But	   the	  
sequencing	  of	  DNA	  cleavage	  products	   revealed	   that	   the	   cleavage	  profiles	  
obtained	   with	   Lam-­‐D	   were	   distinct	   from	   those	   seen	   with	   CPT.	   Both	  
molecules	   intercalate	   at	   the	   sites	   of	   DNA	   cleavage	   corresponding	   to	   T-­‐G	  
sites	  but	  in	  addition	  Lam-­‐D	  can	  induce	  cleavage	  at	  certain	  C-­‐G	  sites.	  Lam-­‐D	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and	   CPT	   share	   a	   common	  mechanism	   of	   action	   at	   the	   topoisomerase	   I–
DNA	  complex	  level	  but	  the	  two	  drugs	  are	  positioned	  in	  a	  slightly	  different	  
manner	   at	   the	   DNA–enzyme	   interface,	   thus	   providing	   distinct	   molecular	  
contacts	   at	   the	   origin	   of	   the	   nonidentical	   cleavage	   profiles.	   Molecular	  
modeling	  studies	  have	  greatly	  contributed	  to	  the	  explanation	  of	  how	  Lam-­‐
D	  fits	  into	  the	  topoisomerase	  I–DNA	  active	  site.36,37	  
But	   the	   story	   of	   Lam-­‐D	   is	   not	   so	   simple.	   If	   topoisomerase	   I	   can	   be	  
considered	   as	   the	   unique	   target	   of	   CPT,	   the	   situation	   is	   clearly	   more	  
complicated	   for	   Lam-­‐D	   because	   its	   cytotoxicity	   cannot	   be	   explained	  
uniquely	  on	  the	  basis	  of	  the	  topoisomerase	  I	  targeting.	  The	  cytotoxicity	  of	  
Lam-­‐D	  has	  been	  evaluated	  using	  the	  mutant	  cell	  lines	  P388CPT5	  and	  CEM-­‐
C2,	   which	   both	   express	   a	   mutant	   topoisomerase	   I	   conferring	   a	   high	  
resistance	   to	   CPT	   and	   other	   CPT-­‐derived	   topoisomerase	   I	   poisons.38	   The	  
two	  cells	  lines	  are	  more	  resistant	  to	  CPT	  and	  Lam-­‐D	  than	  the	  corresponding	  
wild-­‐type	  P388	   and	  CEM	  cell	   lines.	   This	   observation	   confirmed	   the	  direct	  
implication	   of	   topoisomerase	   I	   in	   the	   cytotoxicity	   of	   Lam-­‐D.	   But	   the	  
resistance	  indexes	  (i.e.,	  the	  ratio	  of	   IC50	  values	  for	  a	  pair	  of	  sensitive	  and	  
resistant	  cell	   lines)	  was	  clearly	  different	   for	  Lam-­‐D	  and	  CPT.	  For	  example,	  
the	  top1	  mutated	  gene	   in	  CEMC2	  cells	  confers	  a	  huge	  resistance	  of	  these	  
leukemia	  cells	  to	  CPT	  (RI	  >	  2000)	  whereas	  the	  RI	  was	  about	  30	  times	  lower,	  
around	  70,	  with	  Lam-­‐D.	  Moreover,	   it	  was	  discovered	  that	  Lam-­‐D,	  but	  not	  
CPT,	   was	   able	   to	   induce	   apoptosis	   of	   the	   P388CPT5-­‐resistant	   cell	   line.	  
These	  observation	  strongly	  suggested	  the	  existence	  of	  alternative	  target(s)	  
for	   Lam-­‐D	   in	   cancer	   cells.	   This	   hypothesis	  was	   rapidly	   validated	  with	   the	  
discovery	  of	  a	  nuclear	  topoisomerase	  I-­‐independent,	  direct	  effect	  of	  Lam-­‐D	  
on	  mitochondria.29	  
	  
4.1.2	  
Targeting	  of	  mitochondria	  and	  proapoptotic	  activities	  
	  
Mitochondria	  are	  the	  well-­‐characterized	  intracellular	  organelles	  needed	  for	  
the	  production	  of	  ATP	  for	  all	  cellular	  processes.	  They	  also	  play	  a	  major	  role	  
in	  the	  regulation	  of	  calcium	  flux	  and	  redox	  state.	  Moreover,	  since	  the	  1990,	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mitochondria	  have	  been	  considered	  as	  central	  effectors	  for	  the	  regulation	  
of	   cell	   apoptosis.	   Apoptosis	   is	   a	   cell	   death	   characterized	   by	   a	   number	   of	  
distintive	   biochemical	   and	  morphological	   changes	   occurring	   in	   cells,	   such	  
as	  DNA	   fragmentation,	   chromatin	   condensation,	  and	   loss	  of	  phospholipid	  
asymmetry	   in	   the	   plasma	   membrane	   and	   membrane	   budding.	   During	  
apoptosis,	  a	  family	  of	  proteases	  known	  as	  caspases	   is	  generally	  activated.	  
These	  proteins	   cleave	   key	   cellular	   substrates	   required	   for	   normal	   cellular	  
functions,	   including	   structural	   proteins	   of	   the	   cytoskeleton	   and	   nuclear	  
proteins	  such	  as	  DNA	  repair	  enzymes.	  It	  is	  now	  well	  established	  that	  during	  
apoptosis	  major	  changes	  occur	  at	  the	  level	  of	  mitochondria.	  A	  reduction	  of	  
the	  mitochondrial	  membrane	  potential	  (DCm)	  is	  generally	  observed	  during	  
the	  first	  steps	  of	  apoptosis,	  associated	  with	  the	  release	  into	  the	  cytosol	  of	  
various	  proteins	  localized	  in	  the	  intermembrane	  space,	  such	  as	  cytochrome	  
c,	   AIF,	   Smac/DIABLO	   and/or	   endoG.	   Initial	   studies	   on	   the	   apoptotic	  
pathway	   induced	   by	   Lam-­‐D	   revealed	   a	   very	   early	   mitochondrial	  
dysfunction,	  including	  a	  reduction	  of	  DCm	  and	  the	  release	  of	  cytochrome	  c	  
and	  AIF	   from	   the	  mitochondria	   to	   the	   cytosol.	   It	  was	   then	  observed	   that	  
Lam-­‐D	   could	   induce	   these	   alterations	   directly	   on	   isolated	   mitochondria.	  
Both	   functional	   assays	   and	   direct	   observations	   by	   electron	   microscopy	  
indicated	   that	  mitochondria	   represented	   targets	   for	   Lam-­‐D,	   and	   similarly	  
for	   Lam-­‐M.	  Although	   the	   exact	  mechanism	   implicated	   in	   the	   targeting	   of	  
mitochondria	   is	  not	   fully	  understood,	  we	  have	  accumulated	  evidence	  has	  
been	   accumulated	   that	   an	   opening	   of	   the	   mitochondrial	   permeability	  
transition	  pore	  (mPTP)	  is	  induced	  by	  Lam-­‐D.	  The	  drug	  induces	  a	  swelling	  of	  
isolated	  mitochondria	  and	  this	  effect	  can	  be	  prevented	  by	  a	  preincubation	  
with	   the	   PTP	   inhibitor	   cyclosporin	   A.	   Each	   protein	   constituting	   the	  mPTP	  
can	  be	  considered	  as	  a	  molecular	  target	  for	  Lam-­‐D,	   including	  the	  adenine	  
nucleotide	   translocator	   (ANT),	   voltage-­‐dependent	   anion	   channel	   (VDAC),	  
peripheral	   benzodiazepine	   receptor	   (PBR),	   hexokinase	   (HK),	   Bcl-­‐2	   family	  
members	  (including	  Bax	  and	  Bcl-­‐2),	  mitochondrial	  creatine	  kinase	  (CK),	  and	  
cyclophilin	   D.	   These	   proteins	   and	   receptors	   represent	   potential	   drug	  
targets	   to	   control	   tumor	   cell	   growth.	   But	   we	   also	   cannot	   exclude	   the	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possibility	   that	   Lam-­‐D	   induces	   an	   indirect	   opening	   of	   the	  mPTP,	   forming	  
channels	   or	   pores	   through	   phospholipids	   from	   the	   outer	   or	   inner	  
membranes	  or	  acting	  with	  specific	  complexes	  of	  the	  respiratory	  chain.	  The	  
detailed	  mechanism	  is	  currently	  being	  investigated	  further.38,39	  
Based	   on	   our	   previous	   studies,	   we	   are	   confronted	   with	   an	   uncommon	  
situation	  where	  Lam-­‐D	  seems	  to	  reside	  in	  two	  preferred	  sites	  within	  cells:	  
(i)	  the	  nucleus,	  where	  the	  drug	  forms	  tight	  and	  stable	  complexes	  with	  DNA	  
and	   topoisomerase	   I;	   (ii)	  mitochondria,	  where	  Lam-­‐D	   interacts	  with	  an	  as	  
yet	  unknown	  molecular	  target,	  potentially	  associated	  with	  the	  mPTP.	  Both	  
sites	  and	  their	  associated	  mechanisms	  can	  contribute	  to	  cell	  death	  induced	  
by	   Lam-­‐D	   but	   which	   is	   the	   major	   contributor,	   the	   nucleus	   or	   the	  
mitochondrion?	  The	  question	  remains	  unresolved	  at	  this	  stage	  but	  recent	  
data	  suggest	   that	   topoisomerase	   I	   targeting	  may	  be	  the	  main	  mechanism	  
responsible	  for	  the	  antitumor	  effects	  of	  Lam-­‐D.	  Recent	  results	  indicate	  that	  
at	   low	   concentrations	   (<1	   μM),	   Lam-­‐D	   affects	   preferentially	   the	  
topoisomerase	   I	   pathway,	   without	   any	   direct	   interference	   with	  
mitochondria.	  At	  higher	  concentrations	  (in	  particular	  for	  concentrations>5	  
μM),	  Lam-­‐D	  affects	  both	  the	  nucleus	  and	  mitochondria,	  with	  a	  dual	  action	  
leading	   to	   massive	   and	   rapid	   cell	   death.	   We	   must	   also	   consider	   the	  
hypothesis,	   as	   yet	   purely	   conjectural,	   that	   the	   drug	   can	   target	  
simultaneously	   both	   the	   nuclear	   and	   the	  mitochondrial	   topoisomerase	   I.	  
40The	  topology	  of	  the	  mitochondrial	  genome	  –	  a	  closed	  circular	  mtDNA	  –	  is	  
regulated	   during	   replication	   by	   a	   protein	   encoded	   by	   the	   gene	   mtDNA	  
topoisomerase	   I	   (top1mt)	   localized	   on	   human	   chromosome	   8q24.	   This	  
gene	  is	  highly	  homologous	  to	  the	  nuclear	  top1	  gene	  and	  the	  mitochondrial	  
topoisomerase	   I	  enzyme	   is	   fully	   inhibited	  by	  CPT.29,41	  The	  close	   functional	  
homology	   between	   CPT	   and	   Lam-­‐D	   suggests	   that	   the	   mitochondrial	  
enzyme	  can	  also	  be	  targeted	  by	  Lam-­‐D.	  It	  will	  be	  interesting	  to	  see	  if	  Lam-­‐D	  
does	   interfere	   with	   mitochondrial	   topoisomerase	   I	   and	   if	   this	   molecular	  
effect	  is	  at	  the	  origin	  of	  the	  mitochondrial	  dysfunctions	  (reduction	  of	  DCm	  
and	  mPTP	  opening)	  observed	  in	  cells	  upon	  treatment	  with	  Lam-­‐D.	  
Lamellarin	   D	   is	   not	   the	   only	   marine	   compounds	   capable	   of	   altering	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mitochondrial	   functions.	   This	   is	   also	   the	   case	   for	   stolonoxides,	  which	   are	  
oxidized	   fatty	   acid	  metabolites	   isolated	   from	   the	  Mediterranean	   tunicate	  
Stolonica	   socialis.	   These	   compounds	   are	   able	   to	   inhibit	   mitochondrial	  
respiration;	  more	  precisely	  they	  are	  specific	  inhibitors	  of	  complexes	  II	  and	  
III	   of	   the	   respiratory	   chain.	  Another	  example	   is	   that	  of	   cephalostatin	  1,	   a	  
bis-­‐steroidal	   compound	   isolated	   from	   the	   marine	   worm	   Cephalodiscus	  
gilchristi.	  Like	  Lam-­‐D,	  cephalostatin	  1	  induces	  a	  reduction	  of	  the	  DCm,	  but	  
interestingly	   this	   alteration	   is	   not	   associated	   with	   the	   release	   of	  
cytochrome	  c	  or	  the	  apoptosis-­‐inducing	  factor,	  but	  only	  with	  the	  release	  of	  
the	   Smac/DIABLO	   protein.	   Drugs	   that	   induce	   apoptosis	   by	   directly	  
disrupting	  mitochondrial	  functions	  or	  membrane	  integrity	  seem	  to	  have	  an	  
attractive	   potential	   for	   preventing	   tumor	   growth	   and	   eliminating	   tumor	  
cells	  [84].	  But	  the	  next	  challenge	  will	  be	  to	  identify	  or	  to	  rationally	  design	  a	  
mitochondriotoxic	  drug	  able	  to	  kill	  selectively	  cancer	  cells	  without	  affecting	  
normal	   cells.	   At	   present	   this	   selectivity	   issue	   for	   cancer	   cells	   versus	  
nontumor	  cells	  is	  a	  major	  obstacle	  to	  the	  development	  of	  anticancer	  drugs	  
targeting	  mitochondria.42	  
	  
4.2	  
Results	  and	  discussion	  
	  
Although	  several	  lamellarin	  derivatives	  show	  potent	  anticancer	  potency	  in	  
vitro,	   they	   suffer	   from	   several	   drawbacks	   that	   result	   from	   low	   water	  
solubility	   and	   the	   relatively	   labile	   nature	   of	   the	   lactone	   ring	   under	   basic	  
conditions.	   Therefore,	   a	   number	   of	   analogues	   of	   lamellarin	   have	   been	  
synthesized	  with	  the	  aim	  of	  improving	  their	  inhibitory	  potencies	  as	  well	  as	  
other	  desirable	  physicochemical	  properties.	  We	  decided	  to	  take	  Lamellarin	  
D	   as	   lead	   compound	   to	   design	   new	   analogues	   One	   among	   the	  
modifications	   that	   were	   investigated	   to	   achieve	   these	   goals	   was	   the	  
replacement	  of	  the	  central	  core	  of	  the	  lead	  compound	  with	  a	  β-­‐carbolin-­‐1-­‐
one	  moiety	   and	   the	   replacement	   of	   lactone	   ring	  with	   other	  more	   stable	  
rings,	  which	  would	  produced	  the	  desired	  analogues	  2	  and	  3	  (Fig	  4.3)	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Fig	  4.3	  	  
Molecular	  modelling	  studies	  were	  performed	  to	  explore	  the	  binding	  mode	  
for	  the	  planned	  compounds	  to	  the	  covalent	  topo	  I-­‐DNA	  complex.	  This	  study	  
was	  based	  on	  the	  X-­‐ray	  crystal	  structure	  of	  the	  well-­‐know	  ternary	  complex	  
between	   a	   human	   Topo-­‐I	   construct	   covalently	   attached	   to	   a	  DNA	  duplex	  
with	   bound	   topotecan.7	   For	   comparison	   purposes,	   the	   same	   docking	  
protocol	  used	  to	  study	  the	  complex	  containing	  Lamellarin	  D	  was	  applied	  in	  
the	  present	  work.	  As	  shown	  in	  figure	  4.4	  ,	  the	  ligands	  is	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Overlap	  lamD	  (red)	  and	  3	  (green)	  
Fig	  4.4	  
	  
placed	  in	  the	  topo	  I-­‐DNA	  complex	  in	  almost	  the	  same	  orientation	  as	  Lam-­‐D.	  
Compound	   3	   is	   connected	   better	   than	   compound	   2	   to	   the	   topo	   I-­‐DNA	  
complex	  through	  two	  new	  hydrogen	  bonds	  and	  it	  has	  been	  reasonable	  to	  
assume	   that	   it	   might	   hold	   potent	   topoisomerase	   I	   inhibitory	   activity.	   To	  
investigate	  this	   idea,	  we	  have	  developed	  a	  general	  synthetic	  route	  to	  this	  
type	   of	   novel	   and	   promising	   Lamellarin	   D	   analogue	   starting	   from	   more	  
simple	  analogues,	  which	  were	  synthesized	  to	  study	  reactions	  methods	  and	  
structure-­‐activity	  relationships	  (scheme	  4.1)	  	  	  	  	  	  	  
	  
	  
Scheme	  4.1	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The	  simplified	  analogue	  4	  was	  obtained	  according	  a	  synthetic	  strategy	  in	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Scheme	  4.2	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which	  the	  key	  reaction	  is	  an	  intramolecular	  Friedel-­‐Crafts	  cyclization	  of	  	  
indole-­‐2-­‐carboxylic	  acid	  β-­‐oxoamides,	  catalyzed	  by	  trifluoroacetic	  acid	  (TFA)	  
or	  InCl3.	  This	  method	  was	  developed	  io	  our	  laboratory	  43	  and	  represents	  a	  
simple,	  straightforward	  synthesis	  of	   the	  β-­‐carbolin-­‐1-­‐one	  nucleus.	   	  Due	  to	  
the	   simplicity	   and	   efficiency	   of	   the	   synthesis,	   we	   decided	   to	   extend	   its	  
scope	   to	   the	   preparation	  of	   3,4-­‐diaryl-­‐β-­‐carbolin-­‐1-­‐ones	   (4)	   characterized	  
by	  the	  methoxy-­‐hydroxy	  alternation	  typical	  of	  lamellarins.	  
The	  retrosynthetic	  pathway	  is	  reported	  in	  scheme	  4.2.	  Following	  the	  above	  
strategy,	   initial	  experiments	  were	  carried	  out	   to	   synthesize	   the	  necessary	  
substrates	  9	  and	  10.	  	  
Compoud	   9	   was	   obtained	   from	   vanillic	   acid	   14	   after	   treatment	   with	   2-­‐
bromopropane	  in	  basic	  condition	  and	  subsequentely	  ester	  hydrolysis	  of	  the	  
ester	  15	  (scheme	  4.3).	  	  
	  
	  
	  
	  
	  
	  
Scheme	  4.3	  
	  
Isopropyl	  ether	  was	  used	  as	  a	  phenol	  protecting	  group	  in	  order	  to	  perform	  
its	  selective	  cleavage	  at	  the	  end	  of	  synthetic	  route	  affording	  the	  desidered	  	  
hydroxy-­‐methoxy	  alternation.	  	  
	  
	  
	  
	  
	  
	  
	  
Scheme	  4.4	  
	  
i:	  iPrBr,	  Ka2CO3,	  DMF,	  reflux;	  ii:	  KOH,	  ethanol,	  H2O,	  reflux;	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Synthesis	  of	  compound	  10	  started	  from	  vanillin	  16.	   It	  was	  treated	  with	  2-­‐
bromopropane	   under	   basic	   condition.	   After	   isopropyl	   protection,	   the	  
resulting	   aldehyde	   17	   was	   trasformed	   using	   hydroxylamine	   chloride	   and	  
pyridine	   in	   ethanol,	   into	   the	   oxime	   derivative	   18,	   which	   subsequently	  
reduced	   with	   Raney	   nickel	   alloy	   and	   NaOH	   to	   afford	   the	   benzylamine	  
derivative	  10	  (Scheme	  4.4).	  The	  synthesis	  of	  the	  α-­‐aminoketone	  derivative	  
7	  was	  achieved	  by	  following	  the	  synthetic	  pathway	  outlined	  in	  scheme	  4.5.	  
The	  starting	  materials	  9	  and	  10	  were	  subjected	  to	  a	  coupling	  reaction	  using	  
HOBt	  and	  WSC	  in	  THF	  at	  RT	  to	  afford	  compound	  8.	  This	  was	  subsequently	  
treated	   with	   di-­‐tert-­‐butyldicarbonate	   in	   the	   presence	   of	   N,N’-­‐
dimethylaminopyridine	   in	   acetonitrile	   to	   protect	   the	   	   amide	   nitrogen	  
affording	   BOC-­‐derivative	   19.	   To	   obtain	   α-­‐aminoketone	   7	   molecule	   a	   N-­‐C	  
migration	  reaction	  was	  performed	  44	  
	  
	  
	  
	  
	  
	  
followed	  by	  BOC	  cleavage	  under	  acid	  conditions	  (see	  mechanism	  above).	  In	  
order	  to	  carry	  out	  the	  acyl	  migration,	  amide	  19	  was	  treated	  with	  an	  excess	  
of	   lithium	   diisopropylamide	   	   (LDA).	   Although	   one	   equivalent	   of	   LDA	   is	  
sufficient	   to	   form	   the	   carbanion,	   another	   equivalent	   was	   essential	   for	  
completion	   of	   the	   reaction	   due	   to	   the	   proton	   abstraction	   from	   the	   α-­‐
position	  of	  the	  α-­‐aminoketone.	  The	  optimized	  the	  yield	  of	  20	  was	  obtained	  
using	   LDA	   (3	   equiv.)	   in	   the	   presence	   of	   N,N’-­‐dimethylpropyleneurea	  
(DMPU,	   3%)	   as	   an	   additive	   in	   THF	   at	   -­‐78°	   C.	   Interestingly,	   other	   strong	  
bases,	  such	  as	  NaH,	  KH,	  KHMDS,	  and	  s-­‐BuLi	  with	  sparteine,	  did	  not	  give	  any	  
acyl	  migrated	  product.	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  Scheme	  4.5	  
Compound	  20	  was	  treated	  with	  TFA	   in	  DCM	  at	  RT	  to	  give	  α-­‐aminoketone	  
derivative	  7	  as	  a	  trifluoroacetate	  salt.	  
Indole-­‐2-­‐carboxylic	   acid	   derivatives	   11	   a-­‐b-­‐c	   were	   achieved	   through	   the	  
synthetic	  pathway	  reported	  in	  scheme	  (scheme	  4.6)	  .	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
i:	  HOBt,WSC,	  THF,	  RT,	  N2;	  ii:	  di-­‐tert-­‐butyldicarbonate,	  DMAP,	  
acetonitrile,	  RT;	  iii:	  LDA,	  DMPU,	  THF,	  -­‐78°C,	  N2;	  iv:	  CF3COOH,	  
DCM,RT,	  N2.	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Scheme	  4.6	  
	  
By	   allowing	   	   13	   a-­‐c	   to	   react	   with	   ethyl	   azidoacetate	   in	   the	   presence	   of	  
sodium	  ethoxide	  at	   -­‐15°C	   in	  ethanol,	  12	  a-­‐c	  were	  prepared	   in	  good	  yield.	  
Subsequently	   the	   products	   were	   cyclized	   by	   heating	   to	   give	   indole	  
derivates	   21	   a-­‐c.	   Than	   the	   indole	   was	   N-­‐alkylated	   affording	   22	   a-­‐c.	   The	  
ethyl	   ester	   moiety	   was	   hydrolyzed	   in	   basic	   conditions	   to	   obtain	  
indolecarboxylic	  acids	  11	  a-­‐c	  .	  
The	  reaction	  sequence	  leading	  to	  compounds	  4	  a-­‐c	  is	  shown	  in	  scheme	  4.7.	  
It	  begins	  with	  a	   coupling	   reaction	  between	   the	  α-­‐aminoketone	  7	  and	   the	  
indolecarboxylic	   acid	   derivatives	   11	   a-­‐c	   in	   presence	   of	   HOBt	   and	  WSC	   in	  
THF	  at	  RT	  	  giving	  amides	  6	  a-­‐c	  .	  
	  Compounds	   6	   a-­‐c	   were	   than	   treated	  with	   TFA	   in	   acetonitrile	   at	   80°C	   to	  
perform	   the	   crucial	   cyclization	   step	   by	   which	   the	   β-­‐carbolin-­‐1-­‐one	  
derivatives	   were	   obtained.	   At	   this	   point	   of	   the	   outlined	   synthetic	   route	  
Intermediate	   23	   c	   was	   subjected	   to	   isopropyl	   ether	   cleavage	   reaction	  
carried	   out	   with	   AlCl3	   in	   DCM	   to	   afford	   expected	   compound	   4c.	  
Intermediates	   23	   a-­‐b	   were	   treated	   in	   the	   same	  way,	   but	   this	   procedure	  
gave	   24	   a-­‐b,	   without	   removing	   the	   N-­‐benzyl	   group	   used	   as	   a	   protecting	  
group	   in	   the	   indole	   moiety.	   For	   this	   reason	   compounds	   2a-­‐b	   were	  
subjected	  to	  react	  with	  AlCl3	  but	  in	  a	  different	  solvent	  (anisole)	  and	  under	  
heating	   to	   remove	   the	   N.-­‐benzyl	   protecting	   group,	   and	   to	   afford	   the	  
expected	  products	  4	  a-­‐b.	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Scheme	  4.7	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i:	  HOBt,WSC,	  TEA,	  THF,	  RT,	  N2;	  ii:	  acetonitrile,	  reflux;	  iii,	  iv	  
and	  v	  :	  AlCl3,	  DCM,	  N2,	  0°C-­‐	  RT;	  vi:	  AlCl3,	  anisole,	  reflux,	  N2	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The	  synthetic	  strategy	  reported	   in	  scheme	  4.2	  was	  applied	  successfully	  to	  
the	   synthesis	   of	   lamellarin	   analogue	   3	   but	   with	   further	   modifications	   to	  
allow	   the	   introduction	   ofa	   further	   phenol	   group	   (see	   compound	   5)	   used	  
subsequently	   to	   perform	  a	   cyclization	   reaction.	   This	   kind	  of	   reaction	  was	  
first	   studied	   using	   as	   a	   	   simple	   model	   compound	   30,	   obtained	   via	   the	  
following	   synthetic	   route	   (scheme	   4.8),	   and	   then	   applied	   to	   the	  
development	  of	  a	  lamellarin	  analogue.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Scheme	  4.8	  
	  
Following	   the	   above	   strategy,	   initial	   experiments	   were	   carried	   out	   to	  
synthesize	   the	   necessary	   aminoalchol	   derivative	   25	   and	   the	  
indolecarboxylic	   acid	   26.	   This	   latter	  was	   obtained	   by	   the	   synthetic	   route	  
reported	   in	   scheme	   4.6,	   the	   former	   one	   was	   achieved	   through	   the	  
synthetic	  route	  reported	  in	  the	  following	  scheme	  (4.9).	  
i:	  HOBt,	  WSC,	  THF,	  N2,	  RT;	  ii:	  IBX,	  DMSO,	  N2,	  RT;	  iii:	  TFA,	  acetonitrile,	  riflux;	  iv:	  BBr3,	  DCM,	  RT,	  N2	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Compounds	  25	   and	  26	  were	   subjected	   to	  a	   coupling	   reaction	  using	  HOBt	  
and	  WSC	   in	   THF	   at	   RT	   to	   afford	   the	   intermediate	   hydroxyamide	  27.	  This	  
was	   subsequently	   oxidized	   to	   the	   corrisponding	   aldehyde	   derivative	   28	  
using	  2-­‐iodoxybenzoic	  acid	  (IBX).	  The	  crucial	  cyclization	  step	  was	  obtained	  
with	   TFA	   in	   acetonitrile	   at	   80°C	   affording	   β-­‐carbolin-­‐1-­‐one	   derivative	   29.	  
The	  expected	  product	  30,	  obtained	  by	  cleavage	  of	  the	  methyl	  ether	  using	  
BBr3	  in	  DCM,	  was	  successively	  used	  as	  a	  model	  compound	  to	  perform	  the	  
cyclization	  reaction.	  The	  method	  developed	  is	  shown	  in	  the	  following	  
	  
	  
	  
	  
	  	  	  
	  
	  
	  
Scheme	  4.10	  
	  
	  
The	   retrosynthetic	   pathway	   for	   this	   lamellarin	   analogue	   is	   reported	   in	  
scheme	  4.11	  
	  
	  
	  
i:	  (CH3)2SOI,	  NaH,	  DMSO,	  N2,	  RT;	  ii:	  NaN3,	  LiClO4,	  acetonitrile,	  60°C;	  iii:	  Pd(C),	  H2,	  EtOH	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Scheme	  4.11	  
	  
Initial	  experiments	  were	  carried	  out	  to	  synthesize	  the	  necessary	  substrates	  
9	  and	  36.	  The	  latter	  was	  achieved	  following	  scheme	  4.13,	  by	  modification	  
of	  the	  procedure	  already	  discussed	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Scheme	  4.13	  
	  
in	  order	  to	  have	  an	  additional	  phenol	  group	  in	  ortho	  posistion.	  Compound	  
9	   was	   alkylated	   with	   a	   different	   protecting	   group	   because	   it	   must	   be	  
removed	  in	  a	  different	  step	  with	  respect	  to	  the	  isopropyl	  ethers,	  which	  are	  
maintained	   throughout	   the	   synthetic	   process.	   The	   synthesis	   of	  
benzylamine	   derivative	   36	   was	   performed	   starting	   from	   2,4,5-­‐
trymethoxybenzaldehyde	  37.	   It	  was	  subjected	   to	  a	  selective	  methyl	  ether	  
cleavage	  using	  AlCl3	   in	  DCM,	   to	  afford	   compound	  38	   in	  good	  yield..	  Here	  
the	  possible	  different	  	  reactivity	  of	  the	  two	  phenol	  groups,	  one	  of	  them	  H-­‐
bonded	  to	  the	  ortho	  carbonyl,	  was	  taken	  into	  account	  and	  therefore	  a	  mild	  
base	  was	  used	  to	  avoid	  a	  dialkylation	  reaction.	  Using	  2-­‐bromopropane	  and	  
sodium	  bicarbonate	  in	  DMF	  allowed	  to	  protect	  selectively	  the	  p-­‐OH	  group,	  
to	   give	   compound	   39.	   .	   Now	   this	   compound	   was	   reacted	   with	   MEM	  
chloride	  in	  the	  presence	  of	  the	  strong	  base	  NaH	  to	  alkylate	  	  the	  o-­‐hydroxy	  
group,	   obtaining	   compound	   40,	  which	  was	   thenconverted	   into	   oxime	   41	  
i:	  AlCl3,	  DCM,	  N2,	  RT;	  ii:IPrBr,	  NaHCO3,	  DMF,	  80°C,	  N2;	  iii:	  NaH,	  
THF,	  MEMCl,	  RT,	  N2	  ;	  iv:	  NH3OHCl,	  pyridine,	  EtOH;	  v:	  Al/Ni	  alloy,	  EtOH.	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uby	   treatment	   with	   hydroxylamine	   chloride	   and	   pyridine	   in	   ethanol.	  
Hydrogenation	  of	  41	  was	  carried	  out	  in	  ethanol	  using	  Ni/Al	  alloy	  and	  NaOH	  
to	  give	  the	  benzyamine	  36	  in	  good	  yield.	  
The	  reaction	  sequence	  leading	  to	  compound	  34	  is	  shown	  in	  scheme	  4.14.	  It	  
begins	   with	   a	   coupling	   reaction	   between	   the	   benzylamine	   	   36	   and	   the	  
vanillic	  acid	  derivative	  9.	  Reagents	  were	  allowed	  to	  react	  in	  the	  presence	  of	  
HOBt	  and	  WSC	  in	  THF	  at	  RT	  giving	  amide	  35,	  that	  was	  subsequently	  treated	  
with	   di-­‐tert-­‐butyldicarbonate	   in	   the	   presence	   of	   N,N’-­‐
dimethylaminopyridine	  in	  acetonitrile	  to	  protect	  the	  amide,	  affording	  BOC-­‐
derivative	  42.	  Synthesis	  of	  N-­‐BOC-­‐	  α-­‐aminoketone	  43	  was	  achieved	  using	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Scheme	  4.14	  
	  
the	  same	  procedure	  of	  N-­‐C	  migration	  reaction	  discussed	  in	  the	  scheme	  4.5.	  
The	  so	  obtained	  	  compound	  42	  could	  not	  	  be	  reacted	  similarly	  to	  	  
i:	  HOBt,WSC,	  THF,	  RT,	  N2;	  ii:	  di-­‐tert-­‐butyldicarbonate,	  DMAP,	  
acetonitrile,	  RT;	  iii:	  LDA,	  DMPU,	  THF,	  -­‐78°C,	  N2;	  iv:	  CF3COOH,	  
DCM,RT,	  N2.	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compound	   20	   for	   N-­‐BOC	   removal	   because	   of	   the	   presence	   of	   the	   MEM	  
protecting	   group,	   which	   is	   cleavable	   in	   the	   same	   conditions.	   For	   this	  
reason,	   alternative	   procedures	   were	   investigated,	   such	   as	   thermolytic	  
treatment	   in	  solid	  phase	  under	  N2,	  silica	  gel	  promoted	  cleavage	  and	  ceric	  
ammonium	   nitrate	   treatment	   in	   acetonitrile.	   All	   these	   synthetic	   efforts	  
failed	   to	  produce	  selective	   removal.	  Finally	  a	  different	  kinetic	  cleavage	  of	  
the	   two	  protecting	  groups	   in	  acid	   conditions	  was	  attempted,	   finding	   that	  
the	   N-­‐BOC	   group	   could	   be	   removed	   faster	   than	  MEM.	   The	   reaction	  was	  
carried	  out	  in	  DCM	  and	  TFA	  under	  N2	  at	  0°C	  (its	  course	  being	  monitored	  by	  
1H-­‐NMR	   analysis)	   and	   afforded	  α-­‐aminoketone	  34	   as	   the	   trifluoroacetate	  
salt.	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Scheme	  4.15	  
	  
i:	  HOBt,WSC,	  THF,	  RT,	  N2;	  ii:	  NaI,	  TMSCl,	  acetonitrile,	  -­‐20°C	  ;	  
iii:	  TFA,	  acetonitrile,	  reflux;	  iv:	  CH2I2,	  DCM,	  reflux;	  v:	  AlCl3,	  
DCM,	  N2.	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According	  to	  the	  synthetic	  strategy	  reported	   in	  scheme	  4.15,	   the	  building	  
blocks	   previously	   obtained	   were	   subjected	   to	   a	   coupling	   reaction	   in	   the	  
presence	  of	  HOBt	  and	  WSC	   in	  THF	  at	  RT,	   to	  give	  amide	  32	   in	  good	  yield.	  
The	  key	  step	  to	  obtain	  β-­‐carbolin-­‐1-­‐one	  scaffold	  44	  is	  the	  same	  discussed	  in	  
scheme	   4.8	   but	   in	   this	   case	   it	   was	   not	   possible	   to	   follow	   the	   procedure	  
described	   there,	   because	   in	   the	   acid	   cyclization	   conditions	   the	   MEM	  
protecting	   group	  was	   not	   stable,	   liberating	   formaldehyde	  which	   attacked	  
the	   indole	   moiety.	   To	   avoid	   this	   side	   reaction	   other	   conditions	   were	  
investigated,	  and	  it	  was	  found	  that	  a	  convenient	  reagent	  was	  trimethylsilyl	  
iodide	  (TMSI).	  Compound	  32	  was	  then	  reacted	  with	  2	  eq	  of	  TMSCl	  and	  2	  eq	  
of	   NaI	   in	   dry	   acetonitrile	   at	   -­‐20°C,	   affording	   a	   mixture	   of	   44	   and	   of	   the	  
open-­‐chain	   analogue	   5.	   and	   the	   two	   products	   were	   separated,	   and	  
compound	   5	   was	   converted	   into	   compound	   44	   using	   the	   intramolecular	  
Friedel-­‐Crafts	  cyclization	  method	  as	  described	  in	  scheme	  ……...	  Compound	  
45	  was	  obtained	  using	  the	  ring	  closure	  method	  reported	  in	  scheme	  4.10,	  by	  
reacting	  44	  with	  diiodomethane	  in	  DCM	  under	  basic	  conditions.	  In	  the	  final	  
step	  of	  the	  synthetic	  route	  all	  the	  isopropyl	  and	  benzyl	  ether	  groups	  were	  
removed	  using	  AlCl3	  in	  DCM	  at	  RT	  giving	  the	  valuable	  phenol	  derivative	  3.	  
Selected	   compounds	   were	   tested	   for	   their	   antiproliferative	   activity	   on	  
human	  non-­‐small	   lung	  cancer	  cells	  H-­‐460	  (1	  h	  exposure),	  using	  LamD	  as	  a	  
reference	  compound	  (IC50	  =	  μM).	  The	  test	  results	  are	  reported	  	  in	  Table	  4.2	  
	  	  	  
Compound	   IC50	  
LamD	   	  	  	  	  0,066	  µM	  
3	   	  	  	  	  	  	  0,2	  µM	  
4a	   	  >10	  µM	  
4b	   	  	  	  	  	  	  5	  µM	  
4c	   	  >10	  µM	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23a	   	  >10	  µM	  
23b	   	  >10	  µM	  
23c	   >10	  µM	  
24b	   >10	  µM	  
29	   >10	  µM	  
30	   >10	  µM	  
31	   >10	  µM	  
Tab.	  4.2	  
	  
It	   was	   found	   that	   the	   planned	   lamellarin	   analogue	   3	   gave	   the	   highest	  
citotoxicity	  profile	  of	  the	  series	  synthesized.	  This	  result	  means	  that	  a	  planar	  
scaffold	   is	   important	   for	   enzyme	   binding	   mode.	   Moreover,	   coparing	   the	  
activity	   of	   compoud	   3	   and	   compound	   31	   we	   can	   conclude	   that	   the	  
presence	   of	   a	   methoxy-­‐hydroxy	   alternation	   is	   fundamental	   for	   the	  
cytotoxic	  activity.	  Results	  obtained	  are	  promising	  for	  a	  future	  development	  
of	  new	  Lam	  D	  analogues.	  Further	  biological	  studies	  such	  as	  the	  evaluation	  
of	  topoisomerase	  I-­‐mediated	  DNA	  cleavage	  persistence	  in	  the	  presence	  of	  
compound	  3	  are	  currently	  under	  evaluation.	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4.3	  
Experimental	  methods	  
	  
1HNMR	   spectra	   were	   recorded	   in	   CDCl3	   solutions	   (where	   not	   otherwise	  
stated)	  at	  room	  temperature	  on	  a	  Bruker	  AMX-­‐300	  spectrometer	  operating	  
at	  300	  MHz	   for	   1H	  and	  75	  MHz	   for	   13C.	  Chemical	   shifts	  are	   reported	  as	  δ	  
values	   in	   parts	   per	   million	   (ppm),	   and	   are	   indirectly	   referenced	   to	  
tetramethylsilane	  (TMS)	  via	  the	  solvent	  signal	  (7.26	  for	  1H,	  77.0	  for	  13C)	  in	  
CDCl3.	   Coupling	   constants	   (J)	   are	   given	   in	   Hz.	   Solvents	   were	   routinely	  
distilled	   prior	   to	   use;	   anhydrous	   tetrahydrofuran	   (THF)	   and	   ether	   (Et2O)	  
were	   obtained	   by	   distillation	   from	   sodium-­‐benzophenone	   ketyl;	   dry	  
methylene	  chloride	  (CH2Cl2)	  and	  toluene	  were	  obtained	  by	  distillation	  from	  
CaCl2.	  All	  reactions	  requiring	  anhydrous	  conditions	  were	  performed	  under	  
a	   positive	   nitrogen	   flow,	   and	   glassware	   was	   oven-­‐dried.	   Isolation	   and	  
purification	   of	   the	   compounds	   were	   performed	   by	   flash	   column	  
chromatography	   on	   silica	   gel	   60	   (230-­‐400	   mesh);	   when	   necessary	  
deactivated	  silica	  gel	  was	  used.	  Analytical	  thin-­‐layer	  chromatography	  (TLC)	  
was	  conducted	  on	  Fluka	  TLC	  plates	  (silica	  gel	  60	  F254,	  aluminium	  foil),	  and	  
spots	   were	   visualized	   by	   UV	   light	   and/or	   by	   means	   of	   dyeing	   reagents.	  
Melting	   points	   were	   determined	   on	   a	   Stuart	   Scientific	   SMP3	   instrument	  
and	  are	  uncorrected.	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15.	  4-­‐Isopropoxy-­‐3-­‐methoxy-­‐benzoic	  acid	  isopropyl	  ester	  
	  
COOCH(CH3)2
O
OCH3
CH3
CH3
C14H20O4
Mol. Wt.: 252,31 	  
	  
Vanillic	   acid	   14	   (12	   g,	   0.071	   mol)	   was	   dissolved	   in	   DMF	   (70	   mL)	   under	  
nitrogen	   atmosphere	   and	   K2CO3	   (24.53	   g,	   0.177	   mol)	   was	   added.	   The	  
suspension	  was	   stirred	   for	   15	   at	   room	   temperature	   and	   subsequently	   2-­‐
bromopropane	   (35.11	   g,	   0.285	   mol,	   26	   mL)	   was	   added	   dropwise.	   After	  
refluxing	   for	   4	   h,	   the	   suspension	   was	   filtered	   and	   the	   solvent	   was	  
evaporated	   under	   reduced	   pressure.	   The	   crude	   product	  was	   dissolved	   in	  
ethyl	   acetate	   (80	  mL)	   and	   the	   solution	  was	  washed	  with	  NaHCO3	   (3	   x	   20	  
mL)	  and	  brine	  (3	  x	  20	  mL).	  The	  organic	  layer	  was	  dried	  over	  Na2SO4,	  filtered	  
and	   evaporated	   under	   reduced	   pressure	   affording	   compound	   15	   as	   a	  	  
yellow	  oil	  (17.65	  g,	  98%).	  
	  
1H	  NMR	  (CDCl3):	  7.62	   (1H,	  dd,	   J=	  1.7-­‐8.4	  Hz),	  7.53	   (1H,	  d,	   J=	  1.7	  Hz),	  6.87	  
(1H,	  d,	   J=	  8.4	  Hz),	  5.21	   (1H,	  m),	  4.62	   (1H,	  m),	  3.89	   (3H,	  s),	  1.38	   (6H,	  d,	   J=	  
6.10	  Hz),	  1.34	  (6H,	  d,	  J=	  6.	  10	  Hz)	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9.	  4-­‐Isopropoxy-­‐3-­‐methoxy-­‐benzoic	  acid	  
	  
COOH
O
OCH3
CH3
CH3
C11H14O4
Mol. Wt.: 210,23 	  
	  
	  Compound	  15	  (17.60	  g,	  0.07	  mol)	  was	  dissolved	  in	  90%	  ethanol	  (100	  mL)	  
and	  KOH	  (5.89	  g,	  0.10	  mol)	  was	  added.	  The	  solution	  was	  refluxed	  for	  4	  h.	  
The	   solvent	   was	   evaporated	   under	   reduced	   pressure	   and	   the	   crude	  
product	   was	   dissolved	   in	   water	   adding	   HCl	   solution	   until	   complete	  
precipitation	   occurred	   (pH=	   3).	   The	   suspension	   was	   extracted	   with	   ethyl	  
acetate,	  the	  organic	   layer	  was	  dried	  over	  Na2CO3,	  filtered	  and	  evaporated	  
under	  reduced	  pressure	  giving	  compound	  9	  (12.70	  g,	  87%)	  as	  a	  white	  solid.	  
M.p.:	  120°C	  
	  
1H	  NMR	  (CDCl3):	  7.73	   (1H,	  dd,	   J=	  2.1-­‐8.9	  Hz),	  7.59	   (1H,	  d,	   J=	  2.1	  Hz),	  6.91	  
(1H,	  d,	  J=	  8.9	  Hz),	  4.66	  (1H,	  m),	  3.91	  (3H,	  s),	  1.41	  (6H,	  d,	  J=	  6.10	  Hz)	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17.	  4-­‐isopropoxy-­‐3-­‐methoxybenzaldehyde	  
	  
CHO
O
OCH3
CH3
CH3
C11H14O3
Mol. Wt.: 194,23 	  
	  
Vanillin	  16	  (14	  g,	  0.026	  mol)	  was	  dissolved	  in	  DMF	  (20	  mL)	  under	  nitrogen	  
atmosphere	  and	  K2CO3	  (4.13	  g,	  0.039	  mol)	  was	  added.	  The	  suspension	  was	  
stirred	   for	   15	   min.?	   at	   room	   temperature	   and	   subsequently	   2-­‐
bromopropane	   (6.40	   g,	   0.052	   mol,	   4.88	   mL)	   was	   added	   dropwise.	   After	  
refluxing	   for	   4	   h,	   the	   suspension	   was	   filtered	   and	   the	   solvent	   was	  
evaporated	   under	   reduced	   pressure.	   The	   crude	   product	  was	   dissolved	   in	  
ethyl	  acetate	  (20	  mL)	  and	  the	  solution	  was	  washed	  with	  brine	  (3	  x	  15	  mL).	  
The	   organic	   layer	   was	   dried	   over	   Na2SO4,	   filtered	   and	   evaporated	   under	  
reduced	   pressure	   affording	   compound	   15	   as	   yellow	   solid	   (4.07	   g,	   81%),	  
m.p.115°C.	  
	  
1H	  NMR	  (CDCl3):	  9.84	  (1H,	  s),	  7.36-­‐7.45	  (2H,	  m),	  6.97	  (1H,	  d,	  J=	  8.2	  Hz),	  4.70	  
(1H,	  m),	  3.92	  (3H,	  s),	  1.43	  (6H,	  d,	  J=	  5.9	  Hz)	  
	  
	  
	  
	  
	  
	   129	  
	  
	  
18.	  4-­‐isopropoxy-­‐3-­‐methoxybenzoxime	  
	  
HC
O
OCH3
CH3
CH3
N
OH
C11H15NO3
Mol. Wt.: 209,24 	  
	  
A	  solution	  of	  17	  (4	  g,	  0.021	  mol)	  in	  95%	  ethanol	  (44	  mL)	  was	  treated	  with	  a	  
solution	  of	  hydroxylamine	  hydrochloride	  (1.82	  g,	  0.026	  mol)	  in	  dry	  pyridine	  
(8.13	  mL)	  under	  stirring	  at	  room	  temperature	  for	  90	  min	  and	  at	  0°C	  for	  30	  
min	  to	  facilitate	  the	  oxime	  precipitation.	  The	  white	  solid	  was	  filtered,	  dried,	  
(3.20	  g,	  71%)	  and	  used	  without	  further	  purification.	  130	  °C	  
	  
1H	  NMR	  (CDCl3):	  8.09	  (1H,	  s),	  7.23	  (1H,	  d,	  J=	  1.9	  Hz),	  7.03	  (1H,	  dd,	  J=	  1.9-­‐8.2	  
Hz),	  6.89	  (1H,	  d,	  J=8.2	  Hz),	  4.60	  (1H,	  m),	  3.89	  (3H,	  s,),	  1.40	  (6H,	  d,	  J=	  6.	  10	  
Hz)	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10.	  (4-­‐isopropoxy-­‐3-­‐methoxyphenyl)methanamine	  
	  
CH2NH2
O
OCH3
CH3
CH3
C11H17NO2
Mol. Wt.: 195,26 	  
	  
A	  solution	  of	  18	  (3.15	  g,	  0.015	  mol)	  in	  95%	  ethanol	  (38.5	  mL)	  was	  treated	  
with	   an	   equal	   volume	   of	   2M	   NaOH	   followed	   by	   Al/Ni	   alloy	   (4	   g)	   under	  
stirring	  at	   room	  temperature	   for	  90	  min.	  The	  Al/Ni	  alloy	  was	  removed	  by	  
filtration	   and	   washed	   with	   fresh	   ethanol.	   Filtrate	   and	   washings	   were	  
combined,	  acidified	  with	  0.8	  M	  HCl	  (pH=2)	  and	  extracted	  with	  DCM	  (3	  X	  15	  
mL).	   The	   aqueous	   phase	   was	   treated	   with	   solid	   KOH	   up	   to	   pH=12	   and	  
extracted	   with	   diethyl	   ether	   (3	   X	   10	   mL).	   The	   extracts	   after	   drying	   over	  
anhydrous	  Na2SO4,	   removal	  of	   the	  solvent	  afforded	  10	   (2.88	  g,	  98%)	  as	  a	  
brown	  oil.	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8.	  N-­‐(4-­‐isopropoxy-­‐3-­‐methoxybenzyl)-­‐4-­‐isopropoxy-­‐3-­‐methoxybenzamide	  
	  
O
OCH3
CH3
CH3
O
OCH3
CH3
H3C
O
H
N
C22H29NO5
Mol. Wt.: 387,47 	  
	  
To	  a	  suspension	  of	  HOBt	  (1.89	  g,	  0.014	  mol)	  and	  WSC	  (2.68	  g,	  0.014	  mol)	  in	  
THF	  (110	  mL)	  were	  added	  under	  nitrogen	  atmosphere	  9	  (1.46	  g,	  0.007	  mol)	  
and	   10	   (2.70	   g,	   0.014	   mol).	   The	   reaction	   mixture	   was	   stirred	   at	   room	  
temperature	   for	   24	   h	   and	   the	   solvent	   was	   evaporated	   under	   reduced	  
pressure.	   The	   crude	   product	  was	   dissolved	   in	   ethyl	   acetate,	   the	   solution	  
washed	  with	  NaHCO3,	  HCl	  2M	  and	  brine,	  dried	  over	  Na2SO4	  and	  evaporated	  
under	  reduced	  pressure	  to	  afford	  8	  as	  a	  yellow	  oil	  (	  2,60	  g,	  96%).	  
	  
1H	  NMR	  (CDCl3):	  7.47	  (1H,	  s),	  7.28	  (1H,	  s),	  6.81-­‐6.93	  (4H,	  m),	  6.37	  (1H,	  brs),	  
4.45-­‐4.70	  (4H,	  m),	  3.91	  (3H,	  s),	  3.85	  (3H,	  s),	  1.40	  (6H,	  d,	  J=	  6.2	  Hz),	  1.37	  (6H,	  
d,	  J=	  6.3	  Hz).	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19.	  N,N-­‐BOC-­‐(4-­‐isopropoxy-­‐3-­‐methoxybenzyl)-­‐4-­‐isopropoxy-­‐3-­‐
methoxybenzamide	  
	  
O
OCH3
CH3
CH3
O
OCH3
CH3
H3C
O
N
BOC
C107H146N4O28
Mol. Wt.: 1936,31 	  
	  
Compound	  8	  (2.20	  g,	  0.06	  mol)	  was	  dissolved	  in	  acetonitrile	  (23	  mL)	  under	  
nitrogen	  flow	  and	  DMAP	  (0.073	  g,	  0.0006	  mol)	  and	  di-­‐terbutyldicarbonate	  
(2.62	  g,	  0.012	  mol)	  were	  added.	  	  After	  stirring	  the	  solution	  at	  RT	  for	  16	  h,	  
the	  solvent	  was	  evaporated	  under	  reduced	  pressure	  and	  the	  crude	  product	  
was	   dissolved	   in	  DCM.	   The	   solution	  was	  washed	  with	   saturated	   aqueous	  
NaHCO3	   and	   the	   organic	   layer	   was	   dried	   over	   Na2SO4,	   filtered	   and	  
evaporated	   under	   reduced	   pressure.	   The	   crude	   product	   was	   purified	   by	  
flash	   chromatography	   (hexane:	   ethyl	   acetate,	   6:4)	   affording	   19	   (2.60	   g,	  
88%)	  as	  a	  yellow	  oil.	  
	  
1H	  NMR	   (CDCl3):7.60	   (1H,	   dd,	   1.7-­‐8.8	   Hz),	   7.53	   (1H,	   d,	   1.7	   Hz),	   6.77-­‐6.94	  
(4H,	  m),	  4.63	  (1H,	  m),	  4.48	  (1H,	  m),	  3.87	  (3H,	  s),	  3.83	  (3H,	  s),	  3.62	  (1H,	  d,	  
9.9	  Hz),	  1.45	  (9H,	  s),	  1.35	  (12H,	  d,	  6.5	  Hz).	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20.	  tert-­‐butyl	  1,2-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)-­‐2-­‐
oxoethylcarbamate	  
O
OCH3
CH3H3C
O
OCH3
H3C
CH3
O
HN
BOC
C107H146N4O28
Mol. Wt.: 1936,31 	  
	  
LDA	   was	   previously	   prepared	   by	   mixing	   diisopropylamine	   (1.52	   g,	   0.015	  
mol,	  2.10	  mL)	  and	  DMPU	  (1.05	  mL)	  with	  n-­‐BuLi	  (1.59	  M	  in	  hexane,	  5.55	  mL,	  
0.015	  mol)	  in	  THF	  (14	  mL)	  at	  -­‐78°C	  under	  nitrogen	  atmosphere.	  A	  solution	  
of	   the	   imide	  19	   (2.40	  g,	  0.0049	  mol)	   	   in	  THF	   freshly	  distilled	   (43	  mL)	  was	  
added	   to	   the	  LDA	  solution	  at	   -­‐78°C	  and	   the	  mixture	  was	   stirred	   for	  ??	  h.	  
The	  mixture	  was	  quenched	  with	  aqueous	  NH4Cl,	  diluted	  with	  ethyl	  acetate,	  
washed	  with	   saturated	  aqueous	  NH4Cl	   and	  brine,	   and	  dried	  over	  Na2SO4.	  
Concentration	   in	   vacuo	   followed	   by	   flash	   chromatography	   (hexane:	   ethyl	  
acetate,	  7:3)	  gave	  product	  20	  (1.21	  g,	  55%)	  as	  a	  white	  solid.	  .Mp	  120°C;	  
1H	   NMR:	   7.60(1H,	   dd,	   J=	   1.7,	   8.8	   Hz),	   7.53(1H,	   d,	   J=	   1.7	   Hz),	   6.77-­‐
6.94(4H,m),	  4.63(1H,m),	  4.48(1H,m),	  3.87(3H,s),	   3.83(3H,s),	   3.62(1H,	  d,	   J=	  
9.9	  Hz),	  1.45(9H,	  s),	  1.35(12H,	  d,	  J=	  6,5	  Hz)	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7.	  2-­‐amino-­‐1,2-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)ethanone	  
(trifluoroacetate	  salt)	  
	  
O
OCH3
CH3H3C
O
OCH3
H3C
CH3
O
H3N
CF3COO
C24H30F3NO7
Mol. Wt.: 501,49 	  
	  
Imide	   20	   (1.21	   g,	   2.28	   mmol)	   was	   dissolved	   in	   dry	   DCM	   (4mL)	   under	  
nitrogen	  flow	  and	  TFA	  (2	  mL)	  was	  added	  at	  0°C.	  The	  solution	  was	  stirred	  at	  
RT	  for	  2h.	  The	  solvent	  was	  evaporated	  under	  vacuo	  and	  the	  crude	  product	  
was	  used	  for	  the	  next	  step	  without	  purification.	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12b.	  (Z)-­‐ethyl	  2-­‐azido-­‐3-­‐(3-­‐(benzyloxy)-­‐4-­‐methoxyphenyl)	  acrylate	  
	  
N3
COOCH2CH3
H3CO
BzO
C19H19N3O4
Mol. Wt.: 353,37 	  
	  
Na	  (0.377	  g,	  0.016	  mol)	  was	  dissolved	   in	  anhydrous	  EtOH	  (15mL),	  treated	  
with	   3-­‐benzyloxy-­‐4-­‐methoxybenzaldheyde	   (1	   g,	   0.004	   mol),	   and	   the	  
mixture	   was	   cooled	   to	   -­‐15°C.	   Ethyl	   azidoacetate	   (ethanol	   solution	   25%,	  
0.016	   mol,	   1044	   mL)	   was	   added	   dropwise	   to	   the	   reaction	   mixture.	   The	  
mixture	  was	   stirred	   for	   3	  h	   at	   -­‐15°C,	   then	  warmed	   to	   room	   temperature	  
and	   treated	   with	   saturated	   aqueous	   NH4Cl.	   The	   beige	   solid	   that	   formed	  
was	   collected	   by	   filtration	   and	   washed	   with	   water	   to	   afford	   the	   title	  
compound	  13b	  (1.20	  g,	  88%),	  m.p.	  94-­‐95	  °C	  	  
	  
1H	   NMR	   (CDCl3):	   7.25-­‐7.50	   (7H,	  m),	   6.85-­‐6.95	   (2H,	  m),	   5.21	   (2H,	   s),	   4.38	  
(2H,	  q,	  7.1	  Hz),	  3.95	  (3H,	  s),	  1.39	  (3H,	  t,	  7.1	  Hz).	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21b.	  ethyl	  5-­‐(benzyloxy)-­‐6-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxylate	  
	  
NH
COOCH2CH3
H3CO
BzO
C19H19NO4
Mol. Wt.: 325,36 	  
	  
Compound	  12b	  (1.15	  g,	  0.003	  mol)	  was	  dissolved	  in	  xylenes	  (5	  mL)	  and	  the	  
solution	  was	  warmed	  at	  130°C	  for	  12	  h.	  The	  solution	  was	  cooled	  to	  room	  
temperature	  and	  hexane	  was	  added	   (5mL).	  The	  beige	   solid	  was	  collected	  
by	  filtration.	  The	  filtrated	  was	  concentrated	  in	  vacuo	  and	  purified	  by	  flash	  
chromatography	  (hexane:ethyl	  acetate,	  8:2).	  The	  precipitate	  was	  combined	  
with	  the	  product	  isolated	  by	  chromatography	  to	  afford	  21b	  (0.800	  g,	  76%),	  
m.p.	  177-­‐178	  °C.	  
	  
1H	  NMR	   (CDCl3):	  8.69(1H,s),	  7.30-­‐7.58	   (6H,	  m),	  7.12	   (1H,	  m),	  6.88	   (1H,	   s),	  
5.25	  (2H,	  s),	  4.40	  (2H,s),	  4.40	  (2H,	  q,	  7.02	  Hz),	  3.95	  (3H,	  s),	  1.40	  (3h,	  t,	  7.07	  
Hz).	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22b.	  ethyl	  1-­‐benzyl-­‐5-­‐(benzyloxy)-­‐6-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxylate	  
	  
N
COOCH2CH3
H3CO
O
Bz
C26H25NO4
Mol. Wt.: 415,48
Bz
	  
	  
Indole	   21b	   (0.740	   g,	   0.002	  mol)	   was	   dissolved	   in	   dry	   DMF	   (7	  mL)	   under	  
nitrogen.	  The	  solution	  was	  cooled	  at	  0°C	  and	  NaH	  (oil	  mineral	  susp.	  60	  %,	  
0.170	  g,	  0.003	  mol)	  was	  added	  slowly.	  The	  reaction	  mixture	  was	  warmed	  to	  
room	  temperature	  and	  stirred	  for	  45	  min.	  Then	  benzyl	  bromide	  (0.003	  mol,	  
0.34	  mL)	  was	   added	   and	   the	  mixture	  was	   reacted	   for	   2	   h.	   Reaction	  was	  
completed	  and	  the	  solvent	  was	  removed	  under	  vacuo.	  The	  crude	  product	  
was	  dissolved	   in	  ethyl	  acetate	  and	  washed	  with	  saturated	  aqueous	  brine.	  
The	   organic	   layer	   was	   dried	   over	   Na2SO4,	   filtered	   and	   evaporated	   under	  
reduced	  pressure	  to	  afford	  22b	  (0.900	  g,	  97	  %)	  as	  a	  white	  solid,	  m.p.	  90-­‐91	  
°C.	  	  
	  
1H	  NMR	  (CDCl3):	  7.20-­‐7.48	  (9H,	  m),	  7.12	  (1H,	  s),	  7.02	  (2H,	  m),	  6.79	  (1H,	  m),	  
6.79	  (1H,	  s),	  5.72	  (2H,	  s),	  5.18	  (2H,	  s),	  4.32	  (2H,	  q,	  7.1	  Hz),	  3.95	  (3H,	  s),	  1.36	  
(3H,	  t,	  7.1	  Hz).	  
	  
	  
	  
	  
	  
	  
	  
	  
	   138	  
11b.	  1-­‐benzyl-­‐5-­‐(benzyloxy)-­‐6-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxylic	  acid	  
	  
N
COOH
H3CO
O
Bz
Bz
C24H21NO4
Mol. Wt.: 387,43 	  
	  
Compound	  22b	  (0.890	  g,	  0.002	  mol)	  was	  dissolved	  in	  3:2:1	  THF-­‐MeOH-­‐H2O	  
(5	  mL),	   treated	  with	   LiOH-­‐H2O	   (0.359	  g,	  0.009	  mol),	   and	   the	  mixture	  was	  
stirred	  for	  4	  h	  at	  25	  °C.	  1N	  aqueous	  HCl	  was	  added	  until	  pH	  less	  than	  6,	  and	  
the	   solution	  was	  extracted	  with	  ethyl	   acetate	   (3	   x	  10	  mL).	   The	  combined	  
organic	   extracts	   were	   washed	   with	   brine,	   dried	   over	   Na2SO4,	   and	  
concentrated	  in	  vacuo	  to	  afford	  11b	  (0.600	  g,	  72%).	  M.p:	  130	  °C	  
	  
1H	  NMR	   (CDCl3):	   7.17-­‐	   7.48	   (9H,	  m),	   7.10	   (1H,	   s),	   6.94-­‐7.06	   (2H,	  m),	   6.75	  
(1H,	  s),	  5.71	  (2H,	  s),	  5.15	  (2H,	  s),	  3.94	  (3H,	  s)	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6b.	  N-­‐(1,2-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)-­‐2-­‐oxoethyl)-­‐1-­‐benzyl-­‐5-­‐
(benzyloxy)-­‐6-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxamide	  
	  
NH3CO
OBz HN
O O
OiPrH3CO
OiPr
OCH3
C46H48N2O8
Mol. Wt.: 756,88
Bz
	  
	  
To	  a	  suspension	  of	  HOBt	  (0.335	  g,	  0.003	  mol)	  and	  WSC	  (0.474	  g,	  0.003	  mol)	  
in	  THF	   (20	  mL)	  under	  nitrogen	  atmosphere	  11b	   (0.481	  g,	   0.001	  mol)	  was	  
added.	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  12	  h	  until	  
the	  activated	  ester	  was	  formed.	  Then	  compound	  7	  dissolved	  in	  THF	  (5	  mL)	  
and	   TEA	   (0.002	   mol,	   0.346	   mL)	   were	   added.	   After	   stirring	   the	   reaction	  
mixture	  at	  room	  temperature	  for	  14	  h,	  the	  solvent	  was	  evaporated	  under	  
reduced	   pressure.	   The	   crude	   product	  was	   dissolved	   in	   ethyl	   acetate,	   the	  
solution	   washed	   with	   aqueous	   NaHCO3,	   HCl	   2M	   and	   brine,	   dried	   over	  
Na2SO4,	   and	  evaporated	  under	   reduced	  pressure	   to	  afford	  6b	   as	   a	   yellow	  
solid	  (	  0.520	  g,	  56%).	  Mp:	  127	  °C	  
	  
1H	  NMR	   (CDCl3):	   7.53-­‐7.69	   (3H,	  m),	   7.23-­‐7.44	   (4H,	  m),	   7.11-­‐7.18	   (3H,	  m),	  
7.07	  (1H,	  s),	  6.92-­‐7.01	  (5H,	  m),	  6.77-­‐6.87	  (2H,	  m),	  6.74	  (1H,s),	  6.61	  (1H,	  d,	  
J=	  7.4	  Hz),	  5.74	  (1H,	  ab,	  J=	  16.2	  Hz),	  5.61	  (1H,	  ab,	  J=	  16.2	  Hz),	  5.12	  (2H,	  s),	  
4.65	  (1H,	  m),	  4.49	  (1H,	  m),	  3.93	  (3H,	  s),	  3.88	  (3H,	  s),	  3.81	  (3H,	  s),	  1.40	  (6H,	  
d,	  J=	  6.10	  Hz),	  1.34	  (6H,	  d,	  J=	  6.10	  Hz).	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23b	  9-­‐benzyl-­‐6-­‐(benzyloxy)-­‐3,4-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)	  -­‐7-­‐
methoxy-­‐2H-­‐pyrido[3,4-­‐b]indol-­‐1(9H)-­‐one	  
	   	  
N
H3CO
OBz
NH
O
OiPr
H3CO
OiPr
OCH3
Bz
C46H46N2O7
Mol. Wt.: 738,87 	  
	  
To	   a	   solution	  of	  6b	   (0.500	   g,	   0.7	  mmol)	   in	   acetonitrile	   (5	  mL)	  was	   added	  
TFA	  (0.9	  mmol,	  0,07	  mL)	  and	  the	  reaction	  mixture	  was	  refluxed	  for	  15’.	  The	  
formed	  precipitate	  was	  filtered	  and	  washed	  with	  acetonitrile	  to	  afford	  23b	  
as	  a	  	  white	  solid	  (0.340	  g,	  70%),	  Mp:	  230	  °C	  
	  
1H	  NMR	  (CDCl3):	  7.11-­‐7.51	  (11H,	  m),	  6.65-­‐	  7.04	  (7H,	  m),	  6.43	  (1H,	  s),	  5.96	  
(2H,	  m),	  5.17	  (2H,	  s	  ),	  4.56	  (1H,	  m),	  4.44	  (1H,	  m),	  3.70	  (3H,	  s),	  3.57	  (3H,	  s),	  
3.55	  (3H,	  s),	  1.40	  (6H,	  d,	  J=	  5.7	  Hz),	  1.35	  (6H,	  d,	  J=	  5.7	  Hz)	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4b.	  6-­‐hydroxy-­‐3,4-­‐bis(4-­‐hydroxy-­‐3-­‐methoxyphenyl)-­‐7-­‐methoxy-­‐2H-­‐
pyrido[3,4-­‐b]indol-­‐1(9H)-­‐one	  
	  
N
H
H3CO
HO
NH
O
OH
H3CO
OH
OCH3
C26H22N2O7
Mol. Wt.: 474,46 	  
	  
Anhydrous	   AlCl3	   (0.094	   g,	   0.7	   mmol)	   was	   suspended	   in	   dry	   DCM	   (4	  mL)	  
under	   nitrogen	   and	   compound	   6b	   (0.100g,	   0.1	   mmol)	   was	   added.	   After	  
stirring	   the	   reaction	   mixture	   at	   room	   temperature	   for	   24	   h,	   saturated	  
aqueous	   NH4Cl	   was	   added	   and	   the	   mixture	   was	   extracted	   with	   ethyl	  
acetate.	  The	  organic	   layer	  was	  washed	  with	  brine,	  dried	  over	  Na2SO4	  and	  
evaporated	  under	  reduced	  pressure.	  The	  crude	  solid	  was	  crystallized	  from	  
ethanol	  to	  give	  product	  4b	  (0.003	  g,	  48	  %),	  m.p.	  	  >	  350	  °C.	  
	  
1H	  NMR	  (CDCl3):	  11.53	  (1H,	  s),	  11.15	  (1H,	  s),	  9.25	  (1H,	  s),	  9.08	  (1H,	  s),	  9.00	  
(1H,	  s),	  6.60-­‐6.95	  (7H,	  m),	  6.22	  (1H,	  s),	  3.65	  (3H,	  s),	  3.60	  (3H,	  s),	  2.45	  (3H,	  
s).	  
	  
	  
	  
	  
	  
	  
	  
	   142	  
12a.	  (Z)-­‐ethyl	  2-­‐azido-­‐3-­‐(4-­‐(benzyloxy)-­‐3-­‐methoxyphenyl)	  
acrylate	  
	  
N3
COOCH2CH3
O
H3CO
C19H19N3O4
Mol. Wt.: 353,37
Bz
	  
	  
Na	   (1.13	   g,	   0.049	  mol)	  was	   dissolved	   in	   anhydrous	   EtOH	   (45mL),	   treated	  
with	   4-­‐benzyloxy-­‐3-­‐methoxybenzaldheyde	   (3	   g,	   0.012	   mol),	   and	   the	  
mixture	   was	   cooled	   to	   -­‐15°C.	   Ethyl	   azidoacetate	   (ethanol	   solution	   25%,	  
0.049	   mol,	   25	   mL)	   was	   added	   dropwise	   to	   the	   reaction	   mixture.	   The	  
mixture	  was	   stirred	   for	   3	  h	   at	   -­‐15°C,	   then	  warmed	   to	   room	   temperature	  
and	   treated	   with	   saturated	   aqueous	   NH4Cl.	   The	   beige	   solid	   that	   formed	  
was	   collected	   by	   filtration	   and	   washed	   with	   water	   to	   afford	   the	   title	   1H	  
compound	  12b	  (2.95	  g,	  73%),	  m.p.	  	  102-­‐103	  °C	  .	  
	  
1H	  NMR	  (CDCl3):	  7.53	  (1H,	  d,	  1.9	  Hz),	  7.26-­‐7.50	  (6H,	  m),	  6.85-­‐6.93	  (2H,	  m),	  
5.22	  (2H,	  s),	  4.38	  (2H,	  q,	  7.25	  Hz),	  3.95	  (3H,	  s),	  1.41	  (3H,	  t,	  7.25	  Hz).	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21a.	  ethyl	  6-­‐(benzyloxy)-­‐5-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxylate	  
	  
NH
COOCH2CH3
H3CO
BzO
C19H19NO4
Mol. Wt.: 325,36 	  
	  
Compound	  12b	   (2.90	   g,	   0.008	  mol)	  was	  dissolved	   in	   xylenes	   (20	  mL)	   and	  
the	   solution	  was	  warmed	   at	   130°C	   for	   12	   h.	   The	   solution	  was	   cooled	   to	  
room	   temperature	   and	   hexane	   was	   added	   (5mL).	   The	   beige	   solid	   was	  
collected	  by	  filtration.	  The	  filtrated	  was	  concentrated	  in	  vacuo	  and	  purified	  
by	   flash	   chromatography	   (hexane:ethyl	   acetate,	   8:2).	   The	  precipitate	  was	  
combined	   with	   the	   product	   isolated	   by	   chromatography	   to	   afford	   21a	  
(0.847	  g,	  32%),	  m.p.	  	  220	  °C.	  
	  
1H	  NMR	  (CDCl3):	  8.63	  (1H,	  brs),	  7.23-­‐7.50	  (5H,	  m),	  7.01-­‐7.12	  (2H,	  m),	  6.83	  
(1H,	  s),	  5.20	  (2H,	  s),	  4.35	  (2H,	  q,	  J=	  7.1	  Hz),	  3.92	  (3H,	  s),	  1.38	  (3H,	  t,	  J=	  7.1	  
Hz)	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22a.	  1-­‐benzyl-­‐6-­‐(benzyloxy)-­‐5-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxylic	  acid	  
	  
N
COOH
O
H3CO
BzBz
C24H21NO4
Mol. Wt.: 387,43
	  
	  
Indole	   21b	   (0.840	   g,	   0.003	  mol)	   was	   dissolved	   in	   dry	   DMF	   (8	  mL)	   under	  
nitrogen.	  The	  solution	  was	  cooled	  at	  0°C	  and	  NaH	  (mineral	  oil	  susp.	  60	  %,	  
0.146	  g,	  0.004	  mol)	  was	  added	  slowly.	  The	  reaction	  mixture	  was	  warmed	  to	  
room	  temperature	  and	  stirred	  for	  45	  min.	  Then	  benzyl	  bromide	  (0.004	  mol,	  
0.43	   mL)	   was	   added	   and	   the	   mixture	   was	   reacted	   for	   2	   h.	   When	   the	  
reaction	  was	  completed	  the	  solvent	  was	  removed	  under	  vacuo.	  The	  crude	  
product	  was	  dissolved	  in	  ethyl	  acetate	  and	  washed	  with	  	  brine.	  The	  organic	  
layer	   was	   dried	   over	   Na2SO4,	   filtered	   and	   evaporated	   under	   reduced	  
pressure	  to	  afford	  white	  solid	  22a	  (0.730	  g,	  59	  %),	  m.p.	  	  190-­‐191	  °C.	  	  
	  
1H	   NMR	   (CDCl3):	   7.11-­‐7.47	   (9H,	  m),	   7.07	   (1H,	   s),	   6.91-­‐7.00	   (2H,	  m),	   6.74	  
(1H,	  s),	  5.69	  (2H,	  s),	  5.11	  (2H,	  s),	  4.29	  (2H,	  q,	  J=	  7.1	  Hz),	  3.91	  (3H,	  s),	  1.33	  
(3H,	  t,	  J=	  7.1	  Hz)	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11a.	  1-­‐benzyl-­‐6-­‐(benzyloxy)-­‐5-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxylic	  acid	  
	  
N
COOH
O
H3CO
BzBz
C24H21NO4
Mol. Wt.: 387,43 	  
	  
Compound	  22a	  (0.725	  g,	  0.002	  mol)	  was	  dissolved	  in	  3:2:1	  THF-­‐MeOH-­‐	  H2O	  
(6	  mL),	   treated	  with	   LiOH-­‐H2O	   (0.292	  g,	  0.008	  mol),	   and	   the	  mixture	  was	  
stirred	  for	  4	  h	  at	  25	  °C.	  1N	  aqueous	  HCl	  was	  added	  until	  pH	  was	  less	  than	  6,	  
and	   the	   solution	   was	   extracted	   with	   ethyl	   acetate	   (3	   x	   10	   mL).	   The	  
combined	  organic	  extracts	  were	  washed	  with	  brine,	  dried	  over	  Na2SO4,	  and	  
concentrated	  in	  vacuo	  to	  afford	  11a	  (0.	  500	  g,	  64	  %).	  M.p.	  200	  °C	  
	  
1H	   NMR	   (CDCl3):	   7.13-­‐7.43	   (9H,	  m),	   7.07	   (1H,	   s),	   6.91-­‐6.99	   (2H,	  m),	   6.72	  
(1H,	  s),	  5.68	  (2H,	  s),	  5.	  12	  (2H,	  s),	  3.91	  (3H	  s)	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6a.	  N-­‐(1,2-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)-­‐2-­‐oxoethyl)-­‐1-­‐benzyl-­‐6-­‐
(benzyloxy)-­‐5-­‐methoxy-­‐1H-­‐indole-­‐2-­‐carboxamide	  
	  
NO
H3CO
Bz
HN
O O
OiPrH3CO
OiPr
OCH3
C46H48N2O8
Mol. Wt.: 756,88
Bz
	  
	  
To	  a	  suspension	  of	  HOBt	  (0.739	  g,	  0.005	  mol)	  and	  WSC	  (1.04	  g,	  0.005	  mol)	  
in	   THF	   (44	  mL)	   under	   nitrogen	   atmosphere	   11a	   (2.68	   g,	   0.005	  mol)	   was	  
added.	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  12	  h	  until	  
the	  activated	  ester	  was	  formed.	  Then	  compound	  7	  dissolved	  in	  THF	  (10	  mL)	  
and	   TEA	   (0.005	   mol,	   0,76	   mL)	   were	   added.	   After	   stirring	   the	   reaction	  
mixture	  at	  room	  temperature	  for	  14	  h,	  the	  solvent	  was	  evaporated	  under	  
reduced	   pressure.	   The	   crude	   product	  was	   dissolved	   in	   ethyl	   acetate,	   the	  
solution	   washed	   with	   aqueous	   NaHCO3,	   HCl	   2M	   and	   brine,	   dried	   over	  
Na2SO4	   and	   evaporated	   under	   reduced	   pressure	   to	   afford	  6a	   as	   a	   yellow	  
solid	  (1.13	  g,	  55%),	  m.p.	  	  140-­‐141	  °C.	  
	  
1H	  NMR	  (CDCl3):	  7.50-­‐	  7.68	   (3H,	  m),	  7.21-­‐7.43	   (5H,	  m),	  7.09-­‐7.18	   (3H,	  m),	  
7.06	  (1H,	  s),	  6.88-­‐7.00	  (5H,	  m),	  6.76-­‐6.87	  (2H,	  m),	  6.73	  (1H,	  s),	  6.59	  (1H,	  d,	  
J=	  7.8	  Hz),	  5.72	  (1H,	  ab,	  J=	  16.1	  Hz),	  5.59	  (1H,	  ab,	  J=	  16.1	  Hz),	  5.10	  (2H,	  s),	  
4.62	  (1H,	  m),	  4.49	  (1H,	  m),	  3.91	  (3H,	  s),	  3.86	  (3H,	  s),	  3.79	  (3H,	  s),	  1.38	  (6H,	  
d,	  J=	  6.1	  Hz),	  1.32	  (6H,	  d,	  J=	  6.1	  Hz)	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23a.	  9-­‐benzyl-­‐7-­‐(benzyloxy)-­‐3,4-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxy	  
phenyl)-­‐6-­‐methoxy-­‐2H-­‐pyrido[3,4-­‐b]indol-­‐1(9H)-­‐one	  
	   	  
N
O
H3CO
Bz
NH
O
OiPr
H3CO
OiPr
OCH3
Bz
C46H46N2O7
Mol. Wt.: 738,87 	  
	  
To	  a	  solution	  of	  6a	  (1.10	  g,	  0.002	  mol)	  in	  acetonitrile	  (8	  mL)	  was	  added	  TFA	  
(0.16	  mL)	   and	   the	   reaction	  mixture	  was	   refluxed	   for	   15’.	   The	   precipitate	  
formed	  was	  filtered	  and	  washed	  with	  acetonitrile	  to	  afford	  23a	  as	  a	  white	  
solid	  (0.764	  g,	  71%),	  Mp:	  238	  °C	  
	  
1H	  NMR	  (DMSO):	  7.05-­‐7.51	  (12H,	  m),	  6.63-­‐7.03	  (7H,	  m),	  6.04	  (2H,	  m),	  5.16	  
(2H,	  s),	  4.36-­‐4.60	  (2H,	  m),	  3.60	  (3H,	  s),	  3.57	  (3H,	  s),	  3.37	  (3H,	  s),	  1.25	  (6H,	  d,	  
J=	  5.5	  Hz),	  1.21	  (6H,	  d,	  J=	  5.6	  Hz)	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   148	  
24a.	  9-­‐benzyl-­‐7-­‐hydroxy-­‐3,4-­‐bis(4-­‐hydroxy-­‐3-­‐methoxyphenyl)-­‐6-­‐methoxy-­‐
2H-­‐pyrido[3,4-­‐b]indol-­‐1(9H)-­‐one	  
	  
N
HO
H3CO
NH
O
OH
H3CO
OH
OCH3
C33H28N2O7
Mol. Wt.: 564,58 	  
	  
Anhydrous	  AlCl3	  (0.281	  g,	  0.4	  mmol)	  was	  suspended	  in	  dry	  DCM	  (5	  mL)	  
under	  nitrogen	  and	  compound	  23a	  was	  added.	  After	  stirring	  the	  reaction	  
mixture	  at	  room	  temperature	  for	  24	  h,	  saturated	  aqueous	  NH4Cl	  was	  
added	  and	  the	  mixture	  was	  extracted	  with	  ethyl	  acetate.	  The	  organic	  layer	  
was	  washed	  with	  brine	  ,	  dried	  over	  Na2SO4	  and	  evaporated	  under	  reduced	  
pressure.	  The	  crude	  solid	  afforded	  was	  crystallized	  in	  ethanol	  to	  give	  
product	  24a	  (0,026	  g,	  11%).	  M.p.	  	  297	  °C.	  
	  
1H	  NMR	  (DMSO):	  11.25	  (1H,	  s),	  9.30	  (1H,	  s),	  9.07	  (1H,	  s),	  9.02	  (	  1H,	  s),	  7.15-­‐
7.35	  (5H,	  m),	  6.56-­‐6.93	  (7H,	  m),	  6.13	  (1H,	  s),	  6.02	  (2H,	  m),	  3.64	  (3H,	  s),	  3.60	  
(3H,	  s),	  3.39	  (3H,	  s)	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4a.	  7-­‐hydroxy-­‐3,4-­‐bis(4-­‐hydroxy-­‐3-­‐methoxyphenyl)-­‐6-­‐methoxy-­‐2H-­‐
pyrido[3,4-­‐b]indol-­‐1(9H)-­‐one	  
	  
N
H
HO
H3CO
NH
O
OH
H3CO
OH
OCH3
C26H22N2O7
Mol. Wt.: 474,46 	  
	  
Anhydrous	   AlCl3	   (0.188	   g,	   0.001	   mol)	   was	   suspended	   in	   anisole	   (10	   mL)	  
under	  nitrogen	  and	  compound	  23a	   (0.200	  g,	  0.3	  mmol)	  was	  added.	  After	  
refluxing	  the	  reaction	  mixture	  at	  100°C	  for	  5	  h,	  MeOH	  was	  added	  and	  the	  
solvent	  was	   evaporated	   under	   reduced	   pressure.	   The	   crude	   product	  was	  
purified	  by	   flash	   chromatography	   (DCM-­‐MeOH,	  9:1)	   affording	  product	  4a	  
as	  a	  white	  solid	  (8	  mg,	  5%).	  M.p	  315	  °C.	  
	  
1H	  NMR	  (DMSO):	  11.55	  (1H,	  s),	  11.13	  (1H,	  s),	  9.25	  (1H,	  s),	  9.05	  (1H,	  s),	  8.99	  
(1H,	  s),	  6.58-­‐6.91	  (7H,	  m),	  6.22	  (1H,	  s),	  3.62	  (3H,	  s),	  3.59	  (3H,	  s),	  3.42	  (3H,	  s)	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6c.	  N-­‐(1,2-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)-­‐2-­‐oxoethyl)-­‐1-­‐methyl-­‐1H-­‐
indole-­‐2-­‐carboxamide	  
	  
N
HN
O
OiPr
OCH3
OiPrH3CO
CH3
O
C32H36N2O6
Mol. Wt.: 544,64 	  
	  
To	  a	  suspension	  of	  HOBt	  (0.988	  g,	  0.007	  mol)	  and	  WSC	  (1,39	  g,	  0.007	  mol)	  
in	   THF	   (60	  mL)	   under	   nitrogen	   atmosphere	  11c	   (0.540	   g,	   0.004	  mol)	  was	  
added.	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  12	  h	  until	  
the	  activated	  ester	  was	  formed.	  Then	  compound	  7	  dissolved	  in	  THF	  (10	  mL)	  
and	  TEA	  (0.007	  mol,	  1	  mL)	  was	  added.	  After	  stirring	  the	  reaction	  mixture	  at	  
room	   temperature	   for	   14	   h,	   the	   solvent	   was	   evaporated	   under	   reduced	  
pressure.	   The	   crude	   product	  was	   dissolved	   in	   ethyl	   acetate,	   the	   solution	  
washed	  with	  aqueous	  NaHCO3,	  HCl	  2M	  and	  brine,	  dried	  over	  Na2SO4	   and	  
evaporated	  under	  reduced	  pressure	  to	  afford	  6c	  as	  a	  white	  solid	  (	  0.978	  g,	  
49	  %),	  Mp	  111	  °C	  
	  
1H	  NMR	  (DMSO):	  8.98	  (1H,	  d,	  J=	  7.07	  Hz),	  7.76	  (1H,	  d,	  J=	  8.2	  Hz),	  7.40-­‐7.67	  
(3H,m	  ),	  7.23-­‐7.33	  (2H,	  m),	  7.19	  (1H,	  s),	  6.80-­‐7.15	  (4H,	  m),	  6.64	  (1H,	  d,	   J=	  
7.07	  Hz),	  4.70	  (1H,	  m),	  4.50	  (1H,	  m),	  3.96	  (3H,	  s),	  3.79	  (3H,	  s),	  3.75	  (3H,	  s),	  
1.27	  (6H,	  d,	  J=	  6.3	  Hz),	  1.22	  (6H,	  d,	  J=	  6.3	  hz).	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23c.	  3,4-­‐bis(4-­‐isopropoxy-­‐3-­‐methoxyphenyl)-­‐9-­‐methyl-­‐2H-­‐pyrido[3,4-­‐
b]indol-­‐1(9H)-­‐one	  
	  
N NH
O
OiPr
H3CO
OiPr
OCH3
H3C
C32H34N2O5
Mol. Wt.: 526,62 	  
	  
To	  a	  solution	  of	  6c	   (0.970	  g,	  0.002	  mol)	   in	  acetonitrile	  (10	  mL)	  was	  added	  
TFA	  (0.2	  mL)	  and	  the	  reaction	  mixture	  was	  refluxed	  for	  15’.	  The	  precipitate	  
formed	  was	  filtered	  and	  washed	  with	  acetonitrile	  to	  afford	  23c	  as	  a	  white	  
solid	  (0.556	  g,	  58%),	  m.p.	  	  287	  °C.	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4c.	  3,4-­‐bis(4-­‐hydroxy-­‐3-­‐methoxyphenyl)-­‐9-­‐methyl-­‐2H-­‐pyrido[3,4-­‐b]indol-­‐
1(9H)-­‐one	  
	  
N NH
O
OH
H3CO
OH
OCH3
H3C
C26H22N2O5
Mol. Wt.: 442,46 	  
	  
Anhydrous	   AlCl3	   (0.197	   g,	   0.001	  mol)	   was	   suspended	   in	   dry	   DCM	   (5	  mL)	  
under	  nitrogen	  and	  compound	  23c	   (0.300	  g,	  0.6	  mmol)	  was	  added.	  After	  
stirring	   the	   reaction	   mixture	   at	   room	   temperature	   for	   6	   h,	   saturated	  
aqueous	   NH4Cl	   was	   added	   and	   the	   mixture	   was	   extracted	   with	   ethyl	  
acetate.	  The	  organic	  layer	  was	  washed	  with	  brine	  ,	  dried	  over	  Na2SO4	  and	  
evaporated	   under	   reduced	   pressure.	   The	   crude	   solid	   afforded	   was	  
crystallized	  from	  ethanol	  to	  give	  product	  4c	  (0.08	  g,	  18%),	  m.p.	  	  315	  °C.	  
	  
1H	  NMR	  (DMSO):	  11.40	  (1H,	  brs),	  11.32	  (1H,	  brs),	  9.05	  (1H,	  brs),	  6.53-­‐6.99	  
(10	  H,	  m),	  4.28	  (3H,	  s),	  3.60	  (3H,	  s),	  3.33	  (3H,	  s).	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32.	  2-­‐(2-­‐methoxyphenyl)	  oxiarane	  
	  
O
OCH3
C9H10O2
Mol. Wt.: 150,17 	  
	  
To	  an	   iced-­‐cooled	  suspension	  of	  NaH	   (1.67	  g,	  70	  mmol)	   in	  dry	  DMSO	   (30	  
mL)	  under	  nitrogen	   flow,	   trimethylsulfoxonium	   iodide	   (12.76	  g,	  58	  mmol)	  
was	  added	  gradually	  and	  the	  reaction	  mixture	  was	  stirred	  for	  1	  h.	  Then	  a	  
solution	  of	  2-­‐methoxybenzaldehyde	   (8	  g,	   59	  mmol)	   in	  dry	  DMSO	   (10	  mL)	  
was	   added	   dropwise.	   The	   cooling	   bath	   was	   removed	   and	   the	   reaction	  
mixture	  allowed	  to	  warm	  to	  room	  temperature.	  After	  stirring	  for	  3	  h,	  water	  
was	  added	  and	  the	  product	  extracted	  with	  ethyl	  acetate.	  the	  organic	  layer	  
was	  washed	  several	   times	  with	  NaCl	  solution,	  dried	  over	  Na2SO4	   ,	   filtered	  
over	   a	   silica	   pad	   and	   the	   solvent	   evaporated	   under	   reduced	   pressure	   to	  
give	  32	  (8.50g,	  97%)	  as	  a	  yellow	  oil.	  
	  
1H	  NMR	  (DMSO):	  6.93	  (1H,	  m),	  6.36-­‐6.65	  (3H,	  m),	  3.64	  (	  1H,	  m),	  3.37	  (3H,	  
s),	  2.64	  (	  1H,	  m),	  2.25	  (1H,	  dd,	  J=	  2.8-­‐5.5	  Hz)	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33.	  2-­‐azido-­‐2-­‐(2-­‐methoxyphenyl)	  ethanol	  
	  
OH
OCH3
N3
C9H11N3O2
Mol. Wt.: 193,2 	  
	  
To	  a	  solution	  of	  32	  (6	  g,	  40	  mmol)	  in	  acetonitrile	  (20	  mL)	  NaN3	  (5.20	  g,	  80	  
mmol)	  and	  LiClO4	  (8.51	  g,	  80mmol)	  were	  added.	  The	  reaction	  mixture	  was	  
heated	  at	  60°C	  .	  After	  being	  stirred	  for	  2	  h,	  the	  solvent	  was	  removed	  under	  
reduced	  pressure	  and	  ethyl	  acetate	  was	  added.	  The	  solution	  was	  washed	  
with	  water	  and	  NaCl,	  dried	  over	  Na2SO4,	  evaporated	  and	  purified	  by	  flash	  
chromatography	  (hexane:	  ethyl	  acetate,	  8:2)	  to	  afford	  35	  (2.96	  g,	  36%)	  as	  a	  
yellow	  oil.	  
	  
1H	  NMR	   (CDCl3):	   7.39-­‐7.56	   (2H,	  m),	   7.04-­‐7.25	   (2H,	  m),	   5.32	   (1H,	  m),	   4.01	  
(3H,	  s),	  3.78-­‐4.01	  (3H,	  m)	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25.	  2-­‐amino-­‐2-­‐(2-­‐methoxyphenyl)	  ethanol	  
	  
OH
OCH3
H2N
C9H13NO2
Mol. Wt.: 167,21
	  
To	  a	   solution	  of	   compound	  33	   (2.66	  g,	  16	  mmol)	   in	  ethanol	   (30	  mL)	  10%	  
Pd/C	   catalyst	   (0.327	   g)	   was	   added	   at	   room	   temperature.	   The	   reaction	  
mixture	   was	   stirred	   under	   hydrogen	   atmosphere	   for	   24	   h,	   the	   catalyst	  
filtered	  and	  the	  solvent	  evaporated.	  Ethyl	  acetate	  was	  added	  to	  the	  crude	  
product	  and	  the	  solution	  washed	  with	  water	  and	  NaCl,	  dried	  over	  Na2SO4	  
and	   evaporated	   under	   reduced	   pressure	   to	   afford	   compound	  25	   (1.98	   g,	  
74%)	  as	  a	  colorless	  oil.	  
	  
1H	  NMR	  (DMSO):	  7.42	   (1H,	  d,	   J=	  7.2	  Hz),	  7.19	   (1H,	  m),	  6.84-­‐6.99	   (2H,	  m),	  
4.70	  (1H,	  brs),	  4.20	  (1H,	  dd,	  J=	  3.4-­‐	  7.8	  Hz),	  3.77	  (3H,	  s),	  3.50	  (1H,	  dd,	  J=	  3.4-­‐
9.9	  Hz),	  3.14	  (1H,	  m)	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27.	  N-­‐(2-­‐hydroxy-­‐1-­‐(2-­‐methoxyphenyl)ethyl)-­‐1-­‐methyl-­‐1H-­‐indole-­‐2-­‐
carboxamide	  
	  
N NH
OH3C
OH
OCH3
C19H20N2O3
Mol. Wt.: 324,37 	  
	  
To	  a	  suspension	  of	  HOBt	  (3.24	  g,	  24	  mmol)	  and	  WSC	  (4.60	  g,	  24	  mmol)	  in	  
THF	   (40	  mL)	   under	   nitrogen	   atmosphere,	  25	   (1.90	   g,	   0.012	  mol)	  and	  11c	  
(1.29	  g,	  0.012	  mol)	  were	  added	  The	  reaction	  mixture	  was	  stirred	  at	  room	  
temperature	   for	   24	   h	   and	   the	   solvent	   was	   evaporated	   under	   reduced	  
pressure.	   The	   crude	   product	  was	   dissolved	   in	   ethyl	   acetate,	   the	   solution	  
washed	  with	  NaHCO3,	  HCl	  2M	  and	  brine,	  dried	  over	  Na2SO4	  and	  evaporated	  
under	  reduced	  pressure	  to	  afford	  7	  as	  a	  white	  solid	  (	  2.33	  g,	  94%).	  M.p	  95	  
°C.	  
1H	  NMR	  (CDCl3):	  7.64	  (1H,	  d,	  J=	  8.3),	  7.21-­‐	  7.43	  (5H,	  m),	  7.15	  (1H,	  m),	  6.29-­‐
7.03	  (2H,	  m),	  6.90	  (1H,	  s),	  5.51	  (1H,	  m),	  4.05	  (3H,	  s),	  3.93-­‐4.03	  (2H,	  m),	  3.93	  
(3H,	  s)	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28.	  Preparation	  of	  N-­‐(formyl(2-­‐methoxyphenyl)ethyl)-­‐1-­‐methyl-­‐1H-­‐
indole-­‐2-­‐carboxamide.	  
	  
N NH
OH3C
OCH3
O
C19H18N2O3
Mol. Wt.: 322,36 	  
	  
To	  a	  solution	  of	  IBX	  (1.55	  g,	  5.6	  mmol)	  in	  dry	  DMSO	  (10	  mL)	  7	  (0.907	  g,	  2.8	  
mmol)	  was	   added	  under	   nitrogen	   atmosphere.	   The	   reaction	  mixture	  was	  
stirred	   at	   room	   temperature	   for	   3	   h,	   treated	  with	   ethyl	   acetate,	  washed	  
with	   NaHCO3	   and	   brine.	   The	   organic	   layer	   was	   dried	   over	   Na2SO4,	   and	  
evaporated	  under	  reduced	  pressure	  to	  afford	  28	  as	  a	  yellow	  oil	   (0.900	  g),	  
used	  for	  the	  next	  step	  without	  further	  purification.	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29.	  3-­‐(2-­‐methoxyphenyl)-­‐9-­‐methyl-­‐2H-­‐pyrido[3,4,b]indol-­‐1(9H)-­‐one.	  
	  
N NH
OH3C
OCH3
C19H16N2O2
Mol. Wt.: 304,34 	  
	  
To	  a	  solution	  of	  28	  (0.900	  g)	  in	  acetonitrile	  (10	  mL)	  was	  added	  TFA	  (1	  mL)	  
and	  the	  reaction	  mixture	  was	  refluxed	  for	  15’.	  The	  precipitate	  formed	  was	  
filtered	  and	  washed	  with	  acetonitrile	  to	  afford	  29	  as	  a	  white	  solid	  (0.540	  g).	  
Mp	  250	  °C	  
	  
1H	  NMR	   (DMSO):	   7.88-­‐8.12	   (6H,	  m),	   7.63-­‐7.86	   (4H,	  m),	   3.90	   (3H,	   s),	   3.31	  
(3H,	  s),	  2.52	  (3H,	  s).	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30.	  	  3-­‐(2-­‐hydroxyphenyl)-­‐9-­‐methyl-­‐2H-­‐pyrido[3,4,b]indol-­‐1(9H)-­‐one.	  
	  
N NH
OH3C
OH
C18H14N2O2
Mol. Wt.: 290,32 	  
	  
To	   an	   ice-­‐cooled	   suspension	   of	   29	   (0.540	   g,	   1.8	   mmol)	   in	   dry	  
dichloromethane	  (13	  mL)	  1	  M	  BBr3	  in	  dichloromethane	  (1.33	  g,	  5.3	  mmol,	  
5.3	   mL)	   was	   added	   dropwise	   under	   nitrogen	   atmosphere.	   The	   reaction	  
mixture	   was	   allowed	   to	   warm	   to	   room	   temperature,	   stirred	   overnight,	  
quenched	   with	   aqueous	   HCl	   and	   extracted	   with	   dichloromethane.	   The	  
extract	   was	   washed	   with	   brine,	   dried	   over	   Na2SO4,	   concentrated	   under	  
reduced	  pressure	  and	  purified	  by	  flash	  chromatography	  (dichloromethane:	  
methanol,	  9.5:0.5)	  to	  afford	  30	  (0.200g,	  38	  %)	  as	  a	  yellow	  solid.Mp	  270	  °C	  
	  
1H	  NMR	   (DMSO):	   7.88-­‐8.12	   (6H,	  m),	   7.63-­‐7.86	   (4H,	  m),	   3.31	   (3H,	   s),	   2.52	  
(3H,	  s).	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31.	  8-­‐Methyl-­‐8H-­‐5-­‐oxa-­‐6a,8-­‐diaza-­‐indeno[2,1-­‐b	  phen-­‐anthren	  -­‐7-­‐one	  
	  
N N
OH3C
O
C19H14N2O2
Mol. Wt.: 302,33 	  
	  
	  A	  suspension	  of	  30	   (0.04	  g,	  0.14	  mmol)	  and	  K2CO3	   (0.05	  g,	  0.34	  mmol)	   in	  
DMF	   (4mL)	   was	   stirred	   for	   30’	   at	   room	   temperature	   and	   treated	   with	  
iodomethane	  (0.150	  g,	  0.56	  mmol).	  After	  being	  refluxed	  for	  1h,	  the	  solvent	  
was	  evaporated	  and	  the	  crude	  product	  was	  dissolved	  in	  dichloromethane,	  
washed	   with	   brine,	   dried	   over	   Na2SO4	   and	   purified	   by	   flash	  
chromatography	   (dichloromethane:	   methanol,	   9,5:0,5)	   to	   afford	   31	   as	   a	  
white	  solid	  (12	  mg,	  28%).	  M.p	  280	  °C.	  
	  
1H	  NMR	  (DMSO):	  8.02-­‐	  8.19	  (2H,	  m),	  7.81	  (1H,	  s),	  7.65	  (1H,	  d,	  J=	  8.36	  Hz),	  
7.52	  (1H,	  m),	  7.38	  (1H,	  m),	  7.18	  -­‐7.32	  (2H,	  m),	  7.13	  (1H,	  d,	  J=	  8.07	  Hz),	  5.92	  
(2H,	  S),	  4.23	  (3H,	  S).	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38.	  2,4-­‐Dihydroxy-­‐5-­‐methoxy-­‐benzaldehyde	  
	  
CHO
OH
OH
H3CO
C8H8O4
Mol. Wt.: 168,15 	  
	  
To	   a	   stirred	   suspension	   of	   AlCl3	   (68	   g,	   0.51	  mol)	   in	   dry	  DCM	   (450	  mL),	   a	  
solution	  of	  2,4,5-­‐trimethoxybenzaldehyde	  37	  (25	  g,	  0.127	  mol)	  in	  dry	  DCM	  
(125	  mL)	  was	  added	  dropwise.	  After	  stirring	  for	  4	  h	  at	  room	  temperature,	  
another	  portion	  of	  AlCl3	   (68	  g,	  0.51	  mol)	  was	  added.	  The	   suspension	  was	  
further	  stirred	  for	  19	  h	  and	  the	  reaction	  mixture	  was	  poured	   into	  1	  Kg	  of	  
ice	   to	   which	   45	  mL	   of	   concentrated	   hydrochloric	   acid	   weres	   added.	   The	  
organic	   layer	  was	   separated	   and	   the	   aqueous	   phase	  was	   extracted	   twice	  
with	  DCM	  (200	  mL).	  The	  combined	  organic	   layers	  were	  filtered	  over	  silica	  
gel,	  dried	  over	  Na2SO4,	  evaporated	  and	  the	  residue	  crystallized	  from	  ethyl	  
acetate	  to	  give	  compound	  38	  (17.95	  g,	  84	  %),	  m.p.	  	  150	  °C.	  
	  
1H	  NMR	  (CDCl3):	  11.95	  (1H,	  s),	  9.71	  (1H,	  s),	  7.29	  (1H,	  s),	  6.90	  (1H,	  s),	  6.55	  
(1H,	  s),	  3.92	  (3H,	  s).	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39.	  2-­‐Hydroxy-­‐4-­‐isopropoxy-­‐5-­‐methoxy-­‐benzaldehyde	  
	  
CHO
OiPr
OH
H3CO
C11H14O4
Mol. Wt.: 210,23 	  
	  
2,4-­‐dihydroxy-­‐5-­‐methoxyxybenzaldehyde	   38	   (35.18	   g,	   0.209	   mol)	   was	  
dissolved	   in	   dry	   DMF	   (345	   mL).	   NaHCO3	   (26.29	   g,	   0.313	   mol)	   and	   2-­‐
bromopropane	  (0.313	  mol,	  29.46	  mL)	  were	  added	  under	  nitrogen	  flow.	  The	  
reaction	  mixture	  was	  heated	  at	  70	  °C	  and	  stirred.	  After	  4	  h,	  the	  	  suspension	  
was	   filtered	  and	   the	  organic	   layer	  was	  evaporated.	   To	   the	   crude	  product	  
was	   added	   ethyl	   acetate	   and	   the	   suspension	   was	   filtered.	   The	   organic	  
phase	   was	   dried	   over	   Na2SO4,	   filtered	   and	   evaporated	   under	   reduced	  
pressure.	   The	   crude	   product	   was	   purified	   by	   flash	   chromatography	  
(hexane:ethyl	  acetate,	  1:1)	  affording	  a	  yellow	  oil	  (15	  g,	  34	  %).	  
	  
1H	  NMR	  (CDCl3):	  11.36	  (1H,	  s),	  9.66	  (1H,	  s),	  6.89	  (1H,	  s),	  6.44	  (1H,	  s),	  4.63	  
(1H,	  s),	  1.42	  (6H,	  d,	  J=	  5.9	  Hz).	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40.	  4-­‐Isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy-­‐ethoxymethoxy)-­‐
benzaldehyde	  
	  
CHO
OiPr
OMEM
H3CO
C15H22O6
Mol. Wt.: 298,33 	  
	  
To	   a	   suspension	   of	   K2CO3	   (29.16	   g,	   0.211	  mol)	   in	   dry	  DMF	   (150	  mL)	  was	  
added	  compound	  39	  (14.80	  g,	  0.07	  mol).	  After	  stirring	  for	  15	  min,	  MEMCl	  
(26.63	  g,	  0.211	  mol)	  was	  added	  slowly	  and	  reaction	  mixture	  was	  stirred	  for	  
12	   h.	   The	   solvent	   was	   removed	   under	   reduced	   pressure	   and	   the	   crude	  
product	   was	   dissolved	   in	   ethyl	   acetate,	   washed	   with	   brine,	   dried	   over	  
Na2SO4,	  filtered	  and	  evaporated	  in	  vacuo,	  affording	  a	  yellow	  oil	  (19.70	  g,	  94	  
%).	  
	  
1H	  NMR	  (CDCl3):	  10.29	  (1H,	  s),	  7.29	  (1H,	  s),	  6.82	  (1H,	  s),	  5.31	  (2H,	  s),	  4.65	  
(1H,	  m),	  3.80-­‐3.90	  (5H,	  m),	  3.53-­‐3.60	  (2H,	  m),	  3.36	  (3H,	  s),	  1.40	  (6H,	  d,	   J=	  
6.1)	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41.	  4-­‐Isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy-­‐ethoxymethoxy)-­‐
benzaldehyde	  oxime	  
	  
HC
OiPr
NOH
OMEM
H3CO
C15H23NO6
Mol. Wt.: 313,35 	  
	  
A	  solution	  of	  40	  (17.70	  g,	  0.066	  mol)	  in	  95%	  ethanol	  (400	  mL)	  was	  treated	  
with	  a	  solution	  of	  hydroxylamine	  hydrochloride	   (5.73	  g,	  0,083	  mol)	   in	  dry	  
pyridine	  (40	  mL)	  under	  stirring	  at	  room	  temperature	  for	  90	  min	  and	  at	  0°C	  
for	   30	   min	   to	   facilitate	   the	   oxime	   precipitation.	   The	   white	   solid	   was	  
filtered,	  dried,	  	  and	  used	  (18.48	  g,	  89%)	  without	  further	  purification.	  
	  
1H	  NMR	  (CDCl3):	  8.94	  (1H,	  brs),	  8.40	  (1H,	  s),	  7.19	  (1H,	  s),	  6.80	  (1H,	  s),	  5.20	  
(2H,	  s),	  4.55	  (1H,	  m),	  3.76-­‐3.85	  (2H,	  s),	  3.35	  (3H,	  s),	  1.35	  (6H,	  d,	  J=	  6.10	  Hz)	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36.	  4-­‐Isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy-­‐ethoxymethoxy)-­‐benzylamine	  
	  
CH2NH2
OiPr
OMEM
H3CO
C15H25NO5
Mol. Wt.: 299,36 	  
	  
A	  solution	  of	  41	  (18.40	  g,	  0.059	  mol)	  in	  95%	  ethanol	  (154	  mL)	  was	  treated	  
with	  an	  equal	  volume	  of	  2M	  NaOH	  followed	  by	  Al/Ni	  alloy	  (15.97	  g)	  under	  
stirring	  at	   room	  temperature	   for	  90	  min.	  The	  Al/Ni	  alloy	  was	  removed	  by	  
filtration	   and	   washed	   with	   fresh	   ethanol.	   Filtrate	   and	   washings	   were	  
combined,	  acidified	  with	  0,8	  M	  HCl	  (pH=2)	  and	  extracted	  with	  DCM	  (3	  X	  50	  
mL).	   The	   aqueous	   phase	   was	   treated	   with	   solid	   KOH	   up	   to	   pH=14	   and	  
extracted	   with	   diethyl	   ether	   (3	   X	   30	   mL).	   The	   extracts	   after	   drying	   over	  
anhydrous	  Na2SO4	  and	  removal	  of	  the	  solvent	  afforded	  36	  (17	  g,	  97%)	  as	  a	  
brown	  oil.	  
	  
1H	  NMR	  (CDCl3):	  6.80	  (1H,	  s),	  6.77	  (1H,	  s),	  5.20	  (2H,	  s),	  4.46	  (1H,	  m),	  3.71-­‐
3.83	  (7	  H,	  m	  ),	  3.50-­‐	  3.58	  (2H,	  m),	  3.38	  (3H,	  s),	  1.31	  (6H,	  d,	  J=	  6.10	  Hz)	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35.	  4-­‐Isopropoxy-­‐N-­‐[4-­‐isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy-­‐
ethoxymethoxy)-­‐benzyl]-­‐3-­‐methoxy-­‐benzamide	  
	  
OiPr
OCH3
O
HN
OCH3
iPrO
MEMO
C26H37NO8
Mol. Wt.: 491,57 	  
	  
To	  a	  suspension	  of	  HOBt	  (6.16	  g,	  0.046	  mol)	  and	  WSC	  (8.79	  g,	  0.046	  mol)	  in	  
THF	  (250	  mL)	  under	  nitrogen	  atmosphere,	  9	  (7.9	  g,	  0.04	  mol)	  and	  36	  (16.90	  
g,	   0.06	   mol)	   were	   added.	   Reaction	   mixture	   was	   stirred	   at	   room	  
temperature	  for	  24	  h	  and	  solvent	  was	  evaporated	  under	  reduced	  pressure.	  
The	  crude	  product	  was	  dissolved	  in	  ethyl	  acetate,	  the	  solution	  washed	  with	  
NaHCO3,	   HCl	   2M	   and	   brine,	   dried	   over	   Na2SO4	   and	   evaporated	   under	  
reduced	  pressure	  to	  afford	  35	  as	  a	  yellow	  oil	  (17.70	  g,	  94%).	  
	  
1H	  NMR	  (CDCl3):	  7.42	  (1H,	  s),	  7.21	  (1H,	  dd,	  J=	  1.7-­‐8.4	  Hz),	  6.75-­‐6.93	  (3H,	  m),	  
6.65	  (1H,	  t,	   J=	  5.7),	  5.24	  (2H,	  s),	  4.40-­‐4.65	  (4H,	  m),	  3.88	  (3H,	  s),	  3.79-­‐3.85	  
(2H,	  m),	  3.80	  (3H,	  s),	  3.50-­‐3.56	  (2H,	  m),	  3.30	  (3H,	  s),	  1.36	  (6H,	  d,	  J=	  6.5	  Hz),	  
1.34	  (6H,	  d,	  J=	  6.5	  Hz)	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42.	  (4-­‐Isopropoxy-­‐3-­‐methoxy-­‐benzoyl)-­‐[4-­‐isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐
methoxy-­‐ethoxymethoxy)-­‐benzyl]-­‐carbamic	  acid	  tert-­‐butyl	  ester	  
	  
OiPr
OCH3
O
N
BOC
iPrO
H3CO
OMEM
C31H45NO10
Mol. Wt.: 591,69 	  
	  
Compound	  35	   (17.65	   g,	   0.04	  mol)	  was	   dissolved	   in	   acetonitrile	   (150	  mL)	  
under	   nitrogen	   flow	   and	   DMAP	   (2.99	   g,	   0.024	   mol)	   	   and	   di-­‐
terbutyldicarbonate	   (2.62	   g,	   0.02	   mol)	   were	   added.	   	   After	   stirring	   the	  
solution	  at	  RT	  for	  16	  h,	  the	  solvent	  was	  evaporated	  under	  reduced	  pressure	  
and	   the	   crude	   product	   was	   dissolved	   in	   DCM.	   The	   solution	   was	   washed	  
with	   saturated	   aqueous	   NaHCO3	   and	   the	   organic	   layer	   was	   dried	   over	  
Na2SO4,	   filtered	   and	   evaporated	   under	   reduced	   pressure.	   The	   crude	  
product	  was	  purified	  by	   flash	  chromatography	  (hexane:ethyl	  acetate,	  6:4)	  
affording	  42	  (13.95	  g,	  67	  %)	  as	  a	  yellow	  oil.	  
	  
1H	   NMR	   (CDCl3):	   7.05-­‐7.17	   (2H,	  m),	   6.88	   (1H,	   s),	   6.78-­‐6.85	   (2H,	  m),	   5.10	  
(2H,	  s),	  4.89	   (2H,	  s),	  4.57	   (1H,	  m),	  4.47	   (1H,	  m),	  3.81	   (3H,	  s),	  3.76	   (3H,	  s),	  
3.70-­‐3.74	  (2H,	  m),	  3.46-­‐3.52	  (2H,	  m),	  3.33	  (3H,	  s),	  1.35	  (6H,6H,	  d,	  J=	  6.1	  Hz),	  
1.31	  (6H,	  d,	  J=	  6.1	  Hz),	  1.15	  (9H,	  s)	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43	  .1-­‐[4-­‐Isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy-­‐etxy-­‐methoxy)-­‐phenyl]-­‐2-­‐
(4-­‐isopropoxy-­‐3-­‐methoxy-­‐phenyl)-­‐2-­‐oxo-­‐ethyl]-­‐carbamic	  acid	  tert-­‐butyl	  
ester	  
	  
OiPr
OCH3
OHN
BOC
iPrO OCH3
MEMO
C31H45NO10
Mol. Wt.: 591,69 	  
	  
LDA	  was	  previously	  prepared	  by	  mixing	  diisopropylamine	  (7.29	  g,	  0.07	  mol,	  
2.10	  mL)	   and	  DMPU	   (10.9	  mL)	  with	   n-­‐BuLi	   (2.7	  M	   in	   heptane,	   26.67	  mL,	  
0.07	  mol)	  in	  THF	  (70	  mL)	  at	  -­‐78°C	  under	  nitrogen	  atmosphere.A	  solution	  of	  
the	   imide	   42	   (13.90	   g,	   0.024	   mol)	   in	   freshly	   distilled	   THF	   (209	   mL)	   was	  
added	  to	  the	  LDA	  solution	  at	  -­‐78°C	  and	  the	  mixture	  was	  stirred	  for	  ?????	  h.	  
The	  mixture	  was	  quenched	  with	  aqueous	  NH4Cl,	  diluted	  with	  ethyl	  acetate,	  
washed	  with	   saturated	  aqueous	  NH4Cl	   and	  brine,	   and	  dried	  over	  Na2SO4.	  
Concentration	   in	   vacuo	   followed	   by	   flash	   chromatography	   (hexane:ethyl	  
acetate,	  7:3)	  gave	  product	  43	  (4.11	  g,	  29	  %)	  as	  a	  yellow	  oil.	  
	  
1H	  NMR	  (CDCl3):7.69	  (1H,	  d,	  J=	  8.2	  Hz),	  7.57	  (1H,	  s),	  6.68-­‐6.85	  (3H,	  m),	  6.49	  
(1H,	  d,	  J=	  7.8	  Hz),	  5.85	  (1H,	  d,	  J=	  7.8	  Hz),	  5.27	  (2H,	  m),	  4.62	  (1H,	  m),	  4.49	  
(1H,	  m),	  3.74-­‐3.95	  (2H,	  m),	  3.86	  (3H,	  s),	  3.77	  (3H,	  s),	  3.55-­‐3.65	  (2H,	  m),	  3.38	  
(3H,	  s),	  1.44	  (9H,	  s),	  1.28-­‐1.40	  (12	  H,	  m).	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34.	  1-­‐[4-­‐Isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy-­‐ethoxy	  methoxy)-­‐phenyl]-­‐
2-­‐(4-­‐isopropoxy-­‐3-­‐methoxy-­‐phenyl)-­‐2-­‐oxo-­‐ethyl-­‐ammonium;	  trifluoro-­‐
acetate	  	  
	  
OiPr
OCH3
OH3N
CF3COO
iPrO OCH3
MEMO
C28H38F3NO10
Mol. Wt.: 605,60 	  
	  
Imide	   43	   (1.50	   g,	   2.5	   mmol)	   was	   dissolved	   in	   dry	   DCM	   (30	   mL)	   under	  
nitrogen	  flow	  and	  TFA	  (3	  mL)	  was	  added	  at	  0°C.	  The	  solution	  was	  stirred	  at	  
RT	  for	  2h.	  Solvent	  was	  evaporated	  under	  vacuo	  and	  the	  crude	  product	  was	  
used	  for	  the	  next	  step	  without	  purification.	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32.	  6-­‐Benzyloxy-­‐5-­‐methoxy-­‐1-­‐methyl-­‐1H-­‐indole-­‐2-­‐carboxylicacid	  [1-­‐[4-­‐
isopropoxy-­‐5-­‐methoxy-­‐2-­‐(2-­‐methoxy	  ethoxymethoxy)-­‐phenyl]-­‐2-­‐(4-­‐
isopropoxy-­‐3-­‐methoxyphenyl)	  -­‐2-­‐oxo-­‐ethyl]-­‐amide	  
	  
N
H3CO
CH3
O
H3CO
O
NH
OiPr
OiPr
OMEM
BzO
H3CO
C44H52N2O11
Mol. Wt.: 784,89 	  
	  
To	  a	  suspension	  of	  HOBt	  (0.459	  g,	  0.003	  mol)	  and	  WSC	  (0.650	  g,	  0.003	  mol)	  
in	  THF	   (30	  mL)	  was	  added	  under	  nitrogen	  atmosphere	  33	   (0.519	  g,	  0.002	  
mol).	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  12	  h	  until	  
the	  activated	  ester	  was	   formed.	   Then	   compound	  34	   dissolved	   in	   THF	   (10	  
mL)	  and	  TEA	  (0,004	  mol,	  0,64	  mL)	  were	  added.	  After	  stirring	  the	  reaction	  
mixture	  at	  room	  temperature	  for	  14	  h,	  the	  solvent	  was	  evaporated	  under	  
reduced	   pressure.	   The	   crude	   product	  was	   dissolved	   in	   ethyl	   acetate,	   the	  
solution	   washed	   with	   aqueous	   NaHCO3,	   HCl	   2M	   and	   brine,	   dried	   over	  
Na2SO4	   and	   evaporated	   under	   reduced	   pressure	   to	   afford	  32	   as	   a	   yellow	  
solid	  (	  0.454	  g,	  55%),	  m.p.	  134	  °C.	  
	  
1H	  NMR	  (DMSO):	  8.79	  (1H,	  d,	  J=	  7.5	  Hz),	  7.67	  (1H,	  d,	  J=	  8.6	  Hz),	  7.46-­‐7.58	  
(3H,	  m),	  7.32-­‐7.46	  (7.03-­‐7.25	  (4H,	  m),	  6.83-­‐6.98	  (3H,	  m),	  5.30	  (2H,	  m),	  5.30	  
(2H,	  m),	  5.15	  (2H,	  s),	  4.69	  (1H,	  s),	  4.52	  (1H,	  s),	  3.90	  (3H,	  s),	  3.78	  (6H,	  s),	  3.67	  
(3H,	  s),	  3.17	  (3H,	  s),	  1.20-­‐1.29	  (12H,	  m).	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5.	  7-­‐Benzyloxy-­‐3-­‐(2-­‐hydroxy-­‐4-­‐isopropoxy-­‐5-­‐methoxy-­‐phenyl)-­‐4-­‐(4-­‐
isopropoxy-­‐3-­‐methoxy-­‐phenyl)-­‐6-­‐methoxy-­‐9-­‐methyl-­‐2,9-­‐dihydro-­‐b-­‐
carbolin-­‐1-­‐one	  
	  
N
H3CO
CH3
O
H3CO
NH
OiPrOiPr H3CO
OH
BzO
C40H42N2O8
Mol. Wt.: 678,77 	  
	  
TMSCl	  (0.67	  mmol,	  0.08	  mL)	  and	  NaI	  (0.100	  g,	  0.67	  mmol)	  were	  added	  to	  a	  
solution	  of	  32	  (0.450	  g,	  0.67	  mmol)	  in	  acetonitrile	  (40	  mL)	  at	  –20	  °C	  under	  
nitrogen	   flow.	  After	   stirring	  at	   this	   temperature	   for	  15	  min,	  an	  additional	  
equivalent	  of	  both	  NaI	  and	  TMSCl	  was	  added	  and	  the	  mixture	  stirred	  at	  –20	  
°C	   until	   no	   starting	   material	   remained	   (TLC	   analysis).	   The	   yellow-­‐orange	  
mixture	  was	  quenched	  with	  methanol	  and	  the	  solvent	  removed	   in	  vacuo.	  
The	  residue	  was	  extracted	  	  with	  ethyl	  acetate	  and	  the	  organic	  layer	  washed	  
with	   saturated	   sodium	   thiosulfate	   and	   brine.	   The	   crude	   product	   was	  
purified	   by	   flash	   chromatography	   (hexane:ethyl	   acetate,	   7:3)	   affording	   5	  
(0.140	  g,	  31%)	  as	  a	  white	  solid,	  m.p.:	  220	  °C.	  
	  
1H	  NMR	   (DMSO):	   11.00	   (1H,	   s),	   9.09	   (1H,	   s),	   7.19-­‐7.56	   (7H,	  m),	   6.67-­‐7.00	  
(3H,m),	  6.54	  (1H,	  s),	  6.41	  (1H,	  s),	  6.27	  (1H,	  s),	  5.19	  (2H,	  s),	  4.50	  (1H,	  s),	  4.38	  
(1H,	  s),	  4.24	  (3H,	  s),	  3.58	  (3H,	  s),	  3.43	  (3H,	  s),	  3.39	  (3H,	  s),	  1.22	  (12	  H,	  m)	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45.10-­‐Benzyloxy-­‐3-­‐isopropoxy-­‐13-­‐(4-­‐isopropoxy-­‐3-­‐methoxy-­‐phenyl)-­‐2,11-­‐
dimethoxy-­‐8-­‐methyl-­‐8H-­‐5-­‐oxa-­‐6a,8-­‐diaza-­‐indeno[2,1-­‐b]phenanthren-­‐7-­‐
one	  
	  
N
H3CO
CH3
O
H3CO
N
OiPrOiPr H3CO
O
BzO
C41H42N2O8
Mol. Wt.: 690,78 	  
	  
A	  suspension	  of	  5	  (0.132	  g,	  0.2	  mmol)	  and	  K2CO3	  (0.072	  g,	  52	  mmol)	  in	  DMF	  
(6	   mL)	   was	   stirred	   for	   30’	   at	   room	   temperature	   and	   treated	   with	  
iodomethane	  (0.7	  mL,	  82	  mmol).	  After	  being	  heated	  at	  100	  °C	  for	  1h,	  the	  
solvent	   was	   evaporated	   under	   reduced	   pressure	   and	   the	   crude	   product	  
was	  dissolved	   in	  dichloromethane,	  washed	  with	  brine,	   dried	  over	  Na2SO4	  
and	  purified	  by	  flash	  chromatography	  (petroleum	  ether-­‐ethyl	  acetate,	  1:1)	  
to	  afford	  45	  as	  a	  white	  solid	  (14	  mg,	  12	  %).	  
	  
1H	  NMR	  (DMSO):	  7.17-­‐7.58	  (5H,	  m),	  6.74-­‐7.17	  (4H,	  m),	  6.46-­‐6.72	  (2H,	  m),	  
5.82-­‐6.14	  (3H,	  m),	  5.23	  (2H,	  s),	  4.42-­‐4.72	  (2H,	  m),	  4.24	  (3H,	  s),	  3.78	  (3H,	  s),	  
3.	  52	  (3H,	  s),	  3.26	  (3H,	  s),	  1.07-­‐1.48	  (12H,	  m)	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3.	  3,10-­‐Dihydroxy-­‐13-­‐(4-­‐hydroxy-­‐3-­‐methoxy-­‐phenyl)-­‐2,11-­‐dimethoxy-­‐8-­‐
methyl-­‐8H-­‐5-­‐oxa-­‐6a,8-­‐diaza-­‐indeno[2,1-­‐b]phenanthren-­‐7-­‐one	  
	  
N
H3CO
HO
H3C O
OH
H3CO
OH
N O
OCH3
C28H24N2O8
Mol. Wt.: 516,50 	  
	  
Anhydrous	  AlCl3	  (15.5	  mg,	  0.116	  mmol)	  was	  suspended	  in	  dry	  DCM	  (5	  mL)	  
under	  nitrogen	  and	  compound	  23c	  (10	  mg,	  0.014	  mmol)	  was	  added.	  After	  
refluxing	  the	  reaction	  mixture	  for	  6	  h,	  saturated	  aqueous	  NH4Cl	  was	  added	  
and	   the	  mixture	  was	   extracted	  with	   ethyl	   acetate.	   The	  organic	   layer	  was	  
washed	   with	   brine	   ,	   dried	   over	   Na2SO4	   and	   evaporated	   under	   reduced	  
pressure.	   The	   crude	  product	  was	  purified	  by	  TLC	  preparative	   to	  give	  3	   (6	  
mg,	  83	  %),	  m.p.	  290	  °C.	  	  	  	  1H	  NMR	  (DMSO):	  7.01	  (1H,	  d,	  J=	  8.2	  Hz),	  6.94	  (1H,	  d,	  1.7	  Hz),	  6.88	  (1H,	  s),	  
6.76	  (1H,	  dd,	  J=8.22-­‐1.7	  Hz),	  6.63	  (1H,	  s),	  6.45	  (1H,	  s),	  5.87	  (1H,	  ab,	  J=9.24	  
Hz),	  4.11	  (3H,	  s),	  3.69	  (3H,	  s),	  3.16	  93H,	  s)	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